Mechanisms for the Generation of Structural Diversity in Polyketide Biosynthesis by Walker, Paul
                          
This electronic thesis or dissertation has been





Mechanisms for the Generation of Structural Diversity in Polyketide Biosynthesis
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
Mechanisms for the Generation of Structural 






Paul David Walker 
 
 
A thesis submitted to the University of Bristol as part of the 
requirements for award of the degree of Doctor of Philosophy in the 
Faculty of Science 
 
University of Bristol 
School of Chemistry 
Cantock’s Close 





Kalimantacin β-Branching Pathway 
Polyketide synthases encode a remarkable number of enzymes to catalyse chain 
extension, reductive processing and tailoring reactions leading to structural diversity in 
the polyketide products. Interaction of a modular ACP-bound substrate with a trans-
acting HCS cassette leads to β-branching, as exemplified by kalimantacin A which 
contains four β-branches with an endo or exo double bond or a saturated methyl group 
(green dots). This diversity of β-branches, incorporated by a single HCS cassette, 
provides a fascinating case study to probe the mechanism and selectivity for consecutive 
β-branch incorporations.  
The HCS cassette, modular ACPs and tailoring enzymes from the kalimantacin gene 
cluster were cloned, expressed and purified. In vitro reconstitution of the β-branching 
pathway demonstrated the formation of an endo-β-methyl branch by the HCS cassette. 
The α,β-unsaturation was rigorously assigned by NMR experiments using pantetheine- 
and ACP-bound intermediates. Subsequent reduction (BatK) of this substrate resulted in 
the formation of a saturated-β-methyl branch. A previously unassigned modular ECH 
domain was identified, cloned and expressed as a single domain (mECH) or ACP4-
mECH di-domain (4M). An NMR assay utilising a single carbon-13 label incorporated 
into key biosynthetic mimics was developed and definitively showed the formation of an 
exo-β-methyl branch via mECH-catalysed decarboxylation.  
 
Mupirocin/Thiomarinol Starter Unit Generation 
Previous stable isotope labelling studies carried out on the mupirocin (P. fluorescens) and 
thiomarinol (Pseudoalteromonas sp.) producing strains was the basis for a hypothesis for 
the formation of a 3- or 4-carbon starter unit in the biosynthesis of the fatty acid moiety 
of both compounds. The cassette of enzymes hypothesised to be responsible for the 
generation of a 3-hydroxypropionate (3-HP) and 4-hydroxybutyrate (4-HB) starter unit 
consists of an ACP (M/TacpD), an adenylation domain (MupQ/TmlQ) and a reductase 
(MupS/TmlS). Each of these proteins were expressed and purified, and the proposed 
pathway was then reconstituted in vitro which conclusively demonstrated 3-HP and 4-
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Ac Acetyl 
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AcpS Acyl Carrier Protein Synthase 
aq. Aqueous 
Ar Aryl 
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HCS cassette 3-Hydroxy-3-methylglutaryl CoA-synthase Cassette 
HMG 3-Hydroxy-3-methylglutaryl 
HMGCS 3-Hydroxy-3-methylglutaryl CoA-synthase 
HMGR 3-Hydroxy-3-methylglutaryl CoA-reductase 
HMGS 3-Hydroxy-3-methylglutaryl synthase 
HPLC High Performance Liquid Chromatography 
HRMS High Resolution Mass Spectrometry 
HSQC Heteronuclear Single Quantum Correlation 
Hz Hertz 
Imid. Imidazole 
IPI Isopentyl Pyrophosphate Isomerase 
IPP Isopentyl Diphosphate  
IPTG Isopropyl-β-D-1-thiogalactopyranoside 
IR Infrared 
J Coupling Constant 
KR Ketoreductase 
KS Ketosynthase 
KS0 Ketosynthase (lacking cysteine for condensation) 
LC/MS Liquid Chromatography/Mass Spectrometry 




m.p. Melting Point 
m/z Mass-to-charge Ratio 
MDD Mevalonate Diphosphate Decarboxylase  
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mECH Modular Enoyl-CoA Hydratase 
MG 3-Methylglutaconyl 
MHz Megahertz 
MK Mevalonate Kinase 
MS Mass Spectrometry 
MT Methyl Transferase 
NaHMDS Sodium Hexamethyldisilazide 
NCE New Chemical Entity 
NMR Nuclear Magnetic Resonance 
NOESY  Nuclear Overhauser Effect Spectroscopy 
NRPS Non-ribosomal Peptide Synthase 
OAH Oxyanion Hole 
OD Optical Density 
ORF Open Reading Frame 
Pant Pantetheine 
PCP Peptidyl Carrier Protein 
PCR Polymerase Chain Reaction 
petrol Petroleum Ether 40-60 °C 
PK Polyketide 
PKS Polyketide Synthase 
PMK Phosphomevalonate Kinase  
Ppant Phosphopantetheine 
ppm Parts per Million 
PPTase Phosphopantetheinyl Transferase 
PropAc Propionylacetate 
q Quartet 
Rf Retention Factor 
s Singlet 
SAM S-adenosylmethionine 
SAXS Small Angle X-ray Scattering 
SDS-PAGE 
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1.1 Antimicrobial Resistance 
Antimicrobial resistance (AMR) is a global threat to healthcare, economics and security 
according to the 2016 Review on Antimicrobial Resistance.1 The authors predicted the 
mortality rate from AMR could reach 10 million people per year by 2050, an increase 
from the current rate of 700,000. Several key recommendations were made including 
increasing public awareness, reducing unnecessary use of antimicrobials, improving 
diagnostics and increasing the number of effective antimicrobials available.  
Following the discovery of penicillin in 1928, a golden age of antibiotic discovery 
followed from 1940 to 1960. A medicinal chemistry driven optimisation of existing 
chemical scaffolds has ensued since; however, no new classes of antibiotics were 
introduced until 2000.2,3 Between 1981 and 2010, 69% of all antimicrobial new chemical 
entities (NCE) were naturally derived or inspired. At a time when resistance is on the rise, 
antibiotic discovery and development is in decline.4,5 Utilising modern synthetic 
chemistry is one way to develop more effective antibiotics as demonstrated by Boger et 
al. who have reported potent derivatives of the clinically relevant antibiotic vancomycin.6 
Understanding and rational engineering of biosynthetic pathways is another important 
approach to developing more effective antimicrobials.7,8 In addition to new and more 
potent compounds, Peschel et al. presented the importance of selective “decolonisation 
agents” in the control of antibiotic-resistant populations in the human microbiome.9  
 
Scheme 1 Biological macromolecules are derived from starter units including amino acids and coenzyme A 
thioesters.  
A range of simple building blocks are constructed into the biomolecules that sustain life 
in all organisms. This pool of simple, organic molecules is shared between primary and 




reproduction of the organism, whereas secondary metabolites are non-essential but 
produced for protection or to aid survival. Amino acids are the building blocks utilised in 
the production of proteins, peptides and alkaloids, whilst acetyl-CoA is used in the 
biosynthesis of fatty acids, terpenes and polyketides (Scheme 1).  
1.2 Polyketides 
Polyketides are a diverse range of secondary metabolites produced by bacteria, fungi and 
marine organisms. Many polyketides have found use in a clinical setting, displaying a 
wide array of biological activity, including antibiotic, anti-cancer, immunosuppressants 
and anti-parasitic (Figure 1).10,11  
 
Figure 1 Examples of polyketides and their biological activity.  
This class of natural product was first reported by Collie in 1893,12 and the same author 
proposed in 1907 the origin of polyphenols to be a repeating -CH2CO- “ketide” building 
block.13 It wasn’t until the 1950s, however, that Birch speculated that 6-methyl-salicylic 
acid was produced from a polyketone that underwent condensation to form the aromatic 
compound (Scheme 2).14 This was elegantly demonstrated by the incorporation of 14C by 
the producing organism and subsequent analysis by chemical degradation. Since these 
early experiments, isotopic labelling has been a critical tool in elucidating the structures 
and understanding the biosynthetic pathways of many polyketides.15 This includes the 
feeding of singly or doubly labelled acetate, or other biosynthetic precursors, and 





Scheme 2 14C isotopic labelling by Birch showing the incorporation of C2 acetate units in aromatic polyketides. 
Advances in genome sequencing, genetics and proteomic techniques have developed our 
understanding of biosynthetic gene clusters and the enzymology of the pathways they 
encode.17–19 The diverse range of polyketide chemical structures arises from the broad 
range of enzymatic machinery and architecture available to synthesise these important 
molecules.20,21  
1.3 Polyketide Biosynthesis 
Polyketide biosynthesis proceeds from the transfer of an acyl-CoA substrate onto the thiol 
of an acyl carrier protein (ACP) as shown in Scheme 3.17 Chain extension is carried out 
by a ketosynthase (KS) domain which acylates with the growing polyketide chain from 
an upstream ACP substrate onto a conserved cysteine residue. An acyl transferase (AT) 
domain transfers an extending unit (often malonyl CoA) onto the thiol of the downstream 
ACP, then decarboxylation and reaction with the KS-bound acyl group in a Claisen-like 
condensation results in carbon-carbon bond formation and a new β-keto moiety. The β-
ketone may be reductively processed by a ketoreductase (KR) domain to give a β-
hydroxyl, a dehydratase (DH) domain to give the α,β-unsaturated carbonyl and an 
enoylreductase (ER) to give the saturated alkyl chain. In an analogous catalytic cycle, 
fatty acid synthases (FAS) use all the reductive domains to produce saturated fatty acids, 
whilst polyketide synthases (PKS) may exhibit any number of processing domains and 
generate greater structural diversity.22 Chain termination is achieved by a thiosesterase 
(TE) domain that may, in the presence of water, hydrolyse the polyketide to leave a 
terminal carboxylic acid or cyclise by macrolactonisation with a backbone hydroxyl 
group.  
Further functionalisation of the linear backbone is achieved through alkylation at the α- 
or β-carbons. Substitution at the α-position is achieved by the incorporation of 2-
substituted malonyl extender units or the action of S-adenosylmethionine (SAM) to 
methylate at the nucleophilic α-carbon to the thioester. Alkylation at the β-position is less 





Scheme 3 Fatty acid/polyketide biosynthesis. Fatty acids undergo full reductive processing of the β-ketone (solid black 
arrows) whereas polyketides exhibit a range of oxidation states according to domain architecture (dotted arrows). 
Intermediates can undergo chain extension without a full round of reductive processing (red) or may be released from 
the PKS by a thioesterase domain (blue).  
PKSs may be categorised based on the structural arrangement of domains used for chain 
extension and processing (Figure 2).23 Type I PKSs possess a series of catalytic domains 
covalently linked together to form a single polypeptide chain.22 A set of domains that are 
required for a single round of chain extension and processing are referred to as a module. 
In type II PKSs, the catalytic domains exist as discrete proteins that associate into 






Figure 2 Schematic of the classification of polyketide synthases.  
The type I PKS class may be further sub-divided into iterative and modular types.25 
Iterative PKSs are formed of a single repeat of catalytic domains that are utilised multiple 
times during biosynthesis.26 Modular PKS are large, multi-functional polypeptides that 
contain all the catalytic domains required for complete elongation of the polyketide chain. 
Each domain is used only once as the substrate is extended and processed, passing 
downstream from the N-terminal to the C-terminal of the mega-enzyme.  
The final sub-classification of type I modular PKSs depends on whether the AT domain 
is embedded in the modular system (cis-AT) or whether a free-standing AT (trans-AT) is 
required for the supply of extender units.20,21,27 Inspection of domain order for a cis-AT 
PKS allows for the determination of the likely polyketide product, termed the co-linearity 
principle. However, this is not the case for trans-AT PKSs for which a wide-range of 
additional tailoring steps are often encountered.  
Non-ribosomal peptide synthases (NRPS) exhibit many shared features with type I 
modular PKS. An extender unit (commonly an amino acid) is activated by an adenylation 
(A) domain and ATP to form a mixed anhydride (acyl-adenylate), which is then trapped 
by the thiol of a holo-peptidyl carrier protein (PCP) as shown in Scheme 4. Finally, a 
condensation (C) domain catalyses peptide bond formation between the extender unit and 
a PCP carrying the native chain. Due to the modular nature of PKS and NRPS, it is 
common to encounter products of hybrid PKS-NRPS pathways that contain both PKS 







Scheme 4 Chain extension by a non-ribosomal peptide synthase (NRPS) involves an adenylation (A) domain to 
activate the amino acid extender unit and form a thioester bond with a peptidyl carrier protein (PCP). Amide bond 
formation is catalysed by a condensation (C) domain.  
Cis-AT and trans-AT PKS differ not only in the architecture of the synthases, but they 
have evolved separately from the simpler FAS-like synthases.29 The origins of cis-AT 
PKS arise from genetic replication of modules and subsequent modification of domain 
function. The trans-AT PKSs were genetically assembled by horizontal gene transfer 
between bacteria, resulting in a greater diversity in domain type and order.  
This is exemplified by the 8 commonly found modular architectures for cis-AT PKS, 
whilst over 50 are known for trans-AT PKS.27 Some of the peculiar features of trans-AT 
PKS include: unusual domain order, novel domain types, non-elongating modules, split 
modules, missing or silent domains and trans-acting tailoring domains. These features 
contribute to the remarkable diversity of the compounds isolated from the trans-AT PKS 
that are estimated to constitute 38% of bacterial modular PKS.20,30  
Greater knowledge has been gained about the cis-AT PKS exemplified by the type I 6-
deoxyerythronolide B synthase (DEBS) pathway that produces erythromycin, which has 
been extensively studied to understand the enzymology and structure.21,31,32 More 
recently, back-to-back publications from Skiniotis et al. reported a series of cryo-EM 
structures for a module (PikAIII) from the cis-AT PKS that produces pikromycin.33,34 The 
authors trapped multiple conformations during chain extension and reductive processing 
revealing the mobility of the ACP and conformational change required to achieve precise 
processing and directionality along the PKS.  
In contrast, the trans-AT PKSs have been less well characterised structurally. In 2014, a 
solution-state SAXS structure along with homology modelling and computational 




This work was the first on an entire module from a trans-AT PKS and showed the overall 
conformation of the homo-dimeric module.  
The small ACPs located within each module of the PKS are vital for correct fidelity of 
the assembly-line and must be post-translationally modified to convert the inactive apo-
ACP into the activated holo-ACP. This requires the transfer of a phosphopantetheine 
(Ppant) arm onto a highly conserved serine residue at the base of helix II of the ACP 
(Figure 3). This 20 Å prosthetic arm bears a pendant thiol on to which growing acyl chain 
and extender building blocks are covalently attached via a thioester linkage. The ACP 
transfers the biosynthetic cargo to each catalytic domain for loading, chain extension and 
β-keto processing in a controlled and precise manner.  
 
Figure 3 Actinorhodin ACP from S. coelicolor (pdb: 2k0y) with the conserved serine at the base of helix II in red.  
1.4 β-Branching pathway 
β-alkylation of the polyketide chain is less common than α-alkylation and requires attack 
of an alkyl nucleophile at the electrophilic β-position. Early isotopic feeding studies 
revealed C-2 of acetate as the origin for β-methyls in both mupirocin and 
virginiamycin.36,37 Subsequent gene cluster analysis for polyketides bearing a β-methyl 
branch highlighted a conserved cassette of enzymes likely to facilitate the introduction of 
the alkyl branch. This cassette was termed a 3-hydroxy-3-methylglutaryl CoA-synthase 
(HCS) cassette, although this name may be used interchangeably with an HMGS cassette. 
Since these early reports, many compounds possessing β-branches have been reported 






Figure 4 Examples of polyketides containing β-branches from cis-AT (*) and trans-AT PKS. The green dot shows 




β-branching is most commonly observed in trans-AT PKS pathways, although several 
notable cis-AT polyketides exhibit β-branches, such as curacin and jamaicamide.38 In 
both systems, they arise through the interaction of an HCS cassette with a β-ketothioester 
biosynthetic intermediate bound to a modular acceptor ACP (ACPA). The minimal 
cassette contains a free-standing donor ACP (ACPD), a KS lacking the conserved cysteine 
residue required for condensation (KS0) and a 3-hydroxy-3-methylglutaryl synthase 
(HMGS). Two enoyl CoA hydratase (ECH) domains that belong to the crotonase 
superfamily (CS) of enzymes complete the standard set of five enzymes. However, 
additional tailoring domains may also be present and influence the chemical moiety 
introduced by the cassette.  
 
Scheme 5 Mechanism for the incorporation of an endo-β-methyl 6 or exo-β-methyl 7 branch by an HCS cassette. 
Colour coding is used to indicate domain type and is used consistently throughout this thesis.  
The mechanism of β-branching in the bacillaene biosynthetic pathway was elucidated by 
Calderone and co-workers using biochemical assays and mass spectrometry.39 Malonyl 
CoA loads the free-standing ACPD to give Mal-ACPD 1 which is then decarboxylated by 
KS0 to give Ac-ACPD 2 (Scheme 5). The acetyl group is then transferred to the active site 
cysteine of the HMGS, deprotonated at the α-carbon, and the resulting enolate attacks the 
β-ketone of a β-ketothioester 3 bound to ACPA in an aldol reaction. The HMGS is 




pathway. Consistent with the formation of S-HMG-CoA in mevalonate-dependant 
isoprene biosynthesis, S-HMG-ACPA is the product of the condensation.
40–42 Dehydration 
by ECH1 gives MG-ACPA 5 and decarboxylation by ECH2 furnishes an unsaturated β-
branched 6 polyketide.  
The most common isomer produced by an HCS cassette is an α,β-unsaturated β-branch 
(endo-β-methyl, 6) with the tri-substituted endo double bond arising from the 
reprotonation of the C-4 carbon of 8 by ECH2. The alkene product is often characterised 
by UV spectroscopy for the α,β-unsaturated thioester chromophore.39,43 Decarboxylation 
and reprotonation at C-2 of 8 by an ECH2 domain gives rise to the β,γ-unsaturated β-
branch (exo-β-methyl, 7) and has been characterised in the formation of the vinylchloride 
moiety in jamaicamide.44,45 The endo-β-methyl and exo-β-methyl nomenclature is used 
throughout this thesis to indicate the position of unsaturation in β-branched polyketides.  
 
Scheme 6 Mechanism of mevalonate-dependant isoprene biosynthesis, a pathway with shared mechanistic features to 
polyketide β-branching.  
Comparisons may be drawn between polyketide β-branching and mevalonate-dependent 
isoprenoid biosynthesis from primary metabolism (Scheme 6).38,42,46 In this pathway Ac-
CoA 9 and Acac-CoA 10 form S-HMG-CoA 11 in an aldol condensation catalysed by 
HMG-CoA synthase (HMGCS), a homolog of HMGS. HMG-CoA is then reduced by 




primary alcohol is doubly phosphorylated by mevalonate kinase (MK) and 
phosphomevalonate kinase (PMK) to give 13. Mevalonate diphosphate decarboxylase 
(MDD) activates the tertiary alcohol prior to a decarboxylative elimination to produce 
isopentyl pyrophosphate 14. Isopentyl pyrophosphate isomerase (IPI) catalyses the 
isomerism to dimethylallyl pyrophosphate 15. These two simple 5-carbon building blocks 
are utilised in the biosynthesis of terpenes.47,48  
A wide range of alternative processing has been identified and characterised for 
polyketide β-branching and a summary of all known β-branches, as of January 2019, is 
shown in Scheme 7. The most common pattern of branching is the introduction of a single 
β-branch (mupirocin) or two identical β-branches (corallopyronin). However, there are 
examples of compounds that contain different β-branches, which require PKS selectivity 
to ensure fidelity of β-branching, for example gladiolin, phormidolide and kalimantacin.  
 
Scheme 7 All β-methyl branches reported in the literature and examples of natural products that incorporate each 




The role of ACPs during β-branching 
The mechanism of β-branching is well characterised and the diversity of β-branching 
architecture demonstrates the control required to prevent aberrant modifications. The key 
to achieving selectivity is through the delivery of the correct substrate to each catalytic 
domain by the ACP. ACPA is required to interact with the adjacent KS domains of the 
modular PKS, as well as the trans-acting AT, HCS cassette (HMGS/ECH1/ECH2) and 
additional tailoring enzymes. ACPD on the other hand, must only interact with the HMGS, 
placing a stricter requirement for recognition. Phylogenetic analysis shows that ACPA and 
ACPD clade separately from each other.
49 Through co-crystallisation of ACPD (CurB) and 
HMGS (CurD) from the curacin pathway, the charge and shape complementarity of ACPD 
arising from an unusual helix III position has been shown.41 The affinity of HMGS for 
ACPD was higher than ACPA and coupled with the presence of two ACPD/HMGS pairs 
that install different β-branches in the biosynthesis of myxovirescin,50 the donation of the 
correct substrate by ACPD is key to achieving precise β-branching.  
ACPA may be distinguished from other PKS ACPs by a conserved tryptophan positioned 
six residues after the serine for Ppant attachment (GxDSxxxxxW).51 The burial of this 
tryptophan creates a hydrophobic core that distinctively presents helix II and III for 
interaction with the HMGS. Non-branching PKS modules normally contain a single ACP 
and cryo-EM structures of a whole module from pikromycin biosynthesis elegantly 
showed the architecture and movement of the ACP to the modular catalytic domains.33,34 
However, β-branching modules may contain between 1 to 3 copies of ACPA. Tandem 
ACPs in the mupirocin gene cluster have been shown in vivo to increase the flux through 
the pathway at a rate-limiting, in-trans biosynthetic step.52 This view was reinforced by 
an NMR structure of the di-domain ACPA from mupirocin that showed two, independent 
domains that were predicted to function in parallel.51 Studies on the curacin biosynthetic 
pathway demonstrated in vitro an increased efficiency with tandem ACPs, however, some 
synergistic interaction of the triplet domain was also observed.53 Recently, Kim et al. used 
genetic engineering of the DEBS modular PKS to install a module containing a triplet 
ACP compared to a single ACP in the wild-type. A 2.5x increase in production was 
observed, further suggesting that increasing ACP concentration results in higher flux and 






Canonical β-branching uses a full 5-enzyme cassette to produce endo-β-methyl branches, 
however, a range of β-branches have been reported. Their biosynthesis may rely on 
modified (ECH2), absent (ECH2) or additional (ER) domains. Smith et al. have 
undertaken extensive work on the HCS cassettes from the related cis-AT polyketides 
curacin and jamaicamide (Scheme 8). They initially reported the coupling of the 
ECH1/ECH2 catalysed steps from the curacin pathway to furnish an endo-β-methyl 
branch.40 The crystal structure of CurF ECH2 was then reported along with a proposed 
mechanism for the formation of the endo-β-methyl branch (Scheme 9).55 The preference 
of CurF ECH2 for ACP-bound intermediates over CoA-bound intermediates was also 
highlighted.  
 
Scheme 8 β-branching pathway in the related cis-AT PKS compounds curacin and jamaicamide. Following ECH1-
catalysed dehydration, the pathways diverge to form a chlorinated endo-β-methyl (curacin) that is subsequently cyclised 
to a cyclopropane ring, and an exo-β-methyl (jamaicamide) catalysed by ECH2 domains CurF and JamJ respectively. 
The pink ECH2 annotation refers to a modular configuration of the domain.  
A key publication in 2009 highlighted the divergence between the related biosynthetic 
pathways of curacin and jamaicamide.45 In curacin, following formation of an endo-β-
methyl branch, a modified ER downstream of ECH2 catalyses cyclopropane formation of 
chlorinated intermediate 18 to give 19 (Scheme 8). In jamaicamide, the product of ECH2 
decarboxylation is exo-vinyl chloride 20 that results from C-2 reprotonation. The identity 
of the two β-branches was confirmed by hydrolysis of ACP-bound products as amides, 





Scheme 9 Mechanistic proposal for the formation of an endo-β-methyl by CurF ECH2. His240 deprotonates the 
carboxylic acid, followed by the loss of CO2 and reprotonation by Lys86. Ala78 and Gly118 stabilise the enolate in 
an oxyanion hole.   
Pederin and a series of structurally related compounds that each contain an exo-β-methyl 
branch have been reported.44,56–59 The exo-β-methyl branch is installed by an HCS 
cassette in which the only ECH2 domain is immobilised adjacent to the ACPA as part of 
the modular PKS (Figure 5A). Although not proven, the likely mechanism for the 
formation of the exo-β-methyl is through ECH2-catalysed decarboxylation and 
subsequent C-2 reprotonation akin to jamaicamide biosynthesis. Spliceostatin and 
thailanstatin are additional compounds that from an exo-β-methyl branch with a single, 
modular ECH2 domain, which undergo subsequent oxidation to install an epoxide moiety 
(Figure 5B).60,61 Exo-β-methyl branch installation is discussed in more detail in 
Section 2.1.1.  
 
Figure 5 The formation of exo-β-methyl branches by single, modular ECH2 domains. β-branching ACPA are labelled 
(*). A) The shared modular architecture of pederin and the related compounds onnamide, diaphorin, nosperin and 
psymberin. B) Epoxidation of an exo-β-methyl by a flavin-dependent monooxygenase (Ox) results in epoxide moieties 




Installation of an endo-β-methyl branch generates an α,β-unsaturated thioester that may 
be reduced to the saturated alkyl chain by an ER. In patellazole C biosynthesis, a 
saturated-β-methyl is incorporated by an unusual HCS cassette lacking a trans-acting 
ADPD (Figure 6).
62 The modular PKS PtzD contains a di-domain β-branching ACPA but 
also a candidate for ACPD located at the C-terminus of the polypeptide. This ACP showed 
homology to PedN, the free-standing ACPD from the pederin gene cluster, providing a 
rare example of an in-cis ACPD. PtzQ is a trans-acting ER domain that is hypothesised to 
carry out the reduction of the endo-β-methyl to produce the sat.-β-methyl branch.  
 
Figure 6 Patellazole C contains a sat.-β-methyl branch. PtzGHIJ form the trans-acting HCS cassette, however, ACPD 
was not identified as a free-standing domain. A candidate, with homology to PedN from the pederin gene cluster, was 
identified at the C-terminus of PtzD. The trans-acting ER PtzQ is hypothesised to perform the reduction. β-branching 
ACPA are labelled (*).  
Whilst virtually all β-branching pathways involve an ECH2 decarboxylation, bryostatin 
and bongkrekic acid are two polyketides that lack this enzymatic step. A recent 
publication showed that in bryostatin biosynthesis, the α,β-unsaturated (relative to the 
thioester) intermediate 21 was produced as the result of ECH1-catalysed dehydration 
which was then specifically O-methylated to give 22 (Scheme 10A).63 It is hypothesised 
that a downstream ER may catalyse the isomerism to 23 prior to tetrahydropyran ring 
formation by an unknown mechanism. Similarities in β-branching structure have been 
drawn between bryostatin and bongkrekic acid, which contains two β-branches; an endo-
β-methyl and a non-decarboxylated acrylate 24 as confirmed by isotopic feeding studies 




mechanism for the selective installation of each β-branch.65 Bongkrekic acid is an 
interesting example of divergence of pathways from a common intermediate to introduce 
the two different β-branches within one biosynthetic assembly line. The lack of off-
loading domain from the modular PKS led to a currently unproven and unique hypothesis 
of concurrent β-branching and off-loading.  
 
Scheme 10 Bongkrekic acid and bryostatin contain non-decarboxylated β-branches. A) Generation of O-methylated 
β,γ-unsaturated β-branch (23) by ECH1-catalysed α,β-dehydration, O-methylation and isomerism by a modified ER 
domain. B) Differential formation of an endo-β-methyl and non-decarboxylated β-branch (24) by the HCS cassette in 
bongkrekic acid biosynthesis is less well understood. The identity of ACPD has not been reported.  
In some cases, multiple, different β-branches may be incorporated into the same 
compound requiring the HCS cassette and tailoring enzymes to selectively install each β-
branch with high fidelity. Thus, the HCS cassette must only interact with tryptophan-
flagged β-branching ACPA and the correct branch must be introduced at each ACPA. The 
related compounds gladiolin and etnangien share many structural features but differ in 





Figure 7 A) Gladiolin contains an endo-β-methyl (C-25) and sat.-β-methyl branch (C-35). The trans-acting HCS 
cassette contains two pairs of ECH1/ECH2 domains and an in-cis ER located in module 1 of GbnD1 to reduce the α,β-
unsaturated β-branch. B) Etnangien contains two endo-β-methyl branches (C-4 and C-18) that are installed by a single, 
HCS cassette. β-branching ACPA are labelled (*).  
Etnangien contains two endo-β-methyl branches (C-4 and C-18) incorporated by a 5-
enzyme HCS cassette.66 Other than selectively interacting with the β-branching ACPs, 
the cassette shows no discrimination between the two sites of β-methyl incorporation. In 
gladiolin biosynthesis, the gene cluster encodes a trans-acting HCS cassette, that contains 
two sets of ECH1/ECH2 domains, to incorporate an endo-β-methyl (C-25) and sat.-β-
methyl branch (C-35).67 An ER in module 1 of GbnD1 is located at the point of sat.-β-
methyl incorporation to carry out the reduction. The presence of two sets of ECH1/ECH2 
domains led the authors to speculate on whether the modular ER domain places structural 
constraints on the β-branching ACPAs requiring the recruitment of a second set of 
ECH1/ECH2 domains.  
 
Figure 8 Phormidolide contains five β-methyl branches introduced by one trans-acting HCS cassette and tailoring ECH 




Phormidolide contains the greatest number of β-branches in a single compound currently 
reported in the literature, comprising of three endo-β-methyl and two exo-β-methyl 
branches (Figure 8).68 An HCS cassette, as well as modular ECH domains adjacent to the 
β-branching ACPs, are thought to introduce the different types of β-branch. However, the 
authors state that the role of the modular ECH domains remained unknown.  
One of the most complex β-branching cassettes is found in the gene cluster of 
myxovirescin (Scheme 11).38 The natural product contains two different β-branches: an 
endo-β-methoxymethyl 25 at C-12 arising from hydroxylation (TaH) and O-methylation 
(TaQ) of an endo-β-methyl, and an unusual sat.-β-ethyl branch 27 at C-16 from reduction 
(TaO) of an endo-β-ethyl branch 26. There are two pairs of ACPD/HMGS domains in the 
gene cluster, however, only single copies of KS0, ECH1 and ECH2. In vivo feeding studies 
with labelled precursors established the origin of the C-12 branch to be acetate and the C-
16 branch to be methylmalonyl/propionate.69 In vitro reconstitution of the HCS cassette 
demonstrated two translationally coupled ACPD/HMGS pairs whereby TaB/TaC 
selectively introduce the C-12 branch and TaE/TaF the C-16 branch,43 which was 
supported by in vivo gene deletions.70  
 
Scheme 11 Incorporation of methyl (green) and ethyl (pink) endo-β-branches in the biosynthesis of myxovirescin. The 
gene cluster encodes two ACP/HMGS pairs that select and react either acetyl-ACP (TaB/TaC) or propionyl-ACP 
(TaE/TaF) with the modular β-ketothioester. Dehydration and decarboxylation are carried out by the same ECH1/ECH2 
pair (TaX/TaY). TaH (oxidation) and TaQ (O-methylation) produce the endo-β-methoxymethyl at C-12 25 and TaO 




Furthermore, a ΔTaF mutant produced a compound with endo-β-methyl branches at C-
12 and C-16, showing TaF can complement for TaC.50 However, the opposite 
complementation is not observed, and these results were further supported in vitro 
whereby TaC may react with both ACPAs, whilst TaF only reacts with its cognate ACPA. 
Overall, two distinct sets of enzymatic machinery are utilised in the formation of different 
β-branches, with the shared steps occurring only once the HMGS-catalysed condensation 
has occurred.  
β-alkylation by Michael addition 
β-alkylation of polyketides may also be achieved through a mechanistically different 
pathway.71 In the biosynthesis of rhizoxin, a two-carbon unit is introduced at the β-
position that then cyclises to form a δ-lactone (Scheme 12).72 An unprecedented modular 
architecture (KS-B-ACP) was observed with a newly defined branching domain (B). In 
vitro reconstitution of the module, X-ray crystallography, protein cross-linking and stable 
isotope studies were used to elucidate the mechanism of branching. An ACP-bound 
malonyl group 29 is decarboxylated and attacks the β-position of a KS-bound α,β-
unsaturated thioester 28. The C-5 hydroxyl of 30 subsequently attacks the KS-thioester 
to liberate the δ-lactone product 31.  
 
Scheme 12 Bacterial polyketide rhizoxin contains an unusual two-carbon β-branch. A) The mechanism for the 
formation of the δ-lactone by Michael addition onto the unsaturated α,β-thioester followed by cyclisation. B) The amino 
variant in the synthesis of lactams. C) The formation of pharmacologically-important glutarimide moiety by attack of 




Investigation into the scope of the reaction revealed amine 32 and carboxamide 34 
nucleophiles could be used to synthesise lactam 33 and glutarimide analogues 35.73 
Genetic analysis of the glutarimide-containing polyketides revealed a homolog to the B-
domain, that was labelled an X-domain. A range of chimeras were constructed and used 
to demonstrate complementation between B/X-domains and the structural rather than 
catalytic role they play in the formation of β-branched polyketides.74  
1.5 Kalimantacin 
The kalimantacins were first isolated from Alcaligenes sp. YL-02632S by Kamigiri and 
co-workers in 1996 (Figure 9).75 The major product isolated was kalimantacin A which 
contains an E,Z-diene and C-26 methyl group. Minor compounds kalimantacin B 
containing an E,E-diene and kalimantacin C lacking the C-26 methyl were also isolated. 
The bio-activity of these compounds was reported and kalimantacin A was shown to have 
antibiotic activity against S. aureus and S. epidermis.76  
 
Figure 9 Structure of kalimantacin A-C originally isolated from Alcaligenes sp. YL-02632S. Batumin from 
Pseudomonas batumici and kalimantacin from Pseudomonas fluorescens strain BCCM_ID9359 have subsequently 
been shown to be kalimantacin A.  
In 2000, Smirnov et al. reported the isolation of batumin from Pseudomonas batumici, 
harvested from the Black Sea, that was reported to have the same molecular structure as 
kalimantacin A.77 No further reports were made on these or similar compounds until 2010 
when Lavigne et al. reported the isolation and characterisation of a compound from 
Pseudomonas fluorescens strain BCCM_ID9359.78 The structure elucidated by HRMS 
and NMR corresponded to the structure of kalimantacin A and batumin. Due to the 
presence of 5 unknown stereocenters it was not clear whether kalimantacin A and batumin 
were the same compound. Each of the compounds isolated showed strong, selective anti-
bacterial properties against staphylococci species, including multi-drug resistant strains,75 




Lavigne et al. identified the gene cluster responsible for the production of kalimantacin 
from P. fluorescens through a combination of BLAST searches and gene knock-out 
experiments.78 Sequence analysis identified three large open reading frames (ORF) and a 
series of smaller ORFs encoding a type I PKS/NRPS hybrid synthase and tailoring 
enzymes. From the module and domain analysis it was determined that ACPs were loaded 
by free-standing AT domains, thus falling into the trans-AT PKS classification. A 
subsequent comparison of the gene clusters from P. fluorescens and P. batumici revealed 
they were 100% identical and that both kalimantacin A and batumin are the same 
compound. The name kalimantacin is used throughout this thesis.80  
The biosynthetic pathway presented in Figure 10 includes several updates compared to 
the original publication.78 Firstly, BatH and BatJ were both labelled as AT domains with 
the proposal that BatH transfers the starting acetyl unit and BatJ loads malonyl extender 
units. However, recent work has shown that BatH is an acyl hydrolase (AH) thought to 
be involved in proof-reading.81 Whilst AH domains are related to AT domains, they clade 
separately and their hydrolytic activity has been determined in vitro. Secondly, Keatinge-
Clay et al. proposed a paradigm-shift in the annotation of modules within trans-AT 
PKS.82 Classically, the ACP is used to define the C-terminal domain of each module, with 
the KS and tailoring domains upstream of the ACP. However, recent work has established 
that trans-AT PKS evolved from horizontal gene transfer and that there is a co-evolution 
of the ACP with the downstream KS domain.29,83 Keatinge-Clay presented a 
comprehensive analysis of modular ACPs and demonstrated that those from a common 
modular architecture clade together. As a result, it has been proposed that the ACP 
domain should sit central within a module and that the KS domain should sit as the C-
terminal domain.82 In addition, KS substrate selectivity was shown by Jenner and co-
workers who used intact protein mass spectrometry and a range of short polyketide-like 
mimics to investigate the transfer from upstream ACP to downstream KS. They 
concluded that KS domains clade according to the functionalisation of the substrate 
received from the upstream ACP.84 This results in an updated module numbering and the 
biosynthetic pathway shown in Figure 10 uses this new nomenclature. Finally, the 
original analysis and publication by Lavigne et al. did not identify an ECH domain located 
downstream of the di-domain ACP3/4 within Bat3.78 This additional domain is discussed 






Figure 10 Biosynthetic pathway for kalimantacin A. The gene cluster encodes Bat1-3 which are large ORFs that 
constitute a type I trans-AT PKS. Trans-acting domains include: BatJ (AT) that loads the modular ACPs with 
malonyl-CoA for chain extension, BatF (carbamoyl transferase) and BatM (short-chain dehydrogenase) that 





In the biosynthesis of kalimantacin, 11 malonyl derived building blocks are incorporated 
into the backbone by the type I PKS, along with a glycine incorporated by an NRPS 
module. A series of trans-acting enzymes further modify the backbone. Firstly, the fully 
reduced carbon backbone introduced in module 10 is achieved by the action of a trans-
acting ER domain (Bat K). Following cleavage from the PKS to give 36, BatF installs the 
carbamoyl functionality to the alcohol at C-27 to give 37 and BatM oxidises the C-17 
alcohol to give kalimantacin A. Additionally, a series of four β-methyl branches, 
comprising three different types are incorporated in the polyketide structure by a trans-
acting HCS cassette. The first branch is incorporated at Bat2 module 6 where a sat.-β-
methyl group is introduced at C-15. The remaining three branches are installed 
consecutively in Bat3 modules 11, 12 and 13; an exo-β-methyl, sat-β-methyl and an endo-
β-methyl respectively. Lavigne does not elude as to how the double bond isomers arise 
or how the reduction to produce the saturated methyl group occurs.78  
Working in our lab, Dr Shushan Gao fed the producing P. fluorescens strain with [1,2-
13C2]-acetate and determined the isotopic incorporation into kalimantacin A (Figure 11). 
Consistent with the proposed biosynthetic pathway, 13C NMR analysis revealed 11 intact 
acetate units in the linear backbone, along with four β-methyl branches at C-3, C-5, C-7 
and C-15 derived from [2-13C] of the acetate. In a separate feeding experiment, L-[methyl-
13C]-methionine was shown to be the source of the C-29 α-methyl branch. The absence 
of 13C-enrichment at C-19 and C-20 was consistent with the incorporation of glycine by 
the NRPS module.  
 
Figure 11 Isotopic labelling pattern for kalimantacin A obtained by feeding [1,2-13C2]-acetate and L-[methyl-13C]-
methionine to the wild-type P. fluorescens strain.  
17-Hydroxy kalimantacin 37 was isolated from the knock-out strain ΔBatM arising from 
the lack of final oxidation (Figure 12). The ΔBatF strain is unable to catalyse 
carbamoylation and resulted in the isolation of two kalimantacin analogues; 17-hydroxy-
27-descarbamoyl kalimantacin 36 and 27-descarbamoyl kalimantacin 38. The loss of the 




hydroxylated compounds showed a complete loss of activity, demonstrating these final 
post-PKS tailoring steps are vital to producing the active compound.78  
 
Figure 12 Bioactivity (MIC) of kalimantacin A and its analogues (36-38) isolated from WT and two knock-out strains 
(ΔBatM and ΔBatF) against S. aureus ATCC6538.  
The kalimantacin gene cluster encodes two self-protection mechanisms: secretion of an 
inactive precursor prior to activation upon export and the presence of a FabI isoform. 
Kalimantacin is an inhibitor of FabI, the ER domain from type II fatty acid biosynthesis 
in bacteria.85,86 The proposed mechanism of action has been debated in the literature, 
initiated by Klochko and co-workers who proposed that kalimantacin, analogous to 
mupirocin, acts as an inhibitor of aminoacyl tRNA synthetase.80 This work was based on 
in silico modelling and an apparent similarity between the two molecular structures. This 
hypothesis was strongly rejected by O’Neill et al. who elegantly demonstrated the in vivo 
antibiotic target of activity of kalimantacin and mupirocin to be fatty acid and protein 
biosynthesis respectively.87 This work supports the original hypothesis proposed by 
Lavigne et al.88 The kalimantacin-producing P. fluorescens strain contains a FabI isoform 
(BatG) which can complement for FabI and confers full resistance to the producing 
bacteria but is non-essential for kalimantacin production. There has been much debate in 
the literature about the validity of FASII inhibitors in some strains, however, it remains a 
valid target for the clinically relevant Staphylococcus aureus.89–91  
Export-coupled activation of an inactive intermediate prior to conversion to the toxic 




and hydroxyl oxidation steps to produce the active antibiotic. Carbamoylation as the final, 
activation step has been shown for several secondary metabolites, including novobiocin 
that was 100-fold less active without the carbamoylation.93,94 An additional advantage of 
the final, activating C-17 oxidation is its reversal of the reduction that takes place in Bat 2 
module 5. A subtle difference between more common inactivation mechanisms (O-
phosphorylation and N-acetylation) is displayed by this reaction. Resistance often occurs 
through horizontal gene transfer of antibiotic-inactivating enzymes.95 However, the 
inactive 17-hydroxyl is introduced by a modular PKS, a step that is difficult to acquire 
through gene transfer, and reduces the chance of resistance.  
In 2017, researchers in our lab reported the elucidation of the five previously unassigned 
stereocenters of kalimantacin A and the sixth stereocenter of the diol precursor 
(Scheme 13).96–98 This was achieved through isolation of 17-hydroxy kalimantacin 37 
and degradation by ozonolysis and Grubbs metathesis to fragments 39 and 40. The total 
synthesis of both fragments was completed and their data compared with the 
corresponding natural product fragments to methodically determine each stereocenter.  
 





1.6 Project Aims 
Understanding the mechanisms and selectivity of enzymatic steps within biosynthetic 
pathways may allow for the rational engineering to produce novel compounds. The 
elucidation of the relative and absolute stereochemistry of kalimantacin laid the 
foundations for further work on its biosynthetic pathway to be undertaken. Kalimantacin 
contains four β-methyl branches that consist of three different types: an endo-β-methyl, 
an exo-β-methyl and two saturated β-methyl branches. This unprecedented arrangement 
of polyketide β-branches presented an opportunity to study the selectivity required by the 
biosynthetic machinery to incorporate multiple, different β-methyl branches. Our aim was 
to understand the selectivity of the HCS cassette in the consecutive installation of an exo-
β-methyl at C-7, a saturated β-methyl at C-5 and an endo-β-methyl at C-3. This would 
require the synergy of synthetic chemistry for the preparation of biosynthetic mimics, 
biochemical methods for the expression, purification and characterisation of the HCS 
cassette and tailoring proteins, and the development of analytical techniques to monitor 
the enzymatic reactions.  
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2 Kalimantacin β-Branching Pathway 
2.1 In Vitro Reconstitution of the HCS Cassette 
At the outset of this project it was unclear how a single trans-acting HCS cassette in the 
kalimantacin biosynthetic pathway selectively installed the four β-branches. Whilst each 
type of β-branch has been reported in the literature, there are few compounds that include 
multiple, different β-branches that would require biosynthetic control, and none that 
contain three different types of β-branch.  
2.1.1 Identification of a missing mECH domain 
Investigations began with a BLAST search of BatE, the trans-acting ECH2 from the HCS 
cassette, and a hit was identified for Bat3 with 53.9% amino acid sequence identity to 
BatE (Figure 13A). Bat3 is the third and largest ORF of the kalimantacin type I PKS that 
contains four elongating modules (9-12) and an off-loading module (13). The original 
assignment of Bat3 by Lavigne et al. did not annotate a domain that would be expected 
to show similarity to BatE.78 However, re-analysis of the 328 amino acid sequence linking 
ACP4 and the downstream KS identified a potential modular ECH (mECH) domain.  
 
Figure 13 A) Extract from a BLAST search using BatE as a search query. An unexpected result was the sequence 
similarity to Bat3 which has previously not had an assigned ECH domain. B) Domain order of the third large ORF Bat3 
as assigned by Lavigne et al.78 The updated domain order to include the previously unassigned ECH domain with the 
linker length between catalytic domains shown in blue.  
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Secondary structure prediction (JPred4.0) and homology modelling using the I-
Tasser/Phyre2 servers also suggested structural similarity between BatE and mECH. The 
two domains, along with BatD, belong to the enoyl-CoA hydratase (ECH) subgroup of 
the crotonase superfamily (CS) of enzymes.99–102 Despite low sequence homology, this 
superfamily share a common structural scaffold, binding modes and mechanistic elements 
to catalyse a wide range of reactions. These include (de)hydration (41, BatD), 
(de)carboxylation (42, BatE), C-C/C-X bond formation (43-44), alkene/diene isomerism 
(45) and hydrolysis (46) (Scheme 14).99,100 The shared feature in each mechanism is the 
formation of an oxyanion hole (OAH), in which two backbone NHs hydrogen bond to the 
carbonyl oxygen. Most commonly, crotonase reactions utilise thioester-bound CoA or 
ACP substrates resulting in the activation of a carbonyl group by polarisation of the C=O 
double bond. The electrophilic carbon atom is now more susceptible to nucleophilic 
attack or enolisation. The resulting enolate/oxyanion intermediate is also stabilised by the 
OAH, analogous to the stabilisation seen in the serine and cysteine proteases.103,104  
 
Scheme 14 The range of reactions catalysed by the crotonase superfamily. CoA-thioester bound substrates are most 
common and the shared feature of catalysis is stabilisation of an enolate intermediate in an oxyanion hole (blue). 
Figure adapted from Schofield et al.99  
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Considering the close homology of mECH with BatE and other well characterised ECH2 
domains from polyketide β-branching pathways, it is possible that mECH is also a 
decarboxylase. Its position in the modular PKS after ACP4 and before the elongating KS 
of the downstream module, suggests that it plays a role in the formation of the exo-β-
methyl branch. As introduced earlier, the cis-AT PKS of jamaicamide incorporates an 
exo-β-methyl arising from decarboxylation of MG-ACP and C-2 reprotonation of 
intermediate 47 (Scheme 15).  
 
Scheme 15 ECH2-catalysed formation of endo- and exo-β-methyl branches. Enolate 47 is stabilised in an OAH (blue) 
and selective reprotonation at the C-2 or C-4 carbon results in formation of the endo- or exo-β-branch respectively.  
Analysis of the modular PKS of trans-AT polyketides that possess HCS cassette derived 
exo-β-methyl branches revealed a common modular architecture whereby one or two 
ECH domains lie before the β-branching ACPs (Figure 14). Interestingly, the ACPs and 
ECH domain in the kalimantacin ORF are reversed in order, however, due to the many 
nuances associated with the 3D architecture of the modular PKS it is not thought to be 
significant in determining the β-branching outcome. The common architecture makes it 
likely that these ECH domains play a key role in exo-β-methyl formation and the 
assembly lines were probed further.  
Inspection of the HCS cassette of pederin and the related compounds showed that they 
all contained in-cis ECH2 domains, with the same general architecture (KS-ECH-ECH-
ACP).20,27 Most of the pathways are annotated with two modular ECH domains, however, 
closer inspection shows that the N-terminal domains are truncated, show low sequence 
homology to other ECH2 domains and are likely to be non-functional. This would mean 
there is only a single, full length ECH2 domain in each of the gene clusters. The number 
of ACPs varies between 1 to 3 copies, which is not uncommon for β- branching ACPs.  




Figure 14 Modular architecture for the introduction of exo-β-methyl branches: kalimantacin (A), pederin-related 
compounds (B) and additional exo-β-methyl branch compounds (C). The ECH di-domain in the pederin-related 
compounds and phormidolide possess an N-terminal domain (underlined) that is often truncated and possibly non-
functional. Domain length is annotated for ECH domains except DipP for which the length was not determined in the 
literature and sequence alignment was inconclusive for boundary assignment. ECH2 domains shown in navy blue are 
trans-acting and those in pink are modular. D) Structures of the exo-β-methyl containing compounds. The exo-β-methyl 
in spliceostatin is subsequently epoxidised to give the final product.  
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Spliceostatin is another example that contains modular ECH domains and a trans-acting 
HCS cassette does not possess a free-standing ECH2. Once again, the modular ECH must 
act in-cis to produce the exo-β-methyl branch.105 In these examples, the presence of a 
single ECH2 domain suggests the exo-β-methyl branch must be derived from a modular 
ECH2-catalysed decarboxylation followed by C-2 reprotonation, analogous to the 
mechanistic steps reported for jamaicamide.  
The gene cluster that produces phormidolide encodes the incorporation of five β-methyl 
branches; two exo-β-methyls and three endo-β-methyls.68 A full trans-acting HCS 
cassette is present in addition to modular ECH domains (PhmE and PhmI) at the point of 
exo-β-methyl incorporation. Both of these modular ECH domains show sequence 
similarity to characterised ECH2 (decarboxylase) domains but their biochemical role was 
not confirmed by the authors.68 However, it is striking that the modular ECH domains are 
only present at the point of exo-β-methyl incorporation suggesting a common role in the 
formation of this moiety. This may be through decarboxylation/C-2 reprotonation, or 
alternatively isomerism of an endo-β-methyl branch formed by the trans-acting HCS 
cassette. Other than kalimantacin, this is the only example of a gene cluster that contains 
multiple ECH2 domains and, due to the diverse range of catalysis of the CS, it is possible 
that the modular ECH may catalyse either decarboxylation or isomerism.  
Consideration of these previously characterised pathways led to the following hypothesis 
for the incorporation of the four β-methyl branches in kalimantacin. All four branches 
share the same BatC-catalysed condensation step between Ac-BatA and a modular ACPA-
bound β-ketothioester to form HMG-ACPA (Scheme 16). BatD-catalysed dehydration 
gives MG-ACPA, followed by decarboxylation and C-4 reprotonation by BatE furnishes 
three endo-β-methyl branches (C-3, C-5 and C-15, kalimantacin numbering) as the 
modular architecture is identical for the domains associated with this incorporation. The 
two sat.-β-methyl branches (C-5 and C-15) arise from the subsequent selective reduction 
of the endo-β-methyl branches by the trans-acting ER BatK, which is likely to specifically 
recognise the cognate ACPs. Finally, the exo-β-methyl (C-7, kalimantacin numbering) 
may arise from one of two pathways. Firstly, BatD and BatE produce an endo-β-methyl 
branch which is then isomerised from the conjugated alkene to the exo-β-methyl by 
mECH (Scheme 16, pathway B). Alternatively, following BatD-catalysed dehydration 
mECH intercepts MG-ACPA and catalyses decarboxylation and reprotonation at the C-2 
position to give the exo-β-methyl (Scheme 16, pathway A).  




Scheme 16 Proposed mechanism for the formation of β-methyl branches in the kalimantacin biosynthetic pathway. 
The exo-β-methyl may be made via one of two routes. Route A: Decarboxylation and C-2 reprotonation of MG-ACP 
by mECH. Route B: mECH-catalysed isomerism of an endo-β-methyl.  
Sequence analysis and homology modelling did not reveal any information about the 
likelihood of the mECH domain to catalyse either of these reactions. The crotonase 
superfamily of enzymes catalyse a wide array of reactions, including both 
decarboxylation and isomerism and are notoriously difficult to functionally classify based 
on sequence or 3D architecture.106,107 Single point mutations within enoyl-CoA isomerase 
(ECI) domains led to a change of function from isomerism to hydration, showing the 
subtlety in structure and function.108  
Early literature reports for the isolation of exo-β-methyl containing natural products 
speculated that the moiety may result from isomerism of an endo-β-methyl.109 This has 
since been shown not to be the case in jamaicamide and C-4 reprotonation must apply to 
the pederin-like compounds with only one ECH2 domain in the gene cluster.
45 However, 
uncertainty still exists for the more complex systems, kalimantacin and phormidolide, 
that exhibit a full trans-acting HCS cassette as well as modular ECH domains that result 
in the incorporation of endo- and exo-β-methyl branches.  
2.1.2 Purification of HCS cassette and ACPs 
His6-tagged BatA was expressed using a standard procedure, whereby 2 L of LB medium 
were inoculated and grown to OD600 1.0, induced with 250 µM IPTG and incubated for 
16 h at 16 °C. The cells were removed by centrifugation and the soluble fraction purified 
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by Ni2+- affinity chromatography and buffer exchanged into reaction buffer (50 mM Tris, 
100 mM NaCl, pH 8.0). For long-term storage, BatA was desalted into water and 
lyophilised and stored at -80 °C as a white solid. SDS-PAGE and MS were used to 
confirm the protein mass, which was consistent with apo-BatA (Figure 15).  
 
Figure 15 MS and SDS-PAGE analysis of apo-BatA. The second minor species is a Na+ adduct of the desired protein. 
The His-tag was cleaved by TEV protease giving cut-BatA.  
The pET151 expression vector contains a cleavage site (ENLYFQG) between the N-
terminal His-tag and the desired protein sequences that allows for the removal of the His-
tag by Tobacco Etch Virus (TEV) protease. The protease cleaves between glutamine (Q) 
and glycine (G) to remove the 27 amino acid his-tag containing region, leaving only a 
short 6 amino acid tag on the protein of interest (GIDPFT). Throughout this work, both 
cut- and uncut- BatA have been used with no noticeable difference in their behaviour.  
To check the function of BatA, the inactive apo-BatA was converted into holo-BatA. The 
transfer reaction to form a phosphodiester bond to the ACP is catalysed by a 
phosphopantetheinyl transferase enzyme (PPTase) using CoA as the source of the 
phosphopantetheine (Ppant) arm and Mg2+ as a co-factor. This superfamily of enzymes 
has been categorised into group I (AcpS-type) and group II (Sfp-type) PPTases. Helix II 
of the ACP is the key interaction site for both groups of PPTases with the AcpS-type 
interacting through electrostatics, whilst hydrophobic interactions are key for Sfp-type 
PPTases.110,111 AcpS-type PPTases show narrow-range selectivity for ACPs, mainly 
active with type II fatty acid and polyketide ACPs. AcpS from Streptomyces coelicolor 
has been crystallised and its promiscuity in transferring a wide range of CoA thioesters 
demonstrated.112,113 Sfp from Bacillus subtilis is the archetypal type II PPTase and is well 
characterised.114–116 This group of PPTases are highly promiscuous towards both the ACP 
and CoA derivatives and are regularly used during the in vitro reconstitution of 
biosynthetic pathways.110,111,117  




Figure 16 Activation of apo-BatA (9464 Da) by transfer of a Ppant arm from CoA to a conserved serine residue to give 
holo-BatA (9804 Da).  
The conversion of apo- to holo- BatA was investigated using both types of PPTases: E. 
coli AcpS (ecAcpS) which is a type I PPTase, and MupN which is a type II PPTase from 
the mupirocin biosynthetic pathway. MupN has been shown to load both type I and type 
II mupirocin ACPs, so it was anticipated that it would act on ACPs from a non-cognate 
system.118 Upon incubation with CoA, MgCl2 and ecAcpS for 3 hours, apo-BatA did not 
undergo conversion to holo-BatA. However, incubation under the same conditions with 
MupN resulted in the conversion to holo-BatA after only one hour (Figure 16). The 
selectivity for a type II PPTase was expected and allowed for the activation of 
kalimantacin ACPs.  
BatC is the HMGS that transfers acetate from Ac-BatA to a β-ketothioester attached to a 
modular ACPA. Expression and purification using standard conditions yielded a protein 
of the correct mass by SDS-PAGE and MS (Figure 17). The concentrated protein 
(300 µM) was stored at -80 °C and was stable for two years.  
 
Figure 17 MS and SDS-PAGE characterisation of BatC.  
BatD and BatE are both ECH domains that carry out the dehydration (BatD) and 
subsequent decarboxylation (BatE) of the HMG-ACPA intermediate. Both were 
expressed as soluble proteins, purified by Ni2+-chromatography and analysed by SDS-
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PAGE and MS. Interestingly, BatD runs between 25 and 30 kDa by SDS-PAGE, 
however, the MS indicates a mass of 30402 Da, an error of only 2 Da (Figure 18A). BatE 
shows the same characteristic of running at a lower mass by SDS-PAGE, however, the 
mass recorded (31361 Da) was within 2 Da of the expected mass (Figure 18B).  
 
Figure 18 MS and SDS-PAGE analysis of A) BatD and B) BatE.  
Analytical gel filtration using a pre-calibrated column was carried out on both BatD and 
BatE to determine their oligomeric state in solution. The retention time of BatD 
(13.36 mins) and BatE (13.42 mins) suggested both proteins were trimeric in solution. 
This was consistent with the reported association states of the crotonase superfamily that 
have been reported to be trimers or dimers of trimers (Figure 19).100  
Bat3 is the large ORF which interacts with the HCS cassette to introduce the three 
consecutive β-methyl branches in kalimantacin. The di-domain ACP in module 11 
(ACP3/4) bears the substrate for the exo-β-methyl incorporation, ACP5 (module 12) for 
the sat.-β-methyl and ACP6 (module 13) for the endo-β-methyl. Starting with the tandem 
ACP, the gene for ACP3/4 was synthesised and cloned into pET151. The plasmid was 
transformed, a pre-culture grown and used to inoculate LB medium. Following induction 
with 250 µM IPTG and 16 h incubation at 16 °C, the cells were harvested, and the soluble 
fraction purified by Ni2+-affinity chromatography. A protein of the correct molecular 
mass was observed by SDS-PAGE, however, MS analysis revealed that the di-domain 
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ACP had been expressed in the holo form. This suggests that the ACP interacts with 
ACPS from E. coli and cellular CoA to enable PPT transfer.119  
 
Figure 19 S200 analytical gel filtration trace of BatD (13.36 mins) and BatE (13.42 mins) to determine molecular 
weight/oligomeric state. The trimeric moleuclar weight of both BatD and BatE was used.  
This modification was not ideal as the expression of holo-ACP prevents the subsequent 
loading of biosynthetic substrate mimics by transfer of a functionalised Ppant arm. It is 
possible to load ACPs by trans-thioesterification by incubation of holo-ACP with an 
excess of the desired substrate as an N-acetylcysteamine (SNAC) derivative.81 However, 
this is an inefficient and non-specific reaction which may functionalise alternative 
nucleophilic sites on the ACP. There is currently no reliable method for the removal of a 
PPT arm. Work by Burkart and co-workers has identified AcpH from E. coli and 
homologs from other bacterial organisms that hydrolyse the Ppant arm.120 However, the 
characterised proteins do not show the same level of promiscuity as the PPTases and this 
route was not attempted.  
Production of only holo-ACP3/4 was not entirely consistent and initial purifications also 
yielded a mixture of apo/apo-ACP3/4 and holo/holo-ACP3/4. To remove the holo/holo-
ACP3/4, the mixture was treated with 5 µM CuCl2 and purified by size exclusion 
chromatography (Figure 20). The di-sulfide dimer could be separated from apo/apo-
ACP3/4, however, the inefficient purification method resulted in a low yield of the desired 
protein and the method was no longer investigated.  




Figure 20 S75 size exclusion chromatography (SEC) trace separating the disulfide-bridged holo/holo-ACP3/4 dimer 
from apo/apo-ACP3/4 (26612 Da).  
Inspection of the ACP sequences showed a 57% identity (82% similarity) between ACP3 
and ACP4 and it is likely the function of the tandem domain is to increase flux through 
the PKS rather than any fundamental distinction (i.e. to deliver different substrates).52,53 
As a result, they were cloned as two single domain ACPs by point mutation (ACP3) or 
amplification/recombination (ACP4). Both ACPs were grown in LB, induced (250 µM 
IPTG) and incubated for 16 h at 16 °C, which furnished holo-ACP for both constructs. 
There was a significant difference in yield and stability of the obtained protein, with 
ACP3 yielding less than 0.5 mg/L with a tendency to precipitate from solution, whilst 
ACP4 was expressed around 6-7 mg/L. As a result, optimisation of expression was carried 
out only on ACP4, including using smaller flasks, different E. coli expression strains, 
IPTG concentration and expression time.  
Using a standard protocol of inducing with 250 µM IPTG for 16 h gave only holo-ACP4. 
A time course with the same concentration of IPTG showed that after 2 or 4 h only apo-
ACP4 was obtained and by 6 h, a small fraction of holo-ACP4 was observed. Decreasing 
the induction time reduced the protein yield so to compensate for this the concentration 
of IPTG was increased to 1 mM. Overall, the optimal conditions were deemed to be 1 mM 
IPTG induction for 5 h, yielding 7-8 mg/L apo-ACP4 (Figure 21).  




ACP5 and ACP6 were grown in LB medium and induced with 250 µM IPTG for 16 h at 
16 °C. Both proteins were identified in the soluble fraction, purified by Ni2+-affinity 
chromatography and characterised by SDS-PAGE and MS (Figure 22). A single protein 
band consistent with the mass of apo-ACP was identified for both ACP5 and ACP6.  
 
Figure 22 MS and SDS-PAGE characterisation of A) ACP5 and B) ACP6. 
Figure 21 MS analysis of the apo-ACP 
(10699 Da) and holo-ACP4 (11039 Da) arising 
from 16 h induction at 16 °C. A single species 
of apo-ACP4 could be obtained from a 5 h 
induction. SDS-PAGE analysis of apo-ACP4 
purified by Ni2+ affinity chromatography 
showed a single band of the correct mass.  
Kalimantacin β-Branching Pathway 
39 
 
Subsequent cultures were grown with a 16 h induction time that did, however, 
occasionally result in formation of around 20% holo-ACP. ACP6 was poorly expressed 
when induced with 1 mM IPTG for 5 h so 10-12 h evolved as the optimal induction time. 
These results suggested a difference between the PPTase recognition motifs of ACP3/4 
which are phosphopantetheinylated in vivo following an 16 h induction, compared with 
ACP5 and ACP6 which predominantly express as apo-ACP after the same time.  
Following their expression, all ACPs were desalted into reaction buffer and kept at 4 °C 
for short-term storage. Aliquots of ACP4 and ACP5 in reaction buffer were stored at -
20 °C and gently thawed on ice prior to assays. However, ACP6 was not stable to freeze-
thaw conditions and precipitated after thawing on ice. As a result, ACP6 had to be freshly 
purified from a cell pellet prior to conducting assays.  
2.1.3 Purification of tailoring domains 
Module 10 catalyses a full round of ketoreduction, dehydration and enoyl reduction but 
lacks a dedicated cis-ER. BatK is hypothesised to act as a trans-ER which is recruited to 
this module to reduce the alkene moiety (Figure 23). It is also hypothesised that BatK acts 
on an endo-β-methyl branch attached to the ACP of module 6 and 12 to give the sat.-β-
methyl branch. These three alkene reductions are the only examples in the kalimantacin 
biosynthetic pathway.  
 
Figure 23 Extract of the kalimantacin biosynthetic pathway showing the proposed BatK-catalysed reductions. A) In 
module 6 of Bat2, a sat.-β-methyl is formed on the tri-domain of β-branching ACPs. B) Module 10 of Bat3 lacks an in-
cis ER domain but full reductive processing gives an alkyl chain. ACP5 of module 12 tethers the intermediate for sat.-
β-methyl formation.  
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The gene corresponding to BatK was cloned from genomic DNA and ligated into 
POPINF. The protein was expressed and purified by Ni2+-affinity chromatography. The 
yellow, soluble protein was analysed by SDS-PAGE, which indicated a protein of the 
correct mass, however analysis by MS was not possible (Figure 24). By analytical gel 
filtration, the purified protein appeared to be monomeric, in contrast to the previously 
reported dimeric trans-ER DifA from the trans-AT PKS difficidin biosynthetic 
pathway.121 The yellow colour of BatK suggested co-purification with a FAD/FMN co-
factor.122  
 
Figure 24 Characterisation of BatK by SDS-PAGE and S200 analytical size exclusion chromatography. The retention 
time was consistent with BatK being monomeric in solution.  
Following the identification of the missing mECH domain, a construct was designed for 
recombinant expression. The domain boundaries were assigned by secondary structure 
prediction, homology modelling and comparison with literature crystal structures.55 The 
gene was synthesised, cloned in pET151 and expressed. The soluble fraction was purified 
by Ni2+-affinity chromatography and a protein of the correct expected mass was 
confirmed by SDS-PAGE and MS (Figure 25).  
 
Figure 25 MS and SDS-PAGE analysis of mECH.  
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The expression of all the required protein components was the first step towards 
reconstituting the β-branching pathway in vitro. Demonstrating that each individual 
protein was functional required the preparation of surrogates for biosynthetic 
intermediates which would be loaded onto their respective carrier proteins.  
2.1.4 Synthesis of pantetheines 
A wide range of tools have been developed to study the enzymatic reactions of PKS 
pathways both in vitro and in vivo (Figure 26).117 The gold standard is ACP-bound 
intermediates as the protein-protein interactions between the ACP and catalytic domain 
are often key to the correct delivery of substrate.81 This method has been restricted by the 
high cost and limited choice of commercially available CoA derivatives.123 Moreover, 
functionalisation of CoA by coupling to the thiol is challenging: yields are often poor and 
purification of the product is non-trivial due to their polarity.124 More commonly, SNAC 
thioesters which mimic the end of a Ppant arm of an ACP are used due to their relatively 
straightforward synthetic accessibility.84,125–127 This method generally requires incubation 
of the SNAC intermediates with the target protein, reaction quenching and isolation of 
the functionalised SNAC product. Consequently, a large quantity of SNAC derivative is 
required to monitor the reaction over sufficient time points coupled with the loss of 
material during work up.  
 
Figure 26 The structure of CoA and the structural mimics that are used to monitor enzymatic reactions.  
Building on fundamental work on the CoA biosynthetic pathway, a new chemo-
enzymatic method for the specific, cost-effective and synthetically amenable loading of 
ACPs has been developed.128,129 The biosynthetic route to CoA is shown in Scheme 17, 
with the newly-added functional group of each catalytic step highlighted in green. CoaA 
and CoaE catalyse the synthetically challenging phosphorylation reactions and CoaD the 
adenylation step. CoaB and CoaC are responsible for the condensation and 
decarboxylation of cysteine to introduce the terminal thiol.  




Scheme 17 CoA biosynthetic pathway with the new functional groups added by each enzyme shown in green.  
In the chemo-enzymatic method, synthetic chemistry is used to prepare a functionalised 
pantetheine 54, with an amide coupling reaction replacing the CoaB and CoaC-catalysed 
steps. The terminal thiol may then be functionalised by thiol coupling reactions to give a 
range of acyl-pantetheine derivatives, which may be synthesised in four steps from a 
commercially available source of D-pantothenic acid 53 (Scheme 18).124 These 
pantetheines may be used for enzymatic reactions due to the mimicry of the ACP-bound 
Ppant arm, but may also be sub-optimal.130,131 Once synthesised, acyl-pantetheines may 
be “upgraded” into their CoA derivatives 55 by taking advantage of the promiscuity of 
the CoA biosynthetic machinery.117,132 Using CoaA/CoaD/CoaE and the required co-
factors (ATP and Mg2+), the functionalised pantetheines are converted to the respective 
CoA 55. A further extension of this methodology is the loading of ACPs with the 
functionalised CoA by adding the relevant PPTase into the upgrade reaction. This allows 
for the one-pot, chemoenzymatic loading of apo-ACPs to give functionalised ACPs 56 
for the study of biosynthetic pathways.132  
 




Scheme 18 Preparation of functionalised-ACP 56 in a one-pot, in situ chemoenzymatic pantetheine upgrade and ACP-
loading reaction. D-pantothenic acid 53 is converted to pantetheine derivatives 54, which are upgraded to derivatised 
CoA 55 and then the phosphopantetheine arm (blue) is transferred to apo-ACP by a PPTase to give functionalised 
ACP 56.  
In this project, the synthesis of derivatised pantetheine started with the protection of 
commercially available D-pantothenic acid hemicalcium salt 57 (Scheme 19). An amide 
coupling between acid 58 and cysteamine hydrochloride furnished the key protected 
pantetheine intermediate 59. This compound was a stable, white solid that could be stored 
at ambient conditions prior to functionalising the thiol moiety. 59 was reacted with acetyl 
or propionyl chloride in DCM with DMAP to give the protected acyl-pantetheines. 
Deprotection with a 2:1 acetic acid/water mix gave acetyl-pantetheine 60 (38%) and 
propionyl-pantetheine 61 (66%) over the two steps.  
The reaction of acetyl chloride or propionyl chloride with Meldrum’s acid 65 led to the 
formation of acetyl-Meldrum’s acid 66 and propionyl-Meldrum’s acid 67. These 
compounds were separately reacted with 59 in toluene at 100 °C to give acetoacetate 
(Acac)-pantetheine 62 and propionylacetate (PropAc)-pantetheine 63, following 
deprotection of the acetal. Finally, synthesis of 64 was achieved via an EDCI-mediated 
coupling of 59 with acid 68 in THF. Deprotection under standard conditions gave 64 in 
47% yield over the two steps.  




Scheme 19 Synthesis of key protected pantetheine intermediate 59. Further functionalisation furnished a range of 
acyl (60-61, 64) and β-ketothioester (62-63) pantetheines required for in vitro reconstitution of the β-branching 
pathway.  
To test whether the CoA upgrade enzymes were functional, a preparative-scale 
conversion of Ac-pantetheine to Ac-CoA was trialled.124 After 1 h, the reaction was 
quenched, and the reaction mixture analysed by LC/MS (Figure 27). Ac-pant ( [M-H]- 
m/z 319 Da) was fully consumed, and a new peak corresponding to a more polar product 
was eluted from the column with m/z 808, corresponding to [M-H]- for acetyl-CoA. The 
product was purified on a preparative scale LC column and was confirmed as Ac-CoA by 
1H NMR spectroscopy.  
 




Figure 27 Characterisation of Ac-CoA isolated from the chemo-enzymatic upgrade of Ac-pantetheine. A) The structure 
of Ac-CoA. B) LC/MS trace showing the full conversion of Ac-pant into Ac-CoA after 1 h. C) Assignment of 1H NMR. 
D) 1H NMR (D2O) of Ac-CoA purified by LC/MS.  
2.1.5 Mass spectrometry assay for ACP4-6 
A key part of preparing protein samples for analysis by MS is removal of salt and small 
molecules that are more likely to ionise than the protein of interest. This is most 
commonly achieved through small-scale affinity chromatography where the protein of 
interest is bound to a column, the salt is washed away and followed by elution into a 
volatile solvent, for example acetonitrile.  
Several desalting methods were trialled during this project. A batch method using free C4 
resin was time consuming and resulted in poor recovery of protein and poor ionisation. 
Dialysis into a volatile buffer (for example, ammonium acetate) was investigated but was 
time consuming and not suitable for assays involving time-course monitoring. Finally, a 
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method using C4 resin immobilised in a 10 µL Ziptip (Millepore) was determined to be 
the optimal method. The resin has a high capacity, the method is fast and good ionisation 
of the sample was observed.  
Having shown that Ac-pantetheine 60 may be converted to Ac-CoA, the one-pot 
pantetheine upgrade and ACP loading to form Ac-BatA was investigated. Following the 
literature method of Moore et al., apo-BatA, Ac-pantetheine 60 and the CoA upgrade 
enzymes were incubated with MupN in the presence of MgCl2 and ATP at room 
temperature for 1 h. The literature method used 9 mM ATP for the conversion and this 
proved effective in the test reaction. However, after one hour, only 50% ACP loading was 
observed along with the formation of a fine precipitate. This had not been previously 
observed for the apo- to holo- conversion of BatA, suggesting that one of the reagents for 
the CoA upgrade was promoting protein precipitation. The ATP concentration was 
lowered to 1 mM and following 1 h incubation, a complete conversion of apo-BatA to 
Ac-BatA was observed as confirmed by MS and Ppant ejection assay (Figure 28).  
 
Figure 28 MS analysis of Ac-BatA including the Ppant ejection assay.  
The Ppant ejection assay is a MS technique that relies on the selective fragmentation of 
an ACP. The ions that correspond to a single charge state are isolated and fragmented by 
collision-induced dissociation (CID), leading to the ejection of a singly charged “ejected” 
ion and phosphorylated apo-ACP (Scheme 20). Thioester-bound intermediates are stable 
to the assay conditions, allowing for identification of the tethered species with high mass 
accuracy.  
 
Scheme 20 Ppant ejection assay occurs by collision-induced dissociation of an ACP, producing a singly-charged 
Ppant ejection ion.  
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Following the small-scale proof of concept reaction, large scale conversions of apo-BatA 
to Ac-BatA were set up in which the concentration of apo-BatA was increased (up to 
500 µM) or the reaction volume was increased (up to 10 mL). Longer reaction times, 
double addition of reagents and agitation of the reaction were sometimes required to get 
full conversion to Ac-BatA. With careful monitoring by MS, it is possible to convert 
10 mg of apo-BatA into Ac-BatA. Once complete, reactions were desalted to remove 
excess CoA that might interfere with downstream enzymatic assays.  
The stability of the acetyl group was monitored by MS and after 24 hours at room 
temperature, around 50% of the acetyl group had been hydrolysed to holo-BatA. 
However, when stored at -80 °C, the acetyl group was stable for up to 3 months with 
negligible hydrolysis to holo-BatA. Therefore, large scale conversions of apo-BatA to 
Ac-BatA were undertaken and following desalting, the protein was concentrated and 
aliquoted prior to flash freezing and storage at -80 °C.  
Loading of the modular apo-ACPs was achieved by incubation with Acac-pantetheine 62 
in an analogous one-pot procedure. Although not quantified, each of the modular ACPs 
appeared to load at a different rate, but by monitoring the reaction by MS the progress of 
loading could be followed until completion. If appropriate, reactions would be left longer 
or more reagents added to the reaction. In particular, the addition of an extra equivalent 
of MupN would often expedite the reaction to completion. It should be noted that a small 
amount of holo-ACP was almost always observed during the loading of modular ACPs 
with β-ketothioester-pantetheines, arising from the hydrolysis of the thioester bond.  
The stability of all the modular Acac-ACPs was monitored by MS and the thioester was 
shown to be more labile than Ac-BatA. After 16 h at room temperature, complete 
hydrolysis of Acac-ACP to holo-ACP was observed. Additionally, protein degradation 
was also observed over this time frame. Storage at -20 °C slowed the rate of hydrolysis, 
but even with this safeguard, significant hydrolysis had occurred after 24 h. PropAc-
pantetheine 63 was also prepared and it was hoped that the longer carbon chain would 
provide some additional hydrolytic stability due to the increased alkyl chain.133 However, 
Acac-ACP and PropAc-ACP appeared to be equally labile and both substrates were used 
interchangeably throughout the course of this work. Due to the lability of the β-
ketothioesters, modular ACPs were loaded prior to β-branching assay and used 
immediately.  
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During β-branching assays, approximately equimolar concentrations of Ac-BatA and 
Acac-ACP was desired. Stocks of both ACPs were prepared at around 100 µM and 
following equal volume mixing and addition of catalytic domains, a final concentration 
of 50 µM was commonly achieved.  
2.1.6 Unsaturated β-methyl branches 
Equimolar Ac-BatA and Acac-ACP4 (50 µM) were incubated with BatC (5 µM) at room 
temperature for 1 h. A sample was desalted and analysed by MS and it was immediately 
apparent that despite equimolar concentrations, BatA ionised far more efficiently under 
the MS conditions and approximately 10 times more signal was observed for BatA than 
ACP4. These signals indicated that there was a loss of Ac-BatA and formation of holo-
BatA consistent with the transfer of the acetyl group to BatC, although partial hydrolysis 
could not be ruled out. Further analysis of low intensity peaks resulted in the identification 
of a single charge state corresponding to the following ACP4 species: holo-, Acac- and 
HMG-ACP4 (Figure 29A). The mass shift from Acac-ACP4 to HMG-ACP4 was +60 Da 
and this was confirmed by Ppant ejection of both species (Figure 29B and 29C). This 
initial result showed that the acetyl group had been successfully transferred from Ac-
BatA to Acac-ACP4 via BatC. However, the reaction efficiency was poor with a 
significant amount of Acac-ACP4 starting material still present as well as holo-ACP4 
arising from hydrolysis of the Acac- or HMG-ACP4 thioesters.  
BatD and BatE were added to the assay to catalyse the loss of H2O and CO2 respectively 
and form an unsaturated β-branched product. Addition of BatD alone did not result in a 
mass shift consistent with the loss of water. This was to be expected as the BatD-catalysed 
dehydration is a reversible reaction and so the observation of product would depend on 
the equilibrium position. A small amount of dehydrated species has been characterised 
before by Calderone and co-workers,39 however, due to the difficulty in observing this 
species, most in vitro studies on the HCS cassette couple the dehydration and 
decarboxylation steps.40 This increases the complexity and uncertainty in the assays 
which may yield no results or unexpected species, due to the two proteins acting with 
only a single analytical point.  
Addition of both BatD and BatE consumed HMG-ACP4, but due to the 2 Da mass 
difference between Acac-ACP4 and enoyl-ACP4 overlap of the charge states at 1592 Da 
was observed (Figure 29A). Ppant ejection resulted in the observation of two ions, 
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corresponding to Acac-ACP4 at 359.2 Da and enoyl-ACP4 at 357.2 Da (Figure 29D). 
This was the first successful reconstitution of the β-branching pathway from the 
kalimantacin gene cluster, however, the efficiency of the transformation was generally 
poor.  
 
Figure 29 β-branching MS assay for ACP4 by monitoring the 7+ charge state. A) Single charge state analysis of 
PropAc-ACP4 (top, 1592 Da) being converted into HMG-ACP4 (middle, 1600 Da) by BatC and the subsequent 
conversion to enoyl-ACP4 (bottom, 1592 Da) by treatment with BatD/BatE. The charge state at 1578 Da corresponds 
to holo-ACP4, arising from acyl-ACP4 hydrolysis. B) Ppant ejection from PropAc-ACP4 at 1592 Da gives a 1+ ion at 
359.2 Da and a 6+ ion (phosphorylated ACP4) at 1797 Da. C) Ppant ejection of HMG-ACP4 at 1600 Da gave a 1+ 
species at 419.2 Da. D) Ppant ejection of 1592 Da with zoomed area separating the 1+ ions of unreacted PropAc-ACP4 
(357.2 Da) and enoyl-ACP4 (359.2 Da). E) The structure of the Ppant ejection ions and their exact masses.  
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Optimisation of the condensation step based around the previous literature reports using 
TCEP, shorter reaction times and varying the equivalents of reagents to increase our yield 
of HMG-ACP4 did not result in a dramatic change in the ratio of species.39,41,45 A typical 
reaction profile exhibited approximately 1/3 holo-ACP4, and varying ratios of Acac-and 
HMG-ACP4. The best results achieved were 1/3 holo-ACP4, only trace amounts of Acac-
ACP4 and ~ 2/3 overall conversion to HMG-ACP4. No difference in outcome was 
observed when using frozen aliquots of BatC compared to freshly purified protein. 
Similarly, the BatD/BatE coupled step was also optimised with the best results achieved 
using freshly purified protein that was stored at 4 °C for less than 5 days. Inconsistent 
results were obtained when using frozen aliquots or storage at 4 °C for longer than 1 
week. As a result, these assays often required a higher catalyst concentration, double 
addition of reagents or longer reaction times.  
Due to the abundance of β-branching ACPs in the kalimantacin gene cluster and our 
interest in understanding the formation of the three different, consecutive β-methyl 
branches, the assay was also reconstituted with ACP5 and ACP6 (Figure 30).  
 
Figure 30 Single charge state (8+) monitoring for the β-branching assay for ACP5 (left) and ACP6 (right). PropAc-
ACP (top) is converted to HMG-ACP (middle) when reacted with Ac-BatA and BatC, followed by BatD/BatE-
catalysed conversion to enoyl-ACP (bottom).  
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Once again, both ACPs showed a lower ionisation efficiency under the MS conditions 
than BatA, adding to the difficulty of analysis. Both ACPs successfully formed the HMG-
ACP intermediate by transfer of acetyl from Ac-BatA to PropAc-ACP by BatC. This was 
subsequently converted to into enoyl-ACP by addition of BatD and BatE. Less hydrolysis 
and a cleaner conversion of PropAc-ACP to enoyl-ACP was observed for ACP5 and 
ACP6. Unfortunately, a subsequent computer failure meant a significant loss of MS data 
was encountered. As such, not all Ppant ejection assay data or whole spectra are 
presented.  
In vitro β-branching assays monitored by LC/MS 
MS analysis of these ACPs proved to be a valuable tool in initially characterising the 
pathway. However, a variety of analytical methods were investigated for monitoring the 
challenging in vitro reconstitution of this multi-enzyme pathway. LC/MS analysis 
provides a clearer detection of each species due to separation of the highly ionisable BatA 
and the separation of different modular ACP-bound intermediates.  
 
Figure 31 LC/MS analysis of β-branching on ACP4. A full envelope of charge states and Ppant ejection ions are seen 
for Acac-ACP5 (blue), HMG-ACP5 (red) and enoyl-ACP5 (green).  
Injection of Acac-ACP4 alone gave a full envelope of charge states with good mass 
accuracy when deconvoluted (Figure 31). Ejection of the most abundant charge state gave 
a 1+ ion at 345.2 Da corresponding to Acac-ACP4. Transfer of acetyl from Ac-BatA to 
Acac-ACP4 via BatC resulted in the formation of HMG-ACP4, confirmed by mass shift 
of the envelope of charge states and Ppant ejection (405.2 Da). Ac/holo-BatA were eluted 
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off the column prior to the ACP4-bound intermediates and did not interfere with ACP4 
analysis. HMG-ACP4 eluted at an earlier retention time than Acac-ACP4 resulting in a 
single envelope of charge states. Addition of BatD and BatE to the assay catalysed the 
conversion of HMG-ACP4 to enoyl-ACP4. Enoyl-ACP4 was the last of the ACP4-bound 
species to be eluted from the column and once again this species was characterised by a 
full envelope of charge states and a Ppant ejection ion at 343.2 Da.  
To determine whether separation could be achieved for other ACPs, the assay was 
undertaken with ACP5 and the data presented in Figure 32. Once again, Ac/holo-BatA 
eluted prior to the ACP5-bound intermediates, which eluted in the same order as observed 
for ACP4: HMG-, Acac- and enoyl-ACP5. A full envelope of charge states and the 
complementary Ppant ejection data was collected and confirmed the formation of an 
unsaturated β-methyl branch.  
 
Figure 32 LC/MS analysis of β-branching on ACP5. A full envelope of charge states and Ppant ejection ions are seen 
for Acac-ACP5 (blue), HMG-ACP5 (red) and enoyl-ACP5 (green).  
With the successful MS assay in hand, attempts were made to determine the role of mECH 
in the formation of β-branches. Direct detection of either an endo-β-methyl or exo-β-
methyl branch cannot be made by MS due to the identical masses of both species. 
However, its broad role can be inferred using MS if a domain of known function can be 
complemented by the mECH domain. It was therefore decided to replace BatE with 
mECH to determine whether the modular domain can act with a similar decarboxylase 
activity. Using the LC/MS technique to monitor the assay, Acac-ACP4 was first reacted 
with Ac-BatA and BatC to form HMG-ACP4. BatD and mECH were both added to the 
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reaction mixture and allowed to incubate at room temperature. The reaction was 
monitored (up to 6 h) by LC/MS, however, no peak corresponding to an unsaturated β-
methyl was observed. Heating the reaction did result in a trace amount of species 
corresponding to an unsaturated β-methyl branch, however, this species was also 
observed in the negative control reaction, containing only HMG-ACP4, and arises from 
thermal decarboxylation. These results suggested that mECH cannot complement for 
BatE (Scheme 21).  
 
Scheme 21 Unsuccessful complementation of BatE by mECH.  
2.1.7 Saturated-β-methyl branches 
In addition to the two unsaturated β-methyl branches formed in the biosynthesis of 
kalimantacin, two sat.-β-methyl branches are also formed. Firstly, when the biosynthetic 
intermediate is attached to module 6 located on Bat2, the second large ORF in the gene 
cluster, and secondly, when the intermediate is attached to Bat3 ACP5 (module 12) in the 
middle of a series of three consecutive β-methyl branches. The sat.-β-methyl is 
hypothesised to be formed via the reduction of an HCS cassette derived endo-β-methyl 
by a trans-acting ER domain. BatK is the only ER in the gene cluster and is a free-standing 
domain. Lavigne et al. used yeast two-hybrid (Y2H) to probe interacting proteins within 
the kalimantacin assembly line and they demonstrated that BatK had a specific interaction 
with Bat3 ACP2 and ACP5.134 These interactions are consistent with the proposed 
biosynthetic pathway whereby an unbranched α,β-unsaturated moiety is reduced at ACP2 
and at ACP5 to form the sat.-β-methyl.  
Having shown the formation of the endo-β-methyl on ACP5, the ER-catalysed reduction 
of a β-branched intermediate was then investigated (Figure 33). ACP5 was loaded with 
enoyl-pantetheine 64 under standard one-pot conditions. BatK and NADH were added 
and the reaction monitored by MS, which showed complete consumption of the starting 
material (343 Da) by Ppant ejection assay and the formation of a new Ppant ejected ion 
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(345 Da) after 1 h. The 2 Da mass increase corresponds to the reduction α,β-unsaturated 
double bond by addition of H- from NADH and reprotonation by H+ (Figure 33B). To test 
whether the reaction was ACP-specific, the reaction was also performed on ACP4 and 
ACP6. ACP4 was loaded with enoyl-pantetheine 64, incubated with BatK and NADH, 
and after 1 h complete reduction had taken place (Figure 33A). However, enoyl-ACP6 
under the same reaction conditions, was not reduced to the sat.-β-methyl (Figure 33C). 
Leaving the reaction for up to 6 h did not result in reduction of the alkene and no reduction 
was observed by incubating any of the ACPs with NADH in the absence of BatK.  
 
Figure 33 Reduction of enoyl-ACP by BatK and NADH was monitored by the Ppant ejection assay which results in 
1+ ions corresponding to an unsaturated-β-methyl (343.2 Da) or saturated-β-methyl (345.2 Da) intermediate. A) An 
unexpected reduction by BatK is observed for ACP4. B) Reduction by BatK is observed for ACP5 as expected from 
the proposed biosynthetic pathway. C) No reduction is observed for the intermediate attached to ACP6. No reduction 
occurs in the absence of BatK.  
These results suggest that protein-protein interactions are only partially significant in the 
formation of sat.-β-methyl branches. The reduction at ACP5 and the lack of reduction of 
an intermediate attached to ACP6 were to be expected due to the β-branches incorporated 
in the native system. However, the interaction of ACP4 with BatK demonstrates its ability 
to deliver substrates to a wide range of catalytic domains. ACP4 does not need to 
discriminate against BatK presumably because the exo-β-methyl branch is not a substrate 
of BatK. Remarkably, ACP4 interacts with trans-acting domains from the HCS cassette 
(BatC, D, E), the trans-acting AT (BatJ) and now BatK. Additionally, ACP4 must 
correctly interact and transfer substrates to neighbouring modular domains by bearing a 
malonyl group that is used to undergo chain extension with the upstream KS of module 
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10 and, following β-branching, pass the modified chain to the downstream KS of 
module 11. To achieve correct fidelity through the pathway, control at this ACP must be 
achieved by reaction kinetics (in cis v in trans) or steric occlusion from catalytic active 
sites.  
The in vitro activity is further supported by the isolation of minor metabolites from the 
P. fluorescens wild-type strain. One full-length and two truncated kalimantacin analogues 
were isolated, characterised and their antibiotic activity determined by Angus Weir during 
his Master’s research project (Figure 34). Compound 69 is a full-length kalimantacin 
analogue that possesses a sat.-β-methyl branch at C-7 rather than an exo-β-methyl. This 
likely occurs from aberrant endo-β-methyl formation and subsequent reduction by BatK. 
The two truncated metabolites still possess the exo-β-methyl branch but lack either the 
sat.-β-methyl 70 or endo-β-methyl branch 71, likely due to module skipping. Aside from 
interest in their biosynthetic origin, the MIC values show that 69 suffers from an 
approximately 100-fold loss in antibiotic activity due to the C-7 reduction and the 
truncated intermediates 70-71 lose all antibiotic activity. This intriguing structure-activity 
relationship (SAR) has been followed-up by Angus Weir during his PhD studies.  
 
Figure 34 Minor metabolites 69-71 isolated from P. fluorescens WT strain and their yields and MIC values are 
compared against kalimantacin A.  
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Considering both the in vitro observations and the minor metabolites isolated, ACP4 does 
achieve the remarkable selectivity required to produce kalimantacin as the major isolate. 
Whilst some clarity has been provided for the formation of the three different β-branches 
in kalimantacin, there are still unknown answers in relation to the selectivity achieved.  
To conclude, the results presented demonstrate the successful in vitro reconstitution and 
characterisation by MS of the HCS cassette from the kalimantacin pathway. The 
complexity of the β-branching pathway required the preparation of many biosynthetic 
intermediates and proteins, as well as numerous analytical techniques to probe the 
outcome. All trans-acting domains (BatA, C-E) were functionally active and each of the 
consecutive ACPs (ACP4-6) were able to interact with the cassette to produce an 
unsaturated β-branched product. The geometry of the unsaturated product was not 
determined, although the working hypothesis made it likely that an endo-β-methyl was 
produced. The ability of BatK to reduce an endo-β-methyl branch on ACP4 and 5 was 
proven, as well as the lack of reactivity with ACP6. Finally, a previously unidentified 
modular ECH domain has been identified within Bat3. In this initial phase of the work, 
the domain was expressed as a soluble protein, however, no function has been shown so 
far. This lack of function may point to a mis-folded, non-functional protein that requires 
neighbouring domains or correct oligomerisation for activity.  
2.2 NMR Characterisation of β-Branching 
2.2.1 Pantetheine NMR experiments 
Mass spectrometry, in particular the Ppant ejection assay, has been a powerful tool for 
the analysis of the β-branching pathway.39,45 Small sample volumes, dilute assay 
conditions and high mass accuracy have enabled careful dissection of each catalytic step. 
However, kalimantacin possesses three types of β-methyl branch, two of which are 
indistinguishable by mass alone. Previous in vitro characterisation of alkene β-branches 
has relied on either UV spectroscopy assaying for the α,β-unsaturated thioester 
chromophore or hydrolysis of ACP-bound intermediates and subsequent small molecule 
analysis by GC-MS.39,43,45 It was felt that both of these methods were less than robust and 
an improved analytical technique was sought.  
So far, it has been assumed that the product of reconstituting the HCS from the 
kalimantacin pathway is an endo-β-methyl as it is the most common β-branch observed 
in polyketides and our hypothesis suggests that other β-branches may be formed from this 
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intermediate. Conducting β-branching assays and monitoring by NMR would allow for 
the real time monitoring of such reactions in situ. This could be undertaken with a small 
molecule mimic of the β-branching intermediates to avoid the use of stoichiometric ACPs 
which would dominate the spectrum.  
Since completing the work described in this thesis, Smith et al. reported the 
ECH1- catalysed α,β-dehydration of HMG-CoA, despite the β-branching product 
containing a non-decarboxylated β,γ-unsaturated acrylate moiety.63 This was achieved by 
deuterium labelling to produce d2-HMG-CoA 72 followed by NMR and MS analysis 
confirming the presence of the dehydrated product 73 and no evidence of β,γ-dehydration 
product 74 (Scheme 22). Proton exchange with the solvent, the kinetic isotope effect and 
low turnover are significant limitations to this methodology.  
 
Scheme 22 Formation of an α,β-unsaturated dehydration product was confirmed by MS and NMR.  
It was decided to synthesise HMG-pantetheine 79 and monitor its reaction with BatD and 
BatE. There is literature precedent for the synthesis of the key anhydride intermediate 78, 
which has been previously coupled to SNAC. However, SNAC derivatives have been 
shown to be inactive with ECH1/ECH2 homologs from the bacillaene pathway.
135 
Therefore HMG-pantetheine 79 was chosen as the synthetic target as it represented a 
superior biomimetic. The initial aim was to use the small molecule for NMR studies, 
although, the pantetheine allows for the loading onto an ACP if required. A disadvantage 
of the literature synthetic route is the non-stereoselective formation of HMG-pantetheine 
which will result in diastereomers at the C-3 position of 79. Based on literature reports, 
S-HMG is the product of HMGS condensation, matching the stereochemical outcome of 
HMGCS from primary metabolism, and so a maximum 50% turnover would be expected 
from the final synthetic pantetheine.40,41 However, this was not deemed to be a problem 
as the other diastereomer should not interfere with the assay and HMG-pantetheine 79 
was synthesised (Scheme 23).  
 




Scheme 23 Synthesis of HMG-pantetheine 79.  
Adapting the literature procedure,36 freshly-distilled ethyl acetate 75 was reacted with 
allylmagnesium bromide to give alcohol 76, which was treated with ozone followed by 
an acidic workup. The crude reaction mixture was not concentrated under reduced 
pressure in case of incomplete degradation of the ozonide, instead saturated aqueous 
sodium sulfite was added to quench any remaining peroxide and following extraction into 
ethyl acetate the required diacid 77 was isolated in 15% yield. To maximise recovery, the 
combined aqueous phases were concentrated to dryness, treated with acetic anhydride 
and following work-up anhydride 78 was isolated in a low yield, but enough material was 
recovered to complete the route. Pure di-acid 77 was also converted to anhydride 78 in 
quantitative yield. Anhydride 78 was ring-opened with protected pantetheine 59 by 
heating in toluene, and final acetal deprotection under acidic conditions afforded HMG-
pantetheine 79.  
HMG-pantetheine 79 was dissolved in NMR buffer (50 mM Na phosphate, 100 mM 
NaCl, 10% D2O, pH 8.0) and a control 
1H NMR spectrum was recorded (Figure 35). BatD 
and BatE were then added to the sample and the 1H spectrum was recorded at regular 
intervals. After 45 minutes a small peak was visible at 6.18 ppm. The intensity of the peak 
increased with time and after 13 h the peak had developed an upfield shoulder (6.17 ppm). 
This grew further and after 150 h, the original peak had disappeared leaving just a single 
signal at 6.17 ppm.  





Figure 35 Stacked plot of 1H NMR spectra showing the slow conversion of HMG-pantetheine 79 to enoyl-
pantetheine 64 catalysed by BatD and BatE. The peak at 6.18 ppm (red) corresponds to the alkene proton of MG-
pantetheine 80 and the peak at 6.17 ppm the alkene proton of enoyl-pantetheine 64.  
A two-dimensional TOCSY experiment confirmed the identity of the two peaks (Figure 
36). The downfield peak (6.18 ppm) was assigned to the alkene proton of MG-pantetheine 
80 and gave clear correlations to a CH2 at 3.07 ppm and a CH3 at 2.14 ppm. The upfield 
shifted peak (6.17 ppm) corresponded to the alkene peak of enoyl-pantetheine 64 with 
correlations to two CH3 groups at 1.91 and 2.11 ppm. The spectra and correlations 
observed are consistent with those of the synthetic pantetheine 64.  
 




Figure 36 Two-dimensional TOCSY spectrum showing the correlations from the alkene protons of the MG-
pantetheine 80 (6.18 ppm) and enoyl-pantetheine 64 (6.17 ppm).  
Although mECH showed no activity as a decarboxylase by MS, we sought to validate this 
result by NMR. HMG-pantetheine 79 was incubated with BatD and mECH and the build-
up of MG-pantetheine 80 was observed. Further monitoring over time did not produce 
any evidence for a product of decarboxylation (Scheme 24A). Finally, enoyl-pantetheine 
64 was incubated with mECH to monitor for isomerism of the α,β-unsaturated bond, 
however, no loss of signal or formation of a new peak corresponding to an exo-β-methyl 
81 was observed (Scheme 24B). 
 
Scheme 24 Unsuccessful reactions with mECH by NMR. A) mECH did not complement for BatE as a 
decarboxylase. B) No isomerism activity was observed in the conversion of an endo-β-methyl to an exo-β-methyl.  
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A two-dimensional TOCSY spectrum of MG-pantetheine 80 showed correlations to a 
CH2 at 3.07 ppm and CH3 at 2.14 ppm. To fully characterise MG-pantetheine 80, a two-
dimensional NOESY spectrum was then used to assign the geometry of the alkene 
(Figure 37). A correlation was seen from the alkene proton only to the CH2 protons at 
3.07 ppm, with no correlation to the CH3 at 2.14 ppm. This confirmed the syn-assignment 
of the CH2 and alkene proton, and the arrangement of the methyl group (that would 
normally represent the polyketide chain) trans to the proton (E-isomer).  
 
Figure 37 Two-dimensional NMR assignment of MG-pantetheine 80. A) TOCSY correlations from the alkene proton 
at 6.18 ppm to the CH3 at 2.14 ppm and a CH2 at 3.07 ppm. B) NOESY spectrum showing a correlation from the alkene 
proton at 6.18 ppm only to the CH2 at 3.07 ppm, confirming the cis-arrangement (E-alkene).  
These experiments confirmed the formation of an endo-β-methyl branch from BatD-
catalysed dehydration and BatE-catalysed decarboxylation of HMG-pantetheine 79. 
Additionally, the in-situ accumulation of MG-pantetheine 80 confirmed the E-geometry 
of the trisubstituted double bond, however, no evidence of mECH activity was observed.  
The slow rates of the reaction observed may be due to poor selectivity for a pantetheine 
substrate mimic, rather than an ACP-bound intermediate. Therefore, developing an assay 
that allowed for monitoring of ACP-bound intermediates by NMR was required. Such a 
method exists in the literature and has been used within our group previously.136,137 It 
relies on the uniform incorporation of 13C and 15N into the ACP backbone and the loading 
of a natural abundance Ppant arm onto the ACP. NMR isotope filtration experiments can 
then be recorded whereby all protons attached to either 13C or 15N are filtered (not 
observed), allowing for the recording of a 1H spectrum that only contains signals from 
the Ppant arm and any thioester-bound substrates.  
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A 13C/15N double-labelled sample of ACP4 was prepared by growth in minimal medium 
supplemented with 13C glucose and 15NH4Cl as the sources of isotopic labels. The ACP 
was purified as per the unlabelled material, loaded with enoyl-pantetheine 64 and a 1H 
spectrum of the protein was recorded (Figure 38). Upfield shifted methyl peaks that are 
representative of a folded protein were visible, and they were split into doublets resulting 
from spin-coupling with the enriched 13C.  
 
Figure 38 1H NMR spectrum of enoyl-13C/15N-ACP4. The upfield shifted methyl peaks between -0.5 and -1.0 indicate 
the protein is folded.  
A control filtration experiment was recorded that showed the characteristic peaks for a 
Ppant arm as well as the methyl signals for the unsaturated thioester. However, 
incomplete labelling meant the spectrum also contained unlabelled protein signals 
(Figure 39). mECH was added to the sample and it was monitored by 1H NMR. No loss 
of intensity of the methyl peaks or new peaks were observed, even after the second 
addition of mECH domain, suggesting that either mECH was not functional or it does not 
act as an isomerase. The reproducibility of the spectrum over 8 hours was testament to 
the stability of the ACP-bound intermediate. An attempt was made to load HMG-pant 
onto ACP4 to monitor the BatD/BatE-catalysed conversion to an endo-β-methyl. 
However, the spectrum was too crowded to assign unambiguously and monitor due to 
unlabelled protein signals.  




Figure 39 Stack of 13C,15N-filtered NOESY spectra for enoyl-13C/15N-ACP4 + mECH. Signals corresponding to the 
Ppant arm were observable (grey), however, additional protein peaks arising from incomplete [13C]/[15N] labelling 
made identifying new peaks challenging.  
The filtration experiments were a useful tool for monitoring the potential isomerism 
reaction, due to the sharp methyl peaks in a clear region of the spectrum. The major 
limitation of the methodology is the production of uniformly labelled protein. Growth in 
minimal media alone often resulted in cell death or minimal expression, whilst only 90% 
labelling was obtained when LB media was used for an initial growth prior to media 
exchange into minimal media and expression. As a result, the technique was not 
developed further.  
The conclusion from the MS and NMR work undertaken so far was that the mECH 
domain was not acting as expected. It did not show activity to complement BatE by MS 
and NMR or show any signs of isomerising endo-β-methyl branches by NMR. A literature 
review revealed that Smith et al. were unable to crystallise JamJ, the ECH2 domain from 
the jamaicamide biosynthetic pathway that results in the formation of an exo-β-methyl.55 
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Close inspection of the domain boundaries reveals that JamJ was cloned without the C-
terminal helix found in CurF and present in other ECH2 domains including BatE.
40 When 
designing a construct to clone mECH from Bat3, secondary structure prediction and 
homologous structures suggested inclusion of this helix. However, when excising a 
domain from a modular PKS, the selection of boundaries is critically important. As such, 
site-directed mutagenesis was used to create a truncated mECH domain (short mECH) 
that removed the final helix, consistent with the boundaries used by Smith et al. Following 
the standard expression protocol, short mECH was expressed and purified. The yield was 
very low, the protein was poorly soluble and showed a tendency to precipitate out of 
solution. Therefore, it was decided not to continue working with this construct.  
To confirm if mECH was folded, several biophysical assays were applied to probe the 
structure of the protein. Firstly, analytical gel filtration was conducted to understand more 
about its structure and oligomerisation in solution. The retention time did not suggest a 
defined oligomeric state as determined by poor fit to the calibrants (Figure 40 B and C). 
The retention time suggests the size of protein may be between a monomer and dimer. A 
circular dichroism (CD) spectrum was recorded for mECH and it showed a lack of defined 
peak shape that would be expected for a folded protein (Figure 40D). mECH is predicted 
to have the classic ββα crotonase superfamily fold, therefore negative peaks at 208 nm 
and 222 nm would be expected for the α-helices and a negative peak at 218 nm for anti-
parallel β-strand.138 However, an ill-defined curve is observed, suggesting that the does 
not contain defined secondary structure.  
Finally, a 15N labelled sample of mECH was prepared for high-resolution solution NMR 
analysis. Cells were cultured in LB medium to obtain cellular density prior to media 
exchange into a minimal media supplemented with 15NH4Cl as the nitrogen source. Ni
2+-
affinity chromatography and SEC furnished a protein sample in NMR buffer (pH 7.5) that 
was concentrated to 400 µM and analysed by NMR (700 MHz). 1H-15N HSQC NMR 
revealed a lack of dispersity and broadness of signals that is the signature of an unfolded 
protein (Figure 40A). Coupled with the lack of functional activity, it appears it was not 
possible to reconstitute an active modular ECH domain as an individual enzyme.   




Figure 40 Structural characterisation of mECH. A) 1H-15N HSQC NMR spectra of [15N]-labelled mECH. B) Analytical 
gel filtration of mECH (13.42 mins) run on a calibrated S200 column. C) Fitting of the retention time for mECH from 
the analytical GF indicates that the domain may be monomeric or dimeric, but a poor fit is observed. D) Circular 
dichroism spectrum for mECH does not indicate the expected α-helical dip at 208 nm and 222 nm or the β-strand dip 
at 218 nm.138  
2.2.2 4M expression and structural analysis 
Excising a single, functional domain from a large multi-modular protein is not 
straightforward.139 As has been shown for mECH, a soluble protein could be isolated in 
high yield, however, only upon close structural analysis was the lack of folding observed. 
It was hoped that expression of mECH as a multi-domain protein with either an N-
terminal or C-terminal partner might stabilise the correctly folded structure and allow for 
assay work to be undertaken.  




Figure 41 Order of domains and inter-domain linker lengths in Bat3 and the sequence of the di-domain 4M. ACP4 is 
shown in grey, the linker region in blue and the mECH in pink.  
The order and length of linker of the domains in Bat3 is shown in Figure 41. ACP4 
precedes the modular ECH domain and the two domains are separated by a 42-residue 
linker that is predicted to be unstructured. It was decided to express a di-domain 
comprised of ACP4-mECH (4M) that preserved this linker. Primers were designed, the 
gene amplified and cloned into POPINF. Using the optimised procedure for the 
expression of ACP4, cells were grown, induced with 1 mM IPTG and incubated for 5 h 
at 16 °C. Following Ni2+-affinity chromatography, 4M was isolated and confirmed as 
apo-4M by MS (Figure 42).  
 
Figure 42 SDS-PAGE and MS analysis of the di-domain protein 4M (ACP4-mECH). A single species is observed with 
good mass accuracy.  
Prior to functional studies, structural characterisation of the protein was undertaken. 
Analytical gel filtration of 4M gave a species at 13.42 mins that correlated with the mass 
of a dimeric species (Figure 43 C and D). The crotonase superfamily predominantly form 
trimers or dimers of trimers, whereas structural studies on whole PKS modules show these 
multi-functional proteins form dimers around the KS domain.33,35,100,140 The modular 
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ECH2 CurF domain from the curacin pathway was shown to be trimeric in the solid state, 
but an equilibrium with lower oligomeric states existed in solution.55 A CD spectrum of 
4M contained dips at 208 nm and 222 nm, consistent with an α-helical protein 
(Figure 43E). It was not possible to determine the individual contribution to this signal 
from the α-helical ACP and the mECH domain which contains a mixed α-helical/β-strand 
structure. However, these results indicate that the 4M di-domain may be folded.  
 
Figure 43 Structural characterisation of 4M. A) 1H-15N HSQC spectrum for 4M shows a greater dispersion of peaks 
compared to mECH. B) Overlay of 1H-15N HSQC spectra for 4M (black) and ACP4 (red) shows overlap of the ACP 
peaks as well as additional peaks arising from either the linker region or mECH domain. C) S200 analytical gel filtration 
of 4M. D) The retention time suggests that 4M is dimeric in solution. E) CD spectrum of 4M contains dips at 208 nm 
and 222 nm consistent with an α-helical protein.  
To further probe the structure, a 15N labelled sample was prepared in minimal media and 
analysed by 1D and 2D NMR. The 1H NMR showed a series of characteristic peaks for 
ACP4 that had been previously observed. 1H-15N HSQC NMR showed a much greater 
dispersion and number of signals, although still less than expected, which might be related 
to the large mass of mECH and broad signals (Figure 43A). When the spectrum was 
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overlaid with that of ACP4 many of the signals for ACP4 could be mapped onto the di-
domain spectrum, but numerous additional peaks could be resolved. These were 
surprisingly well dispersed and may arise from the linker region, which may be showing 
some structuring, as well as more mobile parts of the mECH (Figure 43B). The spectrum 
also lacked the concentration of broad, overlapping signals between 7.5-8.5 ppm 
characteristic of unfolded proteins. However, these may be swamped by the strong ACP4 
and linker signals. Nonetheless, this gave a positive indication that 4M might be folded 
and was carried forward into functional studies.  
2.2.3 Synthesis of [13C]-labelled materials 
The success of in vitro NMR assays using HMG-pantetheine coupled with BatD/BatE to 
form an endo-β-methyl branch showed the potential for further development. An NMR 
assay that could analyse intermediates attached to an ACP or cleavage of intermediates 
from an ACP was required. Smith et al. demonstrated the conversion of thioesters from 
ACPs to give stable amide derivatives that were analysed by GC-MS and compared to 
synthetic standards.45 Our aim was to create an NMR assay to analyse intermediates 
attached to the ACP as this would yield more information about the species formed during 
the β-branching pathway. Additionally, in situ analysis removes uncertainty associated 
with degradation or non-enzymatic side-reactions during hydrolysis and work-up.  
 
Scheme 25 β-branching pathway showing the position of a [13C] label (red dot) during the assay. The [13C] label would 
occupy a range of chemical environments allowing for clear discrimination of β-branching intermediates.  
It was envisioned that the incorporation of a [13C] label, specifically introduced at one 
position in a β-branching substrate, would provide the requisite handle for in situ analysis 
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(Scheme 25). Monitoring reactions by direct observe 13C NMR would allow for the 
observation of the enriched [13C] label, whilst the 1% natural abundance 13C of the ACPs, 
catalytic enzymes and other unlabelled components in the assay would not be observed.  
 
Scheme 26 Potential positions of [13C] incorporation into HMG-intermediates (82, 84 and 86) where R may be 
pantetheine or ACP. A) [1-13C] or [2-13C] ethyl acetate would give rise to 82 containing a single [13C] label at C-3 or 
C-6. B) [2-13C] acetyl chloride could give 84 with single a [13C] label at C-6 via [13C]-Acac-pantetheine 83. C) [2-13C] 
acetyl chloride could be used to give 86 with a [13C] label at C-4 via [13C]-Ac-pantetheine 85. However, 84 and 86 
would require the BatC-catalysed condensation of ACPA and ACPD whereas 82 could be directly loaded onto ACPA.  
The position of the [13C] label was key in designing the experiment, and three possibilities 
were envisioned. Firstly, utilising the previously undertaken synthetic route, [13C]-HMG-
intermediate 82 with a [13C] label at C-3 or C-6 could be synthesised from 1- or 2-[13C] 
ethyl acetate (Scheme 26A). The advantage of this intermediate is that it would negate 
the need for the BatC-catalysed condensation of two ACPs, thus simplifying the assay. 
However, the chemical environment of C-6 does not change significantly during β-
branching and the previously used synthetic route to HMG-pantetheine 79 resulted in 
epimers at C-3, limiting the information that could be gained by this method.  
The synthesis of [13C]-Acac-pantetheine 83 or [13C]-Ac-pantetheine 85 could be achieved 
using the previously developed synthetic routes from [2-13C] acetyl chloride, a readily 
available and cost-effective source of [13C]. Following BatC-catalysed condensation, 
[13C]-Acac-pantetheine 83 would introduce a [13C] label at C-6 of HMG-intermediate 84, 
whereas [13C]-Ac-pantetheine 85 would locate the [13C] label at C-4 of HMG-
intermediate 86 (Scheme 26B and C). Analysis of the mechanism of β-branching 
suggested a greater difference in chemical environment would be experienced by C-4 
than C-6, making [13C]-Ac-pantetheine 85 the more favourable biosynthetic mimic.  




Scheme 27 Synthesis of [13C]-Ac-pantetheine 85 and [13C]-Acac-pantetheine 83.  
[13C]-Ac-pantetheine 85 and [13C]-Acac-pantetheine 83 were both prepared (Scheme 27). 
The synthesis of [13C]-Acac-pantetheine 83 utilised [2-13C] acetyl chloride analogous to 
the preparation of the unlabelled material. A higher yield of [13C]-Ac-pantetheine 85 was 
obtained from the EDCI-mediated coupling of 59 with [2-13C] acetic acid (performed by 
Angus Weir) rather than the condensation with [2-13C] acetyl chloride.  
The 1H and 13C NMR for both unlabelled (60) and [13C] labelled (85) Ac-pantetheine are 
shown in Figure 44, and unlabelled (62) and [13C] labelled (83) Acac-pantetheine in 
Figure 45. In the 1H spectrum of [13C]-Ac-pantetheine 85, the coupling between the [13C] 
enriched methyl carbon and the protons at 2.34 ppm can be observed with a 1JH-C coupling 
constant of 130 Hz (Figure 44B). The 13C NMR showed an enriched signal at 30.5 ppm 
corresponding to the acetyl CH3 (Figure 44C and D). The 
1H and 13C spectra for [13C]-
Acac-pantetheine 83 are more complex due to the enol/keto tautomers formed. As such, 
the two methyl signals (1.94 ppm and 2.23 ppm) show 1JC-H coupling constants of 128 Hz, 
to give four signals in the spectrum (Figure 45B). In the 13C spectrum, enhancement 
compared to the unlabelled material was seen for the methyl groups at 30.5 ppm and 
20.8 ppm corresponding to the keto and enol forms respectively (Figure 45C and D).  
Hence it was decided that [13C]-Ac-pantetheine 85 was likely to be a better candidate for 
the proposed β-branching NMR assay. This was due to the single chemical shift and the 
more favourable C-4 position for the [13C] label in an HMG-ACP intermediate following 
reaction of two ACPs. As a result, unlabelled Acac-pantetheine 62 was used as the β-
ketothioester mimic attached to ACPA, and [
13C]-Ac-pantetheine 85 was used as the 
acetyl donor tethered to ACPD.  





Figure 44 1H and 13C NMR characterisation of unlabelled 60 and [13C] labelled (85) Ac-pantetheine. A) 1H spectrum 
of unlabelled Ac-pantetheine 60 with the acetyl CH3 highlighted in blue. B) 1H spectrum of [13C]-Ac-pantetheine 85 
shows coupling of the acetyl CH3 signal (blue) at 2.34 ppm by 1JH-C coupling of 130 Hz. C) 13C spectrum of unlabelled 
Ac-pantetheine 60. D) 13C spectrum of [13C]-Ac-pantetheine 85 shows enhancement of the signal at 30.5 ppm due to 
the selective incorporation of the [13C] label.  





Figure 45 1H and 13C NMR characterisation of unlabelled (62) and [13C] labelled (83) Acac-pantetheine, with the major 
tautomer (keto) shown in blue and the minor (enol) tautomer shown in red. A) 1H spectrum of unlabelled Acac-
pantetheine 62. B) 1H spectrum of [13C]-Acac-pantetheine 83 shows coupling of the keto-CH3 at 2.23 ppm and the enol 
CH3 at 1.94 ppm by a 1JH-C coupling of 128 Hz. C) 13C spectrum of unlabelled Acac-pantetheine 62. D) 13C spectrum 
of [13C]-Acac-pantetheine 83 shows enhancement of the signal at 30.5 ppm and 20.8 ppm due to the selective 
incorporation of the [13C] label.  
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2.2.4 13C NMR assay for ACP4 
With [13C]-Ac-pantetheine 85 in hand, initial NMR experiments were carried out to 
determine whether the [13C] label could be readily observed when attached to an ACP. 
Apo-BatA was loaded with [13C]-Ac-pantetheine, as confirmed by MS analysis, desalted 
into NMR buffer to remove excess pantetheine and concentrated to 345 µM. A 1H 
spectrum showed a dispersion of signals and upshifted methyl peaks were evident which 
arise from the interaction of methyl groups with aromatic side chains and is a good 
indication of folded protein (Figure 46A). A 13C spectrum was recorded which yielded a 
single signal at 32.75 ppm (Figure 46B). The loading was monitored by MS and the Ppant 
ejection assay which gave a peak at 304.2 Da, 1 Da heavier than the unlabelled material.  
 
Figure 46 A) 1H spectrum of [13C]-Ac-BatA contains upfield shifted methyl peaks around 0.0-0.5 ppm which indicate 
protein folding. B) 13C spectrum of [13C]-Ac-BatA gave a single signal (32.75 ppm) and MS analysis by Ppant ejection 
(304,2 Da) confirmed the 1 Da increase in mass relative to unlabelled Ac-BatA (303.2 Da).  
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Before reconstituting the β-branching pathway, apo-ACP4 was converted to [13C]-Ac-
ACP4. Although a non-native substrate of the β-branching pathway, this control was run 
to ensure that the [13C] label could be observed on this ACP by NMR. The loading was 
monitored by Ppant ejection and gave the expected peak at 304.2 Da. The sample was 
concentrated to 340 µM transferred to an NMR tube and a 1H spectrum showed the 
protein was folded (Figure 47A). Once again, the 13C spectrum showed a single signal at 
32.75 ppm, which was identical to the chemical shift recorded for [13C]-Ac-BatA 
(Figure 47B).  
 
Figure 47 A) 1H spectra of [13C]-Ac-ACP4. B) 13C spectrum of [13C]-Ac-ACP4 gives a single signal at 32.75 ppm that, 
along with MS analysis by Ppant ejection (304.2 Da), confirmed the loading of [13C]-labelled acetate on to ACP4.  
The loading of BatA and ACP4 with [13C]-Ac-pantetheine and NMR experiments 
provided information on the ease of loading, amount of [13C] label required and the 
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sensitivity of the NMR experiments. The reaction of two ACPs results in sample dilution, 
therefore it was deemed necessary to get a relatively high stock concentration of [13C] 
label for the NMR experiments. This would allow for shorter NMR experiments which 
would increase the chance of observing transient intermediates. During β-branching 
assays the sample was constantly monitored and NMR spectra recorded at appropriate 
times. Length and frequency of NMR experiments varied according to each individual 
experiment and the amounts of [13C]-labelled products formed.  
To test the methodology during the challenging reconstitution of the β-branching 
pathway, the assay was repeated on ACP4 as previously shown by MS and pantetheine-
bound NMR experiments to give an endo-β-methyl branch. Apo-ACP4 was loaded with 
Acac-pantetheine 62, desalted and concentrated. [13C]-Ac-BatA and BatC were added 
and the reaction mixture transferred to an NMR tube. The 1H NMR showed the 
characteristic upshifted methyl peaks for both ACPs (Figure 48).  
 
Figure 48 1H spectrum of Acac-ACP + [13C]-Ac-BatA + BatC shows upfield shifted methyl peaks corresponding to 
both ACPs.  
The 13C spectra showed two previously uncharacterised peaks in addition to [13C]-Ac-
BatA at 32.75 ppm (Figure 49). The new peak at 50.15 ppm had a chemical shift 
consistent with the CH2 of an ACP-bound HMG-intermediate and MS analysis showed 
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the formation of the HMG-intermediate plus 1 Da for the [13C] label (406.2 Da), by Ppant 
ejection assay. A DEPT-edited 13C spectrum was recorded and the peak at 50.15 ppm was 
inverted consistent with a CH2 group, and adding further evidence to the successful 
formation of [13C]-HMG-ACP4. The peak at 26.00 ppm remained positively phased in 
the DEPT spectra and was assigned as free [13C]-acetate. [13C]-Ac is transferred from 
BatA to BatC prior to condensation to form [13C]-HMG-ACP. However, non-productive 
hydrolysis of [13C]-Ac-BatC results in the formation of free [13C]-acetate. This undesired 
reaction has been reported for the HMGCS of primary metabolism and CurD (HMGS) 
from the curacin β-branching cassette.41,141 The sample was monitored over 16 h by 
recording back-to-back 13C spectra and the complete hydrolysis of [13C]-Ac-BatA to free 
[13C]-acetate could be observed over time. The [13C]-HMG-ACP4 peak at 50.15 ppm 
remained constant consistent with no further reaction progress or hydrolysis.  
 
Figure 49 Stack of 13C spectra of Acac-ACP4 + [13C]-Ac-BatA + BatC with an initial spectrum taken at 1 h up to 
16.5 h after initiation of the assay. A DEPT-edited spectrum resulted in the phase inversion of the peak at 50.15 ppm, 
corresponding to the CH2 group of [13C]-HMG-ACP4. MS analysis of the reaction after 1 h gave a peak at 406.2 Da 
by Ppant ejection assay, corresponding to [13C]-HMG-ACP4.  
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To investigate the dehydration of [13C]-HMG-ACP4, the intermediate was freshly 
generated by BatC, at which point BatD was added and a 1H spectrum was recorded to 
confirm ACP folding (Figure 50).  
 
Figure 50 A 1H NMR spectrum of Acac-ACP + [13C]-Ac-BatA + BatC + BatD.  
A DEPT spectrum was then recorded and showed the same three peaks corresponding to 
[13C]-Ac-BatA, [2-13C]-acetate and [13C]-HMG-ACP4 (Figure 51). The reaction was 
monitored over 11 h, however, no new signal corresponding to the dehydrated 
intermediate [13C]-MG-ACP4 was observed. The reversible nature of the reaction and the 
low yield of MG-pantetheine 80 from our previous experiments suggested that this 
reaction would be difficult to monitor. A 2D HSQC spectrum was recorded and showed 
the 1H-13C correlations for free [13C]-acetate (26.00 ppm/1.91 ppm), [13C]-HMG-ACP4 
(51.15 ppm/2.42 ppm) and two newly identified peaks at 42.10 ppm and 52.1 ppm 
(Figure 52). The peak at 42.10 ppm was not observable in the DEPT spectrum, but due 
to the greater 1H sensitivity of the NMR instrument used, it was possible to detect this 
species.  




Figure 51 Stack of DEPT spectra showing the stability of [13C]-HMG-ACP4 when incubated with BatD. No dehydrated 
product is observed, however, a new minor peak at 52.1 ppm appeared after 11h that could not be assigned.  
 
Figure 52 HSQC spectrum gives 
the 1H-13C correlations for [2-
13C]-acetate (26.00 ppm/1.91 
ppm) and [13C]-HMG-ACP4 
(50.15 ppm/2.42 ppm). The peak 
at 42.10 ppm with a 1H 
correlation to 2.97 ppm 
corresponds to [13C]-MG-ACP4 
The peak at 52.1 ppm could not 
be identified. The peaks shown in 
black are positively phased (CH 
or CH3) and the blue peaks are 
negatively phased (CH2).  
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Although hydrolysis was not observed in the previous BatC-condensation experiment, it 
was thought that one of the two unidentified species may correlate to HMG hydrolysis. 
The unlabelled diacid 77 had been previously synthesised and characterised in (CD3)2CO, 
so the compound was dissolved in the assay NMR buffer and 1H, 13C and 1H-13C HSQC 
spectra were recorded. The 13C chemical shift of the CH2 was 51.2 ppm and showed a 
correlation to a 1H peak at 2.36 ppm (Figure 53A). Neither chemical shifts match the 
observed peak, ruling out hydrolysis of [13C]-HMG-ACP4 and so the identity of the 
species at 52.1 ppm remained unknown.  
 
Figure 53 A) 1H and 13C chemical shifts of the hydrolysed di-acid in d6-acetone and NMR buffer. B) Literature 
assignment in D2O of the E- and Z- isomers of the dehydrated di-acid.142  
The peak at 42.10 ppm, with a 1H correlation at 2.97 ppm, corresponded to dehydration 
intermediate [13C]-MG-ACP4. From the previous pantetheine experiments, the 1H 
chemical shift of the CH2 group of MG-pantetheine 80 was 3.07 ppm. As the intermediate 
is now ACP-bound, the slight change in chemical shift is not unreasonable. To further 
validate this result, a comparison of chemical shifts was made with the previously 
characterised di-acids 88 and 89 (Figure 53B).142 The 13C chemical shift for the CH2 of 
the dehydrated di-acid in D2O were 45.0 ppm (
1H correlation at 3.08 ppm) for the major 
E-isomer 88 and 38.5 ppm (1H correlation at 3.45 ppm) for the minor Z-isomer 89. 
Considering the difference in NMR solvent and the influence of the ACP attached via a 
thioester linkage, these data support the peak at 42.10 ppm corresponding to [13C]-MG-
ACP4.  
Finally, [13C]-HMG-ACP4 was freshly prepared from Acac-ACP4, [13C]-Ac-BatA and 
BatC, at which point BatD and BatE were added and a DEPT spectra was recorded 
(Figure 54C). A new, positively phased peak at 23.51 ppm was observed in addition to 
the previously identified species. Ppant ejection yielded two ions corresponding to an 
unsaturated-β-methyl-ACP4 (344.2 Da) and Acac-ACP4 (345.2 Da).  




Figure 54 Stack of 13C DEPT-edited spectra and MS analysis by Ppant ejection assay of the β-branching pathway for 
ACP4 to give an endo-β-methyl branch. A) [13C]-Ac-BatA, B) Acac-ACP4 + [13C]-Ac-BatA + BatC, C) Acac-ACP4 
+ [13C]-Ac-BatA + BatC + BatD + BatE. The Ppant ejection gives two peaks corresponding to endo-β-methyl-ACP4 
(344.2 Da) and Acac-ACP4 (345.2 Da), both arising from the ejection due to the 1 Da mass difference.  
A 1H-13C HSQC spectrum was acquired and the [13C] labelled CH3 at 23.51 ppm showed 
a 1H correlation at 2.03 ppm (Figure 55). The chemical shifts matched that of the 
previously analysed standards: enoyl-pantetheine 64 and enoyl-13C/15N-ACP4. It was 
possible to assign the [13C] labelled methyl group trans to the alkene-proton with the 
unlabelled methyl group cis, as expected for the linearised polyketide chain, by 
comparison with the previously determined chemical shifts.  
 




Figure 55 1H-13C HSQC spectrum of the reaction Acac-ACP4 + [13C]-Ac-BatA + BatC + BatD + BatE. The [13C]-
labelled methyl at 23.51 ppm shows a correlation to a proton at 2.03 ppm consistent with the formation of the endo-β-
methyl product. [13C]-HMG-ACP (50.15 ppm/2.42 ppm) and [13C]-Ac-BatA (32.75 ppm/2.31) as well as [13C]-acetate 
(26.00 ppm/1.91 ppm) arising from non-productive hydrolysis of [13C]-Ac-BatC are also present in the spectrum. Peaks 
arising from the ACP backbone are visible between 0.5-1.0 ppm (insert).  
With the formation of an endo-β-methyl on ACP4 confirmed, the pathway was 
reconstituted on an alternative β-branching ACP to demonstrate the generality of the 
methodology. ACP5 was loaded with Acac-pantetheine 62, reacted with [13C]-Ac-BatA 
in the presence of BatC and incubated with BatD and BatE. The 1H spectrum for ACP5 
once again showed a folded protein and the DEPT-spectra showed clean conversion to an 
endo-β-methyl in addition to free [2-13C]-acetate (Figure 56). The chemical shifts of the 
product (23.49 ppm) were very similar to that of ACP4 (23.51 ppm), showing that 
different ACPs do not have a major impact on the chemical shift of the thioester-bound 
substrate. A 1H-13C HSQC spectrum revealed a greater difference in chemical shifts in 
the 1H axis between ACP5 (1.95 ppm) and ACP4 (2.03 ppm) than observed in the 13C 
axis (Figure 57). However, MS supported the formation of an unsaturated β-branch with 
Ppant ejection ion at 344.2 Da.  




Figure 56 Characterisation of an endo-β-methyl branch attached to ACP5 from the reaction Acac-ACP5 + [13C]-Ac-
BatA + BatC + BatD + BatE. 13C DEPT-edited spectra and MS analysis by Ppant ejection assay confirming the identity 
of the endo-β-methyl at 23.49 ppm and a mass of 344.2 Da by Ppant ejection. Insert: 1H spectrum showing upfield 
shifted methyl peaks indictive of folding.  
 
 
Figure 57 1H-13C HSQC spectrum of the reaction Acac-ACP5 + [13C]-Ac-BatA + BatC + BatD + BatE. Correlations 
for the [13C]-endo-β-methyl product (23.49 ppm/1.95 ppm) and [13C]-acetate (26.00 ppm/ 1.91 ppm) were observed 
and these were consistent with the chemical shifts for ACP4.  
 
Kalimantacin β-Branching Pathway 
83 
 
2.2.5 13C NMR assay for 4M 
Having demonstrated the power of the methodology, the next step was to apply it to the 
di-domain 4M to determine the function of the mECH domain. Working with 4M was 
likely to present more challenges than ACP4 alone. Firstly, the protein is 43 kDa and 
dimerises to an 86 kDa complex, which is harder to analyse by NMR. Secondly, the 
influence of the mECH domain on the loading of the ACP and the relative stability of 
intermediates was unknown. Finally, the larger protein mass would make it harder to 
achieve high concentrations of ACP-bound intermediates, affecting the sensitivity of the 
assay. It would also require a large mass of protein per experiment, therefore requiring 
good protein expression and handling to prevent sample loss.  
 
Figure 58 A) 1H spectrum of [13C]-Ac-4M. B) 13C DEPT spectrum of [13C]-Ac-4M gave a peak at 32.75 ppm along 
with MS analysis by Ppant ejection (304.2 Da). The peaks at 65.29ppm and 74.87 ppm correspond to glycerol.  
Kalimantacin β-Branching Pathway 
84 
 
[13C]-Ac-pantetheine 85 was loaded onto 4M, desalted into NMR buffer and concentrated 
to 150 µM. A 1H spectrum was recorded and, as expected, weaker and broader peaks were 
observed (Figure 58A). However, upfield shifted methyl peaks that could be correlated 
to ACP4 were present, indicating the ACP is folded. A DEPT spectrum was then recorded 
and the characteristic positive CH3 peak at 32.75 ppm was observed (Figure 58B). This 
result meant that the mobility of the substrate attached to ACP4 was not influenced by 
the adjacent mECH domain and that intermediates were likely to be solvent exposed and 
therefore accessible to other catalytic enzymes and would be observable by 13C NMR.  
To reconstitute the β-branching pathway, Acac-pantetheine 62 was loaded onto apo-4M 
and after 1 h full loading was achieved. [13C]-Ac-BatA and BatC were then added and the 
sample monitored by DEPT NMR, showing the conversion to [13C]-HMG-4M (Figure 
59). Once again, a significant proportion of non-productive hydrolysis to form [13C]-
acetate was also observed. Brief optimisation of this step found that a lower concentration 
of BatC reduced the production of [13C]-acetate. Hydrolysis could also be minimised by 
the stepwise addition of the desired amount of BatC and [13C]-Ac-BatA in two portions, 
with the second addition 30 mins after the first. Whilst not preventing hydrolysis, a greater 
proportion of [13C]-HMG-4M was obtained.  
 
Figure 59 13C DEPT spectrum showing the formation of [13C]-HMG-4M. It was not possible to analyse this 
intermediate by MS.  
Freshly formed [13C]-HMG-4M was incubated with BatD to determine whether mECH 
acts as a decarboxylase in the absence of BatE. The sample was monitored by DEPT 
NMR and pleasingly a new, negatively phased peak at 118.63 ppm was observed 
(Figure 60C). MS analysis of the sample gave a Ppant ejection ion at 344.2 Da, consistent 
with a [13C]-unsaturated β-branch. Previous, analogous assays containing ACP4 did not 
show a peak at 344.2 Da by Ppant ejection that might arise from spontaneous 
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decarboxylation. Additionally, no endo-β-methyl peak was observed around 23.51 ppm, 
in accord with the new peak at 118.63 ppm being due to the exo double bond. A second 
peak at 42.10 ppm, previously only identified in the HSQC of the [13C]-HMG-ACP4 and 
BatD reaction, was also present. As previously discussed, it is likely that this peak 
corresponds to [13C]-MG-4M.  
 
Figure 60 Stack of 13C DEPT-edited spectra and MS analysis by Ppant ejection assay of the β-branching pathway for 
the di-domain 4M to give an exo-β-methyl branch. A) [13C]-Ac-BatA, B) Acac-4M + [13C]-Ac-BatA + BatC, C) Acac-
4M + [13C]-Ac-BatA + BatC + BatD.  
To validate this result, β-exo-pantetheine 81 was prepared and analysed by NMR (work 
carried out by Angus Weir). Due to the propensity of the double bond to migrate into 
conjugation with the thioester, it was only possible to prepare a mixture of enoyl-
pantetheine 64 and β-exo-pantetheine 81 (Figure 61A). The 13C NMR of β-exo-
pantetheine 81 contained a peak at 118.36 ppm consistent with the chemical shift of the 
exo-β-methyl formed on 4M (Figure 61B). The slight chemical shift perturbation arises 
from the attachment of the intermediate to an ACP resulting in a subtly different chemical 
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environment relative to the pantetheine. This result proves that the mECH domain acts as 
a decarboxylase which produces an exo-β-methyl by C-2 reprotonation (Figure 61C). This 
reactivity also rules out the possibility that mECH is an isomerase, as the exo-β-methyl is 
formed directly and does not require BatE.  
 
Figure 61 A) Synthesis of β-exo-pantetheine 81 as a mixture with enoyl-pantetheine 64. B) 13C spectrum of β-exo-
pantetheine 81 contains a peak for the exo-methylene at 118.36 ppm (grey). C) Mechanism of decarboxylation and C-
2 reprotonation by mECH.  
Finally, [13C]-HMG-4M was incubated with both BatD and BatE. The reaction contains 
two decarboxylase domains, creating a competition for the formation of either an endo- 
or exo-β-methyl. DEPT spectra showed the formation of a peak at 118.63 ppm and 
23.51 ppm, which correlate to an exo-β-methyl and an endo-β-methyl respectively 
(Figure 62). It was not possible to validate this result by MS due to low forward flux of 
the pathway resulting in low product formation.  
 
 




The presence of [13C]-Ac-BatA and [13C]-HMG-4M, in addition to the dehydrated 
intermediate at 42.10 ppm suggested that the flux through the pathway was inefficient or 
stalled. This points to the limitation of the model system used to reconstitute the β-
branching pathway in vitro. The 3D architecture of the modular PKS, correct biosynthetic 
intermediate and directionality of the pathway that offloads substrates from the ACP will 
have a major impact on the flux of the system which may lack some components required 
for tight control.  
Figure 62 Stack of 13C DEPT spectra of the β-
branching pathway for the di-domain 4M to give 
an endo-β-methyl (23.51 ppm) and exo-β-methyl 
branch (118.63 ppm) from the reaction Acac-
4M + [13C]-Ac-BatA + BatC + BatD + BatE. 
A) 4 h, B) 8 h, C) 12 h, D) Zoom of spectra 
around 108-126 ppm showing the exo-β-methyl 
forming after 12 h. The persistence of the 
dehydrated intermediate at 42.10 ppm suggests 
poor efficiency of the reaction.  
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2.2.6 Bioinformatic analysis of ECH2 domains 
The differential formation of endo-β-methyl and exo-β-methyl branches via an ECH2-
catalysed decarboxylation/selective reprotonation observed for BatE and mECH 
respectively suggests a key difference in active site architecture to ensure correct β-branch 
formation. Sequences of ECH2 domains that produce either endo-β-methyl and exo-β-
methyl branches were aligned using Clustal Omega (Figure 63)143. All domains are part 
of trans-AT PKS pathways, except for the well-studied cis-AT polyketides curacin and 
jamaicamide. 
 
Figure 63 Truncated sequence alignment for ECH2 domains producing endo- and exo-β-methyl branches. The 
conserved catalytic histidine and OAH-forming residues are shown in red and orange respectively. A PGxG motif that 
differentiates the endo- and exo-β-methyl producing domains is shown in green along with a key aromatic residue (Phe 
or Tyr) in blue. A) ECH2 domains from trans-AT PKS that produce an endo-β-methyl branch contain a PGMG motif 
and conserved phenylalanine (Phe132, BatE). B) ECH2 domains from cis-AT PKS that produce endo- (CurF) and exo- 
(JamJ) β-methyl branches in which the PGxG motif is not observed. C) ECH2 domains from trans-AT PKS that produce 
exo-β-methyl branches contain a PGAG motif and a conserved tyrosine (Tyr129, Bat3_mECH).  
Using the literature structure of CurF ECH2, the catalytic His240 (CurF) and OAH-
forming residues Ala78 and Gly118 (CurF) were conserved across all domains.55 Careful 
analysis of the alignment revealed a PGMG (139-142, BatE) motif present in the endo-β-
methyl producing and an equivalent PGAG (136-139, mECH) motif in the exo-β-methyl 
producing ECH2 domains. The only exceptions to the motif were CurF and JamJ ECH2 
which contain PVGA and PVGS motifs respectively. The absence of the conserved motif 
in these cis-AT PKS domains might arise from the separate evolution of these pathways 
from the trans-AT PKS.29 Another difference in the two sets of ECH2 domains was an 
aromatic amino acid 7-residues upstream of the PGxG motif. The endo-β-methyl 
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producers have a phenylalanine (Phe132, BatE) whilst the exo-β-methyl producers 
contain a conserved tyrosine (Tyr129, mECH).  
To explore the 3D architecture of the ECH2 domains and the position of the key residues, 
homology models of mECH and BatE from the kalimantacin pathway were constructed 
using the Phyre2 and I-Tasser servers. The structures generated by each of the servers 
displayed the same overall architecture, consisting of the classic CS fold, but there was a 
dramatic difference in the position of the C-terminal domain. These α-helical domains are 
vital in the formation of oligomers in the CS, with trimers or dimers of trimers the most 
common oligomeric state observed.100 Depending on the position of the C-terminal helix, 
the interactions may be categorised as monomer self-association, intra-trimer or inter-
trimer. In the monomer self-association, the C-terminal helix forms the active site of the 
monomer by folding back across the core structure.144 However, by orientating the helix 
away from the core, monomer structure, it may form the active site of an adjacent 
monomer within the trimeric structure (intra-trimer) or across the trimer-trimer interface 
(inter-trimer).145  
The models generated by Phyre2 contained the self-association fold with the active site 
created by the C-terminal domain of the monomer. In contrast, both I-Tasser models 
contained a C-terminal domain folded away from the monomer structure, as expected for 
an inter/intra-trimer oligomer. The CurF ECH2 domain was shown to form the self-
association fold in the solid-state trimer solved by Smith et al.55 Therefore, the Phyre2 
models were used to map the key catalytic residues in the active site.  
His231 (BatE), His 228 (mECH) and the OAH-forming residues - Gly67/Gly109 in BatE 
and Gly64/Ala106 in mECH - were mapped onto their respective structures and showed 
very similar positions around the active site (Figure 64A and D). The C-terminal domain 
encloses the active site with the final helix creating a capping loop over the entrance to 
the substrate channel. The PGxG motif is located in a loop adjacent to the active site in 
both BatE and mECH. In BatE, Met141 sits at the bottom of the active site, close to the 
OAH-forming Gly67 and Gly109, creating a hydrophobic surface of the narrow channel 
that leads to the catalytic His231 and forcing Phe132 away from the active site (Figure 65 
B and C).  
 




Figure 64 Phyre 2 homology models for BatE and mECH both represented as the monomer self-association fold. A) 
Homology model of BatE. B) Zoom of BatE active site with the catalytic H231 and OAH-forming residues G67 and 
G109 (orange). M141 from the PGMG motif blocks the bottom of the active site and along with F132 forms a 
hydrophobic compartment. C) Surface representation of the active site shows a channel for substrate feeding lined by 
the key catalytic residues. D) Homology model of mECH. E) Zoom of the mECH active site with the catalytic H228 
and OAH-forming residues G64 and A106 (orange) in conserved positions. A138 from the PGAG motif does not block 
the bottom of the active site and Y129 is positioned close to the OAH and is a likely proton-source for the C-2 
reprotonation to form an exo-β-methyl branch.  
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In contrast, the equivalent Ala138 residue of the PGAG motif in mECH occupies a similar 
position to Met141, but the smaller alanine creates a more open cavity (Figure 64 
E and F). This allows Tyr129 to occupy a position within the active site cavity, proximal 
to the OAH-forming residues. It is therefore hypothesised that Tyr129 is the proton source 
that, following decarboxylation, reprotonates at the C-2 position to form an exo-β-methyl 
branch. Due to the absence of a polar residue in the BatE active site, it is proposed that 
His231 may deprotonate and, following decarboxylation, reprotonate the C-4 position to 
give the endo-β-methyl branch. The methionine residue may facilitate this reaction by 
forming the narrow cavity to orientate the substrate towards His231 compared to the more 
open cavity arising from Ala138 in mECH.  
2.2.7 Mechanisms for β-branch selectivity 
The difference in ECH2 sequence and structure offers a hypothesis for the formation of 
both the endo- and exo-β-methyl branches that were observed experimentally. However, 
it is also important to rationalise how the kalimantacin biosynthetic pathway – containing 
several enzymatic β-branching pathways - achieves the required selectivity to produce a 
single polyketide product. This may be understood by considering the type I PKS 
oligomerisation, 3D architecture and the interaction of trans-acting catalytic domains.  
The ECH2 integrated into CurF is the only ECH2 domain in the curacin biosynthetic 
pathway and the only example of a β-branching ECH2 structurally characterised in the 
literature.55 It was shown to be trimeric in the solid state, but a concentration-dependant 
equilibrium between trimeric and lower oligomeric species was observed in solution. 
Analysis of the monomeric units showed that they form the self-association fold, whereby 
the active site is covered by the C-terminal domain of the same monomer. This would 
allow for a fully functional enzyme without the requirement for oligomerisation. The 
authors state that it is currently not clear how the modular, trimeric ECH2 domain might 
associate with downstream domains (KS, DH) that are known to dimerise.  
In the kalimantacin biosynthetic pathway, the free-standing ECH2 (BatE) was shown to 
be trimeric in solution whereas the 4M di-domain was dimeric. Whilst the trans-acting 
BatE oligomerises as would be expected of a CS protein, the dimeric 4M construct creates 
uncertainty over the assembly of type I PKS modules that contain both, normally trimeric, 
ECH2 domains as well as, normally dimeric, chain extension (KS) domains. Either the 
ECH2 adopts a less common dimeric structure or trimerisation at the ECH2 domain 
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occurs, creating large, complex oligomeric structures. The formation of biosynthetic 
megacomplexes was reported by Keatinge-Clay et al. who identified a motif capable of 
mediating this association.146 How these domains ultimately associate will undoubtedly 
affect the possible interactions of the modular ACPs that are required to deliver the 
growing polyketide chain in-cis as well as interact with trans-acting domains.  
In the formation of the C-7 exo-β-methyl branch at ACP4, BatD (trimeric in solution) 
dehydrates HMG-ACP4 prior to decarboxylation. The in-cis mECH then decarboxylates 
the dehydrated intermediate and selectively reprotonates it to form the exo-β-methyl 
branch. Our in vitro results show that BatE can interact with ACP4 expressed as a single 
domain and as part of the 4M di-domain to form an endo-β-methyl branch. Additionally, 
the in vivo formation of a C-7 sat.-β-methyl branch in a kalimantacin minor metabolite 
69 suggests it is possible for BatE (and subsequently BatK) to interact with ACP4 in the 
wild-type system. However, the pathway shows high efficiency in the formation of the 
exo-β-methyl branch due to the low titres of the minor compound. It is hypothesised that 
this high selectivity is achieved kinetically, with faster flux of biosynthetic intermediates 
at ACP4 in-cis than in-trans. mECH would therefore act faster on the dehydrated 
intermediate than BatE, resulting in exo-β-methyl formation. If BatE were to act faster 
than mECH, the result would be the formation of the minor sat.-β-methyl branch via BatK 
reduction.  
An alternative mechanism for selectivity is the steric occlusion of BatE from ACP4. This 
would require ACP4 to discriminate between the two trimeric proteins BatD and BatE. 
Following BatD-catalysed dehydration, a structural rearrangement would have to take 
place to prevent BatE from decarboxylating the dehydrated intermediate. Structural 
rearrangements of a whole module from the modular cis-AT PKS that produces 
pikromycin were presented by Skiniotis et al. in 2014.34 Using cryo-EM, the authors were 
able to capture a series of distinct catalytic states and demonstrate the rearrangement 
required between each step. Each structural rearrangement is necessary to pass the ACP-
bound intermediate from one catalytic domain to the next to produce the correct 
polyketide. As each domain is fused as part of a single polypeptide chain, the position of 
all domains is well defined for each catalytic step.  
In the kalimantacin pathway, however, the catalytic domains are acting in-trans. This 
means that BatD must associate with the modular ACP rather than simply rearranging to 
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a defined location to deliver the substrate as happens for in-cis substrate channelling. 
Following dehydration, a structural rearrangement would have to occur quickly to prevent 
BatE association with the ACP. The timing of this structural rearrangement and 
recognition of each catalytic domain must be very strict to prevent the wrong substrate 
being delivered to each of the in-trans catalytic domains. It may therefore be a substrate-
controlled process, in which the ACP must recognise pre- and post- catalysis substrates. 
These steric arguments, whilst plausible, would need to be rigorous to prevent aberrant 
β-branch formation, and perfect fidelity is not achieved as BatE/BatK are able to produce 
the sat.-β-methyl minor metabolite 69.  
Whilst the CS has been extensively studied, there is little structural information available 
for domains that interact with ACP-bound rather than CoA-bound substrates, particularly 
the ECH domains from HCS cassettes. Understanding their structures, oligomerisation in 
a type I PKS and active site residues will all be critically important to understand how the 
channelling of substrates occurs in β-branching modules. In particular, the control 
required for the selective interaction of modular ACPs with trans-acting domains is 
poorly understood and offers an exciting area for future research.  
2.3 Kalimantacin Isolation, Analysis and Synthetic Studies 
2.3.1 Natural product isolation and stability 
Kalimantacin A shows promise as an antimicrobial agent, however, there was uncertainty 
over the stability of the molecule (Figure 65). In such a highly functionalised compound, 
the E,Z-diene may isomerise and cleavage of the chain via a retro-aldol reaction may 
occur. In addition to the natural diene geometry, small amounts of the E, E-isomer had 
been isolated from P. fluorescens by previous members of the Willis group.97  
 
Figure 65 Structures of kalimantacin A and B and the co-eluting side DKP side product 91.  
Kalimantacin β-Branching Pathway 
94 
 
To investigate this further, two separate stocks of P. fluorescens were streaked onto LB 
agar, a pre-culture prepared and used to inoculate a 1 L culture. After 4 days, the cells 
were separated, and the supernatant extracted with ethyl acetate to give a crude oil. By 
LC/MS, both fermentations had produced kalimantacin and the separate crude extracts 
were purified by column chromatography. After the first column (MeOH/CH2Cl2/AcOH), 
kalimantacin A was mixed with diketopiperazine 91 (DKP) as previously reported.97 This 
material was further purified using MeOH/EtOAc/AcOH as the eluent. Batch 1 gave 95% 
pure kalimantacin which was characterised by 1H, 13C NMR and HRMS and the data 
recorded were in good agreement with the literature (Figure 66A).78  
 
Figure 66 Expansion of 1H NMR (CDCl3) spectra of the kalimantacins. A) The compound from batch 1 was in 
agreement with the literature assignment of kalimantacin A containng the E,Z-diene .78 B) In batch 2, kalimantacin A 
was isolated with ~80% purity, however, a small amount of kalimantacin B containing the E,E-diene was co-purified.76 
The peak at 5.47 ppm corresponds to the 10-H of kalimantacin B, whilst other minor peaks were also evident (*).  
In addition to kalimantacin A, the 1H NMR spectrum of batch 2 showed several minor 
peaks that were assigned to the E,E-diene moiety, with the multiplet at 5.47 ppm (10-H) 
being one of the most characteristic (Figure 66B). This was assigned from the 1H NMR 
data published for kalimantacin B produced by the alcaligenes species.76 This double 
bond isomer has previously been observed both in the isolation of kalimantacin-like 
natural products, but also in the chemical synthesis of related compounds.98 One 
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hypothesis for the formation of both isomers was that the acidic work-up conditions 
catalysed isomerism of the E,Z-diene to the E,E-diene. To test this theory, the 
fermentation was repeated, and half the supernatant was acidified to pH 2 with HCl then 
extracted, whilst the remaining half was extracted at pH 7.  
Following the same chromatography procedure, the yields from the non-acidified (18 mg) 
and acidified (19 mg) work ups were comparable and in both cases a small quantity of 
the E,E-isomer (10%) could be observed as shown in Figure 67. This result suggests that 
there is not an acid-driven isomerisation between the E,Z natural product and the E,E 
minor isomer. However, it does demonstrate the inconsistency in the production of the 
minor isomer as a different ratio was obtained in each of the fermentations.  
 
Figure 67 Expansion of 1H NMR (CDCl3) spectra for kalimantacin. A) Isolated under normal conditions at pH 7 and 
B) following acidification to pH 2 with HCl. Around 10% kalimantacin B is present in both samples, determined by 
the characteristic 10-H peak at 5.47 ppm.  
To understand more about the stability of kalimantacin A, 2 mg/ mL of kalimantacin from 
both batch 1 and 2 were stored separately in an NMR tube in CDCl3 under normal lab 
conditions of 25 °C and exposed to light. 1H NMR spectra were recorded every 7 days 
for 5 weeks (Figures 68 and 69).  




Figure 68 Stack of expanded 1H NMR spectra for kalimantacin A isolated in batch 1 and stored in CDCl3 at 25 °C.  
 
Figure 69 Stack of expanded 1H NMR spectra for kalimantacin A/B isolated in batch 2 and stored in CDCl3 at 25 °C.  
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During the time course, no change in the proportion of E,E- and E,Z- isomers was 
observed, indicating the stability of the molecule to light, ambient temperature and the 
mildly acidic conditions provided by the deuterated chloroform. This result suggests that 
the proportion of E,Z- and E,E- isomers is determined during the fermentation and 
isolation procedure and remains constant thereafter.  
Further work conducted by Angus Weir (a PhD student in our group) has resulted in 
fermentation broths that give rise to 60% kalimantacin A and 40% of the E,E-isomer 
kalimantacin B. Furthermore, excluding light during fermentation yielded variable ratios 
of diene geometry and storing a pure sample of kalimantacin A at room temperature 
resulted in isomerism to kalimantacin B. Despite extensive work, it is still not possible to 
completely control the proportion of diene isomers isolated from fermentation broths. 
Conflicting evidence about the isomerism of the E,Z-diene to an E,E-diene in dilute 
solution and neat suggest that the compound is unstable around this moiety. A better 
understanding of this process is required.  
2.3.2 Synthetic studies 
To study a complex pathway like the kalimantacin PKS-NRPS, a reliable source of 
material either from natural sources or chemical synthesis is required. Natural product 
isolation from the WT and mutant strains provides a rich source of late-stage 
compounds.96 However, early stage intermediates and chemical probes of the biosynthetic 
pathway are also necessary. Most commonly, simplified structures that contain several 
key functional groups for enzymatic transformation are included due to the synthetic 
accessibility of these simplified intermediates.39 This has been demonstrated in Chapter 
2.1-2.2, however, use of the correct substrate may increase efficiency or specificity in 
vitro. Preliminary work was undertaken to synthesise a key building block to provide 
kalimantacin-like biosynthetic intermediates.  
Diene 92 is the proposed biosynthetic intermediate attached to ACP3/4 which, following 
interaction with the HCS cassette, yields an exo-β-methyl branch. Retrosynthesis of 92 
through disconnection of the diene moiety would lead to a key vinyl iodide fragment 93 
(Scheme 28), which could be used in the synthesis of β-branching biosynthetic 
intermediates, as well as in the total synthesis of kalimantacin or the diol precursor. 
Furthermore, access to analogues via a total synthesis could be used in SAR studies to 
determine the key functionalities in the active compound.  




Scheme 28 Target biosynthetic intermediate 92 where R is a thioester linkage to CoA/ACP.  
The synthetic efforts of Dr Iain Thistlethwaite and Dr Freya Bull led to the elucidation of 
the relative and absolute stereochemistry of kalimantacin A.96 Utilising the knowledge 
gained during that work, a synthetic route to key vinyl iodide 93 was designed. The vinyl 
iodide originates from a disconnection through the diene system of kalimantacin diol 
which may be constructed in the forward synthesis via a metal-catalysed sp2-sp2 cross 
coupling.  
 
Scheme 29 Retrosynthetic analysis of key vinyl iodide fragment 93 leading to readily available or easily synthesised 
starting materials (shown in red). The key compounds for synthesis are carboxylic acid 96, Grignard reagent 99 and 
azide 102 which are shown in blue.  
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A retrosynthetic analysis of vinyl iodide 93 is shown in Scheme 29. The vinyl iodide 
would be prepared from a protected alkyne 94. Disconnection of the amide bond furnishes 
a protected acid 96 which can be made from readily available ethyl (R)-3-hydroxybutyrate 
97. Amine 95 would be masked as azide 98, allowing for the addition of Grignard reagent 
99 into the carbonyl compound 102 which may either be the aldehyde or Weinreb amide. 
This in turn can be prepared from readily available ester 103. Finally, the Grignard 
reagent 99 can be synthesised from halide 100 via an asymmetric alkylation of 101.  
Adapting the previously reported route,97 poly-(R)-3-hydroxybutanoate 104 was refluxed 
for 7 days with EtOH and H2SO4 (Scheme 30). The reaction was found to proceed smoothly 
without the addition of dichloroethane as a co-solvent and, after purification by vacuum 
distillation, ester 97 was isolated in a 73% yield, comparable to the previous report.97 A 
Fráter-Seebach stereoselective alkylation of 97 with LDA and MeI afforded 105 as a single 
diastereomer. TBS protection of the alcohol and ester hydrolysis under basic conditions 
furnished the desired acid 107 in 57% yield over the two steps.  
 
Scheme 30 Synthesis of carboxylic acid 107 from poly-(R)-3-hydroxybutanoate 104.  
For the azide fragment, starting from commerically available alcohol 103, the chloride 
was displaced in an SN2 reaction with sodium azide (Scheme 31). The Rf of the starting 
material 103 and product 108 were the same and so the reaction could not be monitored 
by TLC analysis. Upon work-up, 1H NMR and IR spectroscopy indicated the 
consumption of starting material and the formation of the azide as indicated by the strong 
asymmetric stretching band at 2098 cm-1. Alcohol 108 was protected as silyl ester 109 in 
excellent yield. 109 was treated with DIBAL-H at -78 °C for 10 min and after work up 
and purification afforded aldehyde 110 in 96% yield. Hydrolysis of ester 109 under basic 
conditions also proceeded smoothly, furnishing acid 111 that was coupled with N,O-
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dimethylhydroxylamine hydrochloride to give Weinreb amide 112. Having both 
compounds (110 and 112) available allows flexibility in the later synthetic route. 
Grignard addition to the aldehyde 110 is likely to proceed with no stereocontrol of the 
resulting alcohol. It is expected that an oxidation/selective reduction would give the 
desired trans-relationship of the 1,3-diol. By reacting the Grignard 99 with Weinreb 
amide 112, the expected ketone would be ready for selective reduction, omitting the need 
for oxidation. The azide functionality is required at this stage to prevent cyclisation to 
form an unwanted 6-membered ring as observed previously when using protected 
amines.97  
 
Scheme 31 Synthesis of azide compounds containing either an aldehyde 110 or Weinreb amide 112 moiety.  
With the azide fragments 110 and 112 in hand, synthesis of Grignard reagent 99 was 
required. The first approach to selective alkylation employed auxiliary 114 and TMS-
protected propargyl bromide 115 as the alkylating agent (Scheme 32). However, the 
reaction was poor yielding (16%) and so the use of the opposite auxiliary with a 
methylating agent was investigated.  
 
Scheme 32 Selective alkylation using Evan's auxiliary 114.  
Protected acid 123 was reacted with Evans auxiliary 117 via a mixed anhydride 
intermediate giving 118 in an 83% yield (Scheme 33). Despite using two or greater 
equivalents of base and TMSCl in excess, it was not possible to directly TMS protect 
pent-4-yn-oic acid 124. As a result, protection of alcohol 125 and oxidation of the 
resulting compound 126 was required (Scheme 34). Acylated auxiliary 118 was treated 
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with NaHMDS at -78 °C then methyl iodide was added. The reaction was tried several 
times, including warming the reaction to around -50 °C to try to promote the alkylation, 
however, a maximum yield of 40% of 119 was obtained.  
In parallel, the unprotected alkyne 124 was coupled to auxiliary 117 in an analogous 
process. Treatment of 120 with NaHMDS and MeI again furnished the desired product 
121 but in a disappointing 52% yield. Interestingly given the similarities in pKa of the α-
proton and the alkyne proton, no alkylation of the terminal alkyne was observed. As a 
proof-of-concept, reductive cleavage of 121 gave the desired alcohol 122 in 83% yield.  
 
Scheme 33 Synthesis and alkylation of Evan's auxiliaries using A) protected alkyne 118 B) unprotected alkyne 120.  
To explore the feasibility of using the desired Grignard reaction, the test substrate 127, 
lacking the methyl group at C-2, was synthesised from 125 (Scheme 34). Converting 127 
to the corresponding Grignard reagent was attempted employing conditions used within 
the group in the synthesis of a similar reagent.98 Despite this, the desired Grignard was 
not formed, possibly due to the small scale of the reaction. Having synthesised fragments 
107, 110 and 112, the synthesis of Grignard reagent 99 and optimisation of the Evan’s 
alkylation are the key steps in the construction of kalimantacin-like biosynthetic 
intermediates. However, time did not permit any further investigations.  




Scheme 34 Synthesis of acid 123 and bromide 127.  
This initial work was built on by Angus Weir during his Master’s research project and 
has subsequently been furthered by PhD student Jon Davies. The aim is to create a flexible 
synthetic route that allows for the synthesis of biosynthetic-intermediates, analogues of 
kalimantacin and to complete a total synthesis.  
2.4 Conclusions and Future Work 
2.4.1 Conclusions 
Reconstitution of the kalimantacin β-branching pathway and monitoring by 13C NMR and 
Ppant ejection assay has provided a powerful tool for the monitoring of complex, multi-
enzyme catalysis of ACP-bound substrates. The simplicity of the single [13C] label, 
sensitivity of high-field NMR spectrometers and complementation by MS has allowed 
for the detailed characterisation of each enzymatic step and robust identification of the 
intermediates formed (Scheme 35).  
The HCS cassette, modular ACPs and tailoring enzymes from the kalimantacin gene 
cluster were cloned, expressed and purified. In vitro reconstitution of the β-branching 
pathway firstly demonstrated the formation of an endo-β-methyl branch. The α,β-
unsaturation and stereochemistry of the dehydrated intermediate (MG-ACP) was 
confirmed by pantetheine- and ACP-bound NMR experiments. These techniques are 
more rigorous than those previously reported in the literature.45 An ACP-bound endo-β-
methyl was also shown to be a substrate for the reduction by BatK to form a saturated β-
methyl branch. Finally, a previously unassigned mECH domain was identified in Bat3. 
The domain was excised from the PKS, expressed and purified. It showed no function in 
a range of MS and NMR experiments and structural characterisation revealed a mis-
folded domain.  
 




Scheme 35 Biosynthetic pathway for the formation of endo-β-methyl, exo-β-methyl and sat.-β-methyl branches by a 
single HCS cassette in kalimantacin biosynthesis.  
This led to the expression of the di-domain ACP4-mECH (4M) and development of an 
NMR assay that utilised the specific incorporation of a single [13C] label into key 
biosynthetic substrate mimics. By this NMR assay, the formation of an exo-β-methyl 
branch was demonstrated in vitro in the presence of BatD and 4M but the absence of 
BatE. This means mECH acts as a decarboxylase that intercepts MG-ACP rather than an 
isomerase acting on an endo-β-methyl branch.  
Finally, careful sequence analysis revealed a PGMG/PGAG motif that was conserved 
across ECH2 from trans-AT PKS that either produce an endo- or an exo-β-methyl branch 
respectively. Homology modelling located these residues in a loop adjacent to the active 
site. In the endo-β-methyl producing ECH2 domains, Met141 forms a narrow active site 
channel and His231 is hypothesised to both deprotonate prior to decarboxylation, and 
then reprotonate at the C-4 position to form the endo-β-methyl. In mECH, Ala138 allows 
for a more open active site in which His228 deprotonates and Tyr129 seems ideally 
positioned, proximal to the OAH-forming residues, to reprotonate at the C-2 position in 
the formation of an exo-β-methyl.  
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2.4.2 Future Work 
There is considerable scope to further develop the work presented in this thesis. Structural 
characterisation of the ECH2 domains (BatE and mECH) by X-ray crystallography would 
allow for validation of the active site configuration. This would provide valuable 
information into the key residues for catalysis and offer insight into the mechanism of 
selectivity. This could be further probed by rational engineering of the ECH2 domains by 
point-mutation, crystallography and functional studies to understand the significance of 
the PGxG motif.  
The NMR assay developed proved to be key in identifying and characterising the 
unsaturated β-methyl branches. The advantage of the assay was a single [13C] label signal, 
formation of the correct stereoisomer of [13C]-HMG-ACP and distinct chemical shifts and 
phase inversion by DEPT NMR at each stage of the β-branching pathway. The 
disadvantages of the assay were the time required in ACP loading and preparation, 
reliance on acetyl transfer in each reaction, substrate dilution by mixing of two ACPs and 
non-productive hydrolysis of [13C]-Ac-BatC. These factors combined often led to a low 
flux of intermediates through the β-branching pathway.  
A solution to this problem would be the pre-forming of [13C]-HMG-CoA 129 for transfer 
onto the desired ACP. This could be achieved by reacting [13C]-Ac-CoA 128 and Acac-
CoA 10 in the presence of mvaS, the HMGCS domain from the mevalonate-dependant 
isoprenoid pathway (Scheme 36).42,63 This reaction would produce the correct 
stereoisomer and might allow for the purification of [13C]-HMG-CoA 129. It may then 
be expediently loaded onto the desired ACP, giving a high proportion of the correct 
substrate with no dilution of the [13C] label. This higher effective concentration gives 
greater sensitivity and would allow for shorter NMR experiments and better observation 
of short-lived species.  
 
Scheme 36 Generation of [13C]-HMG-CoA 129 would allow for direct loading of ACPs with an advanced 
biosynthetic intermediate, thus simplifying β-branching NMR assays.  
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3 Mupirocin/Thiomarinol Starter Unit Generation 
3.1 Introduction to mupirocin/thiomarinol 
Mupirocin is a mixture of pseudomonic acids A-C (PA-A to PA-C) that were first isolated 
from Pseudomonas fluorescens NCIMB 10586 in 1971,147 with PA-A accounting for 
approximately 90% of the mixture (Figure 70A). The chemical structures of each 
component were reported in 1974, 1977 and 1980 respectively.148–150 The carbon skeleton 
of each compound is related, with a polyketide-derived monic acid portion that is 
esterified onto a fatty-acid derived 9-hydroxynonanoic acid.151  
 
Figure 70 Mupirocin is a mixutre of pseudomonic acids A-C. A) The structures are composed of a PKS-derived monic 
acid portion esterified to a fatty acid-derived 9-hydroxynonanoic acid. B) Outside a narrow pH range (pH 4-9) the C-7 
hydroxyl may attack the 10,11-epoxide forming inactive cyclic ethers 130 and 131.  
Mupirocin is a commercially available antibiotic used for the treatment of topical skin 
infection and marketed as Bactroban™. It is active against Gram positive bacteria and 
most significantly is used clinically to treat methicillin resistant Staphylococcus aureus 
(MRSA). Its wider application is limited by its poor bioavailability, a result of the 
metabolic instability of the compound when exposed to acidic conditions, at which point 
the C-7 hydroxyl group attacks the 10,11-epoxide forming antibiotic-inactive ethers 130 
and 131 (Figure 70B).152  
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Analysis of the bioactivity of each component of mupirocin reveals a similar potency of 
PA-A and PA-C.153 PA-C lacks the epoxide moiety of PA-A so does not suffer from this 
mode of acidic inactivation in vivo, however, it is only a minor component of the mixture. 
Increasing the titres of PA-C would allow for further study and possibly widening the 
application of this compound.  
The antibacterial target for mupirocin is the bacterial isoleucyl-tRNA synthetase (IleRS), 
therefore inhibiting protein and RNA biosynthesis.154 Co-crystallisation revealed that the 
C-14 region of PA-A mimicked isoleucine binding, whilst the THP ring and α,β-
unsaturated ester occupy the ATP-binding pocket.155,156 The fatty acid chain is important 
for complex stability and binds in a hydrophobic pocket.  
A number of feeding experiments using different labelled isotopomers of acetate resulted 
in the incorporation of 18O, 13C and 2H (Figure 71).36,151 The labelling pattern was 
consistent with the head-to-tail condensation of acetate in the polyketide portion to form 
a heptaketide with SAM-mediated α-methylation at C-16 and C-17 and an acetate-derived 
endo-β-methyl branch at C-15. The fatty acid portion is proposed to be derived from a 3-
carbon unit that has undergone three head-to-tail acetate condensations to give the C9 
acid. These labelling studies were one of the earliest reports demonstrating the origin of 
the C-15 β-branch to be the methyl group of a cleaved acetate.36  
 
Figure 71 Isotopic feeding studies using the mupirocin WT producing strain Pseudomonas fluorescens NCIMB 10586. 
A) The acetate feedstocks with differential isotopic enrichment. B) The resulting labelling pattern of PA-A.  
Mupirocin is assembled by a type I trans-AT PKS/FAS encoded by a 74 kb gene cluster 
consisting of 6 large ORFs, labelled mupirocin multifunctional proteins (MmpA to 
MmpF) and 29 smaller ORFs (MupA-X and MacpA-E) encoding for a range of tailoring 
enzymes.157 MmpD and MmpA are the modular PKS components that synthesise the 
majority of the linear polyketide backbone (Figure 72). An HCS cassette interacts with 
the final di-domain ACP of MmpA to give an endo-β-methyl branched monic acid.  




Figure 72 The modular assembly of the carbon skeleton of monic acid which is further modified by tailoring enzymes. 
Trans-acting enzymes provide additional functionality, including MmpC (ER), MupA (oxygenase) and a 5-enzyme 
HCS cassette (MacpA, MupGHJK) to install the endo-β-methyl branch.  
The metabolic flux then diverges from 132 along parallel pathways (Scheme 37A). In the 
major pathway, epoxidation of the 10,11-alkene is catalysed by the C-terminal 
oxidoreductase of the di-domain MmpE.158 THP ring formation is controlled by MupW 
and MupZ,159 whilst esterification of the polyketide with 3-hydroxypropionate (3-HP) 
and three rounds of fatty acid biosynthesis furnishes PA-B.160 The exact timing of 
esterification and fatty acid chain extension is not known and 133 and 134 are putative 
intermediates. Conversion of PA-B to the major metabolite PA-A requires a series of 
oxidative and reductive steps on the THP ring culminating in the removal of the C-8 
hydroxyl group.161 The minor pathway lacks the epoxidation step, however, THP 
formation, esterification and fatty acid biosynthesis, analogous to the major pathway, 
forms the minor component PA-C.158  
The mupirocin biosynthetic pathway contains 11 type I ACPs that are part of the modular 
PKS as well as 5 type II ACPs. These free-standing ACPs (MacpA-E) are encoded by 
ORFs that lie in the tailoring region of the gene cluster and are essential for antibiotic 
production.162 Each mutant strain (ΔMacpA-MacpE) could be complemented in-trans by 
its cognate ACP, however, no complementation was observed upon the overexpression 
of any noncognate ACPs.118 Therefore each ACP has a defined role in the production of 
mupirocin.  




Scheme 37 A) Tailoring enzymes produce PA-A, via PA-B, along the major metabolic pathway, whilst PA-C is 
produced by a parallel, minor pathway. The ACP-bound species 133 and 134 are putative intermediates in which the 
alkene epoxidation (purple) is hypothesised to occur prior to esterification and fatty acid production (green). B) 
Mupirocins W1-W2 have been isolated from ΔMupW and mupirocins W3 and W6 from ΔMupW/O. Mupirocins W4-
W5 have only been isolated from MmpEΔOR/ΔMupW.158  
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MacpC is the acetyl-donor ACP of the HCS cassette that introduces the β-methyl branch 
at C-15,163 whilst MacpE is bound to PA-B during several of the steps in the conversion 
to PA-A.164 The closest homologue of MacpD is DifC from the difficidin gene cluster and 
both ACPs lie adjacent to an acyl-CoA synthase (MupQ/DifD) and a 3-oxo-acyl ACP 
reductase (MupS/DifE) in their respective gene clusters. These cassettes are thought to be 
responsible for the formation of a 3-HP starter unit in mupirocin and an acrylate moiety 
in difficidin.165,166  
The closest homologues of MacpA were ACPs linked to fatty acid biosynthesis whilst 
ACPs related to type I polyunsaturated fatty acid biosynthesis were the closest to 
MacpB.118 It is therefore likely that one or both are involved in tethering the intermediates 
during the 9-hydroxynonanoic acid biosynthesis. An interesting feature of both MacpA 
and MacpD is the presence of an unusual C-terminal extension that may form a fifth helix. 
Shields and co-workers constructed MacpA/D mutant strains whereby 9 and 21 residues 
from the C-terminus of the ACP were deleted.118 Mutated MacpA was unable to 
complement the WT ACP in a ΔMacpA strain. In contrast, mutated MacpD could 
complement the ΔMacpD strain, but with lower efficiency than the full-length ACP. The 
authors concluded that decreased protein affinity or disrupted protein structure result in 
the decrease in antibiotic production, demonstrating the importance of this final putative 
helix and suggesting it might be an important feature for enzyme recognition.  
In the biosynthesis of oxytetracycline, an unusual malonamate starter unit is used to prime 
the PKS (Scheme 38). Tang et al. showed that OxyD, which shows homology to an 
asparagine synthetase, was responsible for the formation of malonamate.167 The proposed 
mechanism is the activation of malonyl-OxyC (an ACP) by OxyD and ATP, followed by 
condensation with glutamine as the source of nitrogen. In 2003, the NMR structure for 
OxyC was solved by Crump et al. and showed, in addition to the typical 4 α-helices, a 
13-residue C-terminal extension.168 The similarity in proposed mechanism for 
malonamate in oxytetracycline and 3-HP in mupirocin biosynthesis suggests that the C-
terminal extension of OxyC and MacpD is important for the interaction with OxyD and 
MupQ respectively.  




Scheme 38 Malonamate starter unit generation in the biosynthesis of oxytetracycline. The ACP (OxyC) contains an 
unusual C-terminal extension similar to that observed for MacpA and MacpD.  
Timing of THP formation, esterification and fatty acid biosynthesis 
Whilst some insights have been gained into the formation of the THP ring and the 
seemingly illogical conversion of PA-B to PA-A, the timing of the ring formation relative 
to fatty acid esterification and chain extension is still unknown. Conflicting evidence for 
the order of THP ring formation and esterification exist.  
A single knock-out strain ΔMupW, and a double knock-out strain ΔMupW/O were 
generated and these yielded a range of isolable ring-opened compounds termed 
mupirocins W1-W6 (Scheme 37B).158 Mupirocins W1-W3 and W6 are shunt products 
that arise from attack of the C-7 hydroxyl onto the 10,11-epoxide to generate a cyclic 
ether. W1-W3 contain C9, C7 and C5 fatty acid chains respectively, whilst W6 lacks a 
fatty acid chain. Mupirocins W4 and W5 are the alkene equivalent (non-epoxidised) 
compounds with C9 and C7 fatty acid chains. These compounds demonstrated that 
esterification and chain extension of the ring-opened compounds was possible. However, 
this order of steps appears to be inefficient due to the formation of metabolites with varied 
chain lengths, suggesting that THP ring formation may happen prior to esterification.  
Mupirocins W4 and W5 were fed into a strain that lacked the HMGS for β-methyl 
incorporation (ΔMupH) as shown in Scheme 39A.158 The well documented phenotype of 
this strain is mupirocin H, arising from blocked flux along the type I pathway and cyclic 
ether formation.169 It was hoped that W4 and W5 would be converted into PA-C, however, 
mupirocin W4 was not turned over and mupirocin W5 was only converted into W4 
resulting from one round of fatty acid chain extension (Scheme 39A). These results 
support the hypothesis that once esterification and chain extension has taken place, 
epoxidation and THP ring formation is not permissive.  
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However, Wang and co-workers reported the reaction cascade for THP formation in 
mupirocin biosynthesis is catalysed by both MupW and MupZ.159 Using a whole cell 
biotransformation, they demonstrated in vitro that MupW4 and W5 could be converted 
to desepoxy PA-B 135 and desepoxy PA-B C7 136 with a C9 and C7 fatty acid chain 
respectively (Scheme 39B). This result shows that THP ring formation may occur after 
esterification, creating uncertainty over the order of events in the WT pathway.  
 
Scheme 39 Conflicting evidence for the timing of THP formation relative to esterification. A) Metabolites isolated 
from P. fluorescens knock-out strains suggest ring closure occurs prior to fatty acid chain extension. Feeding of 
mupirocin W4 and W5 to ΔMupH did not result in ring closure to form PA-C, but mupirocin W5 with a C6 fatty acid 
chain was converted into W4 with a C8 fatty acid chain. Structure of mupirocin H is shown in the blue box. B) 
mupirocin W4 and W5 were converted to the ring-closed products by incubating with MupW/MupZ in a whole cell 
biotransformation suggesting esterification may occur first.  
Investigations into the function of MupR in the gene cluster determined its role as a 
regulator of the pathway.170 When MupR was supplied in-trans to the ΔMupR strain, the 
whole pathway was upregulated, allowing for isolation of minor metabolites previously 
not observed during fermentation of the WT strain. Two compounds identified were 137 
and 138 which are the C7 derivatives of PA-A and PA-B respectively (Figure 73). The 
isolation of these products, along with mupirocins W2, W3 and W5 with a shortened fatty 
acid chain, supports the hypothesis that esterification occurs prior to chain extension. It 
is unlikely that esterification of shorter chain fatty acids occurs, rather, premature 
offloading from the fatty acid machinery likely forms the truncated compounds.  




Figure 73 Shunt metabolites isolated from the in-trans over-expression of MupR in the wild-type P. fluorescens strain. 
Their isolation suggests the step-wise construction of the fatty acid portion following esterification.  
Thiomarinol 
Thiomarinol A is the major compound isolated from the marine bacterium 
Pseudomonas sp. SANK 73390 (Figure 74). Minor metabolites with varying 
oxygenation, alkylation and chain fatty acid chain length were also isolated from the WT 
organism.171 They show promising antibiotic activity against Gram positive and Gram 
negative bacteria, including MRSA. The chemical structure consists of a polyketide-
derived monic acid esterified onto 8-hydroxyoctanoic acid to form marinolic acid, a 
compound structurally related to mupirocin. Interestingly, thiomarinol contains the 10,11-
alkene thus eliminating the in vivo metabolic instability observed for PA-A.165 A 
pyrrothine moiety is then joined via an amide bond to furnish the thiomarinols, which are 
unusual, hybrid antibiotics with both the marinolic acid and pyrrothine portions 
displaying antibiotic activity.172,173  
 
Figure 74 Structure of thiomarinol A isolated from Pseudomonas sp. SANK 73390 and marinolic acid/amide 
metabolites isolated from the WT and ΔNRPS strains.171  
Feeding labelled acetates to the producing strain resulted in the expected head-to-tail 
condensation of acetate in the monic acid portion of thiomarinol A (Figure 75). The 
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oxygen atoms at C-1, C-5, C-7 and C-13 arise from acetate whereas those at C-4 and C-6 
are derived from an alternative oxygen source. α-methylation by SAM is consistent with 
modular C-MeT domains, the C-15 β-methyl branch is observed from the cleaving of 
acetate by an HCS cassette and the pyrrothine moiety is constructed from two cysteine 
residues. However, an unexpected labelling pattern was observed for the C8 fatty acid 
portion. A non-standard pattern and a reduced level of labelled acetate incorporation was 
observed for C5’-C-8’ compared to the remainder of the molecule. Normal levels of 
incorporation at C-1’ to C-4’ were observed, suggesting a 4-carbon starter unit forms C-
5’ to C-8’ that is subsequently extended by condensation of two head-to-tail acetate units. 
Succinyl CoA is a source of 4-hydroxybutyrate,174 and by feeding [2,3-13C2]-succinate or 
[2,3-13C2]-4-hydroxybutyrate, an intact 
13C-13C coupling constant was observed, 
identifying the source of the 4-carbon starter unit.  
 
Figure 75 Isotopic feeding studies with the thiomarinol WT producing strain Pseudomonas sp. SANK 73390. A) 
Isotopically enriched precursors. B) The resulting labelling pattern of thiomarinol A where coloured dots correlate 
position of incorporation with the source of the [13C] label. The asterisks (*) show the intact incorporation of 4-
hydroxybutyrate, arising from succinate, into the fatty acid chain.  
A 97 kb gene cluster encodes a hybrid PKS/FAS/NRPS with strong homology to the 
mupirocin gene cluster.175 A modular PKS assembles the carbon backbone which is 
cleaved to give 143 and THP ring formation is then achieved in an analogous manner to 
mupirocin to give putative intermediate 144 (Scheme 40). ACP-bound 4-hydroxybutyrate 
(4-HB) 145 is most likely esterified prior to two rounds of fatty acid chain extension to 
give 147 and an amide condensation to install the pyrrothine moiety 148 give thiomarinol 
A. Minor metabolites have been isolated from the WT and ΔNRPS strains that feature 
marinolic acid with C8 (139), C6 (140) and C4 (141) fatty acid chains as well as hydrolysis 
of the pyrrothine to give marinolic amide 142. Reminiscent of the mupirocin pathway, 
the formation of these chain shortened compounds provides insight into the timing of 
esterification and extension, suggesting that ester-bond formation with the 4-carbon 
starter unit precedes FA biosynthesis.  




Scheme 40 Biosynthesis of thiomarinol A, marinolic acids (139-141) and marinolic amide (142) minor metabolites.  
Starter unit generation 
A conserved structural feature between mupirocin and thiomarinol A is the esterification 
of a polyketide-derived monic acid portion with a fatty acid. The starter unit in mupirocin 
is 3-hydroxypropionate which undergoes three rounds of fatty acid biosynthesis to give a 
C9 chain, whereas thiomarinol starts with 4-hydroxybutyrate and undergoes two 
elongations to give a C8 chain. These two fatty acid starter units are thought to be 
assembled by a three-enzyme cassette consisting of an ACP (M/TacpD), an acyl-CoA 
synthetase (MupQ/TmlQ) and a 3-oxo-reductase (MupS/TmlS).165 Both sets of enzymes 
show significant sequence identity between the two pathways at 45.4%, 46.1% and 61.8% 
for the ACP, MupQ/TmlQ and MupS/TmlS respectively.  
In mupirocin, it is hypothesised that MupQ selects malonyl-CoA and activates it as mixed 
anhydride 149, prior to attack by holo-MacpD to form 150 (Scheme 41A). The domain 
type and mechanism are comparable to adenylation domains from NRPS that select amino 
acid extender units.176,177 The unusual bis-thioester intermediate 150 is then reduced by 
MupS, which would deliver two equivalents of NADH selectively to the CoA thioester 
to give the 3-carbon alcohol via the aldehyde 151. Thiomarinol proceeds via the same 
mechanistic pathway, except the 4-carbon starter unit is formed by the selection of 
succinyl CoA by TmlQ. This hypothesis was originally proposed through the observation 
of a homologous cassette of enzymes (DifC, DifD, DifE) in the difficidin biosynthetic 
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pathway that are proposed to form an acrylate starter unit 154 (Scheme 41B).166 It is likely 
that the 3-carbon starter unit arises by the same mechanism as for mupirocin via 152, 
however, the unsaturated moiety may be achieved by the dehydration of 153.  
The aim of this project was to investigate the mechanism of starter unit generation by in 
vitro reconstitution of the proposed pathway. This required the expression and 
purification of the appropriate trans-acting ACPs and catalytic enzymes, and reaction 
monitoring by MS, including the Ppant ejection assay.  
 
Scheme 41 Starter unit generation by adenylation, thioesterification and subsequent reduction. A) MacpD, MupQ and 
MupS produce a 3-hydroxypropionate whilst TacpD, TmlQ and TmlS produce 4-hydroxybutyrate. B) A homologous 
cassette of enzymes in the biosynthesis of difficidin produces a 3-carbon acrylate starter unit.  
3.2 Results and Discussion 
3.2.1 Protein expression and purification 
The genes encoding M/TacpA, TacpD, MupQ, MupS, TmlQ and TmlS were amplified 
from genomic DNA and cloned into POPINF whilst the gene for MacpD was synthesised 
and cloned into pET151. All proteins were transformed and expressed under standard 
conditions, yielding soluble protein that was purified by Ni2+-affinity chromatography 
(Figures 76 and 77). ACPs were desalted into reaction buffer (50 mM Tris, 100 mM NaCl, 
pH 8.0) and stored at 4 °C or lyophilised and stored as white solids at -20 °C. MupQ/S 
and TmlQ/S were desalted into storage buffer, concentrated (~50 µM), flash frozen in 
aliquots and stored at -80 °C. Difficulty was experienced when concentrating 
MupQ/TmlQ due to loss of protein from precipitation and sticking to the membrane of 
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the spin concentrator. MupS/TmlS required the addition of 500 mM NaCl to the storage 
buffer and a minimum concentration of 10% glycerol to prevent complete precipitation.  
 
Figure 76 Characterisation of the protein cassette from the mupirocin gene cluster by SDS-PAGE and MS. All proteins 
contained an N-terminal His6-tag. A) MS of apo-MacpA. B) MS of apo-MacpD. C) MS of MupQ. D) MS of MupS. E) 
SDS-PAGE analysis of apo-MacpA, apo-MacpD, MupQ and MupS confirmed proteins at the expected molecular mass.  
 
 
Figure 77 Characterisation of the protein cassette from the thiomarinol gene cluster by SDS-PAGE and MS. All 
proteins contained an N-terminal His6-tag A) MS of apo-TacpA. B) MS of apo-TacpD. C) MS of TmlQ was difficult 
to analyse by MS and only a poor-quality spectrum with an 11 Da mass error could be obtained. D) MS of TmlS. E) 
SDS-PAGE analysis of apo-TacpA, apo-TacpD, TmlQ and TmlS confirmed proteins at the expected molecular mass.  
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M/TacpA and M/TacpD were all expressed as apo-ACP as confirmed by MS. Conversion 
to holo-ACP, by incubation with CoA, MgCl2 and MupN, was monitored by MS and, 
upon completion, holo-ACP was desalted into reaction buffer supplemented with TCEP 
to remove excess CoA. The reaction could be carried out on a large scale (5-10 mg ACP) 
and the desalted protein was stored at -20 °C for up to 6 months.  
3.2.2 In vitro starter unit generation 
 
Scheme 42 Formation of a 3- or 4- carbon intermediate arising from the adenylation of malonyl or succinyl CoA 
respectively and subsequent attack of holo-ACP. The intermediate was then reduced by 2 equivalents of NADH to 
give 3-hydroxypropionate or 4-hydroxybutyrate, the proposed starter units in mupirocin and thiomarinol fatty acid 
biosynthesis respectively.  
Having prepared the appropriate ACPs and catalytic domains, the reconstitution of the 
native mupirocin system to generate a 3-carbon starter unit was investigated (Scheme 42). 
Holo-MacpD was incubated with MupQ and malonyl CoA. MS analysis showed 
consumption of holo-MacpD and quantitative formation of a new species with a mass 
(16098 Da) consistent with the proposed 3-carbon intermediate attached via thioester 
linkages to both MacpD and CoA (Figure 78, entry 1 and B). The native thiomarinol 
system was then reconstituted in vitro by incubating holo-TacpD with succinyl CoA and 
TmlQ giving complete conversion to a 4-carbon intermediate with a mass of 15455 Da 
(Figure 78, entry 5 and F).  
Having shown the formation of the 3- or 4- carbon intermediates bound between ACP 
and CoA thioesters, the selectivity of the adenylation step was investigated by varying 
the ACP, the adenylation domain and the CoA. MacpD was incubated with succinyl CoA 
and TmlQ which resulted in the quantitative formation of a 4-carbon activated 
intermediate with a mass of 16110 Da (Figure 78, entry 4 and C). Similarly, TacpD was 
incubated with malonyl CoA and MupQ which gave complete conversion to the 
respective 3-carbon intermediate (Figure 78, entry 8 and E). These results demonstrate 
the ability of both M/TacpD to operate with the non-native adenylation domain.  
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Entry ACP Co-factor Q Adenylation 
1 MacpD Mal MupQ ✓ (B) 
2  Succ MupQ  
3   Mal TmlQ  
4 
 Succ TmlQ ✓ (C) 
5 TacpD Succ TmlQ ✓ (F) 
6  Mal TmlQ  
7   Succ MupQ  
8  Mal MupQ ✓ (E) 
9 MacpA Mal MupQ  
10  Succ TmlQ  
11 TacpA Succ TmlQ  
12  Mal MupQ  
13 BatA Mal MupQ  
 
Incubating MacpD with either succinyl CoA/MupQ (Figure 78, entry 2) or malonyl 
CoA/TmlQ (Figure 78, entry 3) resulted in no intermediate formation, however, non-
productive trans-thioesterification of the malonyl/succinyl group from CoA to holo-
MacpD was observed. The same mis-match of adenylation domain and co-factor was 
investigated for TacpD, but once again trans-thioesterification was the only product 
Figure 78 Reaction of M/TacpD 
with native and non-native 
adenylation domains. Successful 
reactions occurred for the correct 
co-factor/adenylation domain pair 
(MupQ + Mal-CoA or TmlQ + 
Succ-CoA) to introduce a 3- or 4- 
carbon unit respectively. 
M/TAcpA and BatA were unable 
to complement for M/TacpD with 
either pair. A) Holo-MacpD. B) 
Holo-MacpD + MupQ + Mal-CoA 
(entry 1). C) Holo-MacpD + TmlQ 
+ Succ-CoA (entry 4). D) Holo-
TacpD. E) Holo-TacpD + MupQ + 
Mal-CoA (entry 8). F) Holo-
TacpD + TmlQ + Succ-CoA 
(Entry 5).  
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(Figure 78, entry 6 and 7). These results show that the adenylation domain is responsible 
for substrate selection and no promiscuity is observed. In a highly specific manner, 
malonyl CoA is selected and activated by MupQ, whilst succinyl CoA is selected by 
TmlQ. These findings correlate well with the selectivity of adenylation domains from 
NRPS pathways which are responsible for activating the correct amino acid as the 
extender unit in the construction of the peptides.178,179  
Entry ACP Adenylation S Reduction 
1 MacpD 3 carbon MupS ✓ (A) 
2   TmlS  
3  4 carbon TmlS  
4   MupS  
5 TacpD 4 carbon TmlS ✓ (B) 
6   MupS  
7  3 carbon MupS ✓ (C) 
8   TmlS ✓ (C) 
 
Figure 79 Reduction of 3- or 4- 
carbon adenylate intermediates by 
native or non-native reductase 
domains. A) MacpD + MupQ + 
Mal-CoA + MupS + NADH 
(entry1). B) TacpD + TmlQ + Succ-
CoA + TmlS + NADH (Entry 5). C) 
TacpD + MupQ + Mal-CoA + 
MupS/TmlsS + NADH (entries 7 or 
8). D) Ppant ejection for A. E) 
Ppant ejection for B. F) Ppant 
ejection for C.  
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Having shown the formation of a 3- and 4-carbon adenylate intermediate on both MacpD 
and TacpD was achieved by the correct pairing of adenylation domain and CoA, the 
subsequent reduction by MupS/TmlS was investigated. Addition of MupS and NADH to 
the 3-carbon intermediate bound to MacpD resulted in the reduction to a species 
consistent with the formation of MacpD-3-HP (Figure 79, entry 1 and A). To confirm 
reduction to the alcohol rather than the aldehyde, the product was confirmed by Ppant 
ejection that gave a peak at 333.14 Da (Figure 79D). TacpD-4-HB was generated by 
adding TmlS and NADH to the 4-carbon intermediate bound to TacpD (Figure 79, entry 5 
and B), which was confirmed by Ppant ejection assay (Figure 79E).  
Next, the promiscuity of the reductase domains was investigated. Entries 4 and 6 
(Figure 79) show that MupS cannot reduce the 4-carbon unit regardless of whether it is 
attached to MacpD or TacpD. However, MupS was able to reduce the 3-carbon 
intermediate attached to TacpD (Figure 79, entry 7). TmlS was able to reduce the 3-
carbon intermediate attached to the cognate TacpD (Figure 79, entry 8, C and F) but failed 
to reduce either the 3- or 4- carbon intermediate attached to MacpD (Figure 79, entry 2 
and 3).  
Finally, to confirm the previously reported inability of MacpA to complement MacpD in 
vivo,118 MacpA was incubated with malonyl CoA/MupQ or succinyl CoA/TmlQ under 
standard conditions (Figure 78, entry 9 and 10). No evidence of the desired bis-thioester 
intermediate was detected by MS and the only product observed was trans-
thioesterification of the CoA-bound acyl group to the thiol of holo-MacpA (Figure 80A 
and C). Repeating the reactions with TacpA in place of MacpA yielded the same result, 
as once again only thioesterification onto holo-TacpA was observed (Figure 80B and D). 
Further indication of the tight ACP-adenylation domain specificity was confirmed by the 
inability of BatA, a 4-helix, free-standing ACP from the kalimantacin biosynthetic 
pathway, to react with malonyl CoA/MupQ (Figure 78, entry 13). These results show 
specific interaction of M/TacpD with the adenylation domains and either malonyl or 
succinyl CoA is vitally important for the correct fidelity through the pathway.  
 




Figure 80 Ppant ejection ions shows trans-thioesterification rather than adenylation when M/TacpA was used rather 
than M/TacpD. When malonyl CoA is used, decarboxylation was also observed and results in the detection of acetyl-
Ppant. A) MacpA + malonyl CoA + MupQ produces malonyl-MacpA (347.2 Da, green) and acetyl-MacpA 
(303.2 Da, red). B) TacpA + malonyl CoA + MupQ produced malonyl-TacpA (347.2 Da, green) and acetyl-TacpA 
(303.2 Da, red). C) MacpA + succinyl CoA + TmlQ produced succinyl-MacpA (361.2 Da, purple). D) TacpA + 
succinyl CoA + TmlQ produced succinyl-TacpA (361.2 Da, purple).  
To test whether MupB was a candidate for the esterification of a short chain fatty acid 
onto the monic acid, it was cloned, expressed and purified. Freshly generated MacpD-
3HP was incubated with enoyl-pantetheine 64 or enoyl-acid 68 and MupB (Scheme 43). 
The reaction was monitored by MS, however, no evidence of esterification product 155 
was observed. Uncertainty exists over whether MupB would act as the ester-forming 
enzyme and due to time constraints further work was not undertaken on this reaction.  
 
Scheme 43 MupB-catalysed esterification of MacpD-3HP was not possible with pantetheine 64 or acid 68.  
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3.3 Conclusions and Future Work 
3.3.1 Conclusions 
The cassette of enzymes hypothesised to be responsible for the generation of a 3-HP and 
4-HB starter unit in the biosynthesis of mupirocin and thiomarinol respectively consists 
of an ACP (M/TacpD), an adenylation domain (MupQ/TmlQ) and a reductase 
(MupS/TmlS). Each of these proteins was expressed, purified and characterised by SDS-
PAGE and MS. The proposed pathway was then reconstituted in vitro and proved the 
formation of 3-HP and 4-HB (Scheme 44). In mupirocin biosynthesis, malonyl-CoA is 
activated by MupQ and ATP to form an adenylate intermediate, which is then trapped by 
holo-MacpD. The resulting three-carbon bis-thioester is subsequently reduced by MupS 
and 2 equivalents of NADH to form MacpD-3-HP. In thiomarinol biosynthesis, holo-
TacpD receives activated succinyl-CoA from TmlQ, and the resulting four-carbon 
intermediate is reduced by TmlS and NADH to form TacpD-4-HB. The adenylation 
domains (MupQ/TmlQ) were shown to be selective for malonyl- and succinyl-CoA 
respectively, whereas the reductase domains (MupS/TmlS) showed some promiscuity for 
ACP identity and chain length.  
 
Scheme 44 Mupirocin/thiomarinol starter unit generation. A) 3-HP formation by MacpD, MupQ and MupS from the 
mupirocin gene cluster. B) 4-HB formation by TacpD, TmlQ and TmlS from the thiomarinol gene cluster.  
3.3.2 Future Work 
Further work aims to further structurally characterise the enzymes of the pathway. X-ray 
crystallography structures of the adenylation (MupQ/TmlQ) and reductase (MupS/TmlS) 
domains would offer insight in to the selectivity observed. Particularly interesting would 
be the active site differences between MupQ and TmlQ that allows for the strict selection 
of CoA derivatives that differ by only CH2. This could be further probed by mutagenesis 
of active site residues to potentially alter the domain selectivity.  
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The C-terminal extension of M/TacpD was highlighted as an unusual feature, but one that 
was also been observed in an ACP (oxyC)/adenylation (oxyD) domain pair in the 
biosynthesis of oxytetracyclines.167,168 Understanding the secondary structure formed by 
these extensions and how they mediate protein-protein interactions would be important 
for future engineering of the pathway. NMR studies should be undertaken to understand 
whether this extension forms any secondary structure and whether this is influenced by 
the addition of MupQ/TmlQ or MupS/TmlS. A C-terminal extension was also observed 
in M/TacpA, however, these ACPs were unable to complement for M/TacpD. The role 
of the free-standing ACPs M/TacpA as well as M/TacpB (previously insoluble118) are 
currently unknown and may provide insight into substrate delivery and timing in the latter 
stages of mupirocin/thiomarinol biosynthesis.  
Finally, the identity of the enzyme that catalyses esterification is not known, although 
candidates do exist in the gene cluster (MupB/MupL). The timing of post-PKS processing 
steps, including the order of esterification, fatty acid chain extension and THP ring 
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Mikrobiolohichnyĭ zhurnal (Kiev, Ukr.  1993), 2008, 70, 41–46. 
80 V. V. Klochko, L. B. Zelena, J. Y. Kim, L. V. Avdeeva and O. N. Reva, Int. J. 
Antimicrob. Agents, 2016, 47, 56–61. 
81 M. Jenner, J. Afonso, C. Kohlhaas, P. Karbaum, S. Frank, J. Piel and N. J. Oldham, 
Chem. Commun., 2016, 52, 1–4. 
82 D. A. Vander Wood and A. T. Keatinge-Clay, Proteins Struct. Funct. Bioinforma., 
2018, 86, 664–675. 
83 L. Zhang, T. Hashimoto, B. Qin, J. Hashimoto, I. Kozone, T. Kawahara, M. Okada, 
T. Awakawa, T. Ito, Y. Asakawa, M. Ueki, S. Takahashi, H. Osada, T. Wakimoto, 
H. Ikeda, K. Shin-ya and I. Abe, Angew. Chemie Int. Ed., 2017, 56, 1740–1745. 
84 M. Jenner, S. Frank, A. Kampa, C. Kohlhaas, P. Pöplau, G. S. Briggs, J. Piel and 
N. J. Oldham, Angew. Chemie Int. Ed., 2013, 52, 1143–1147. 
85 R. J. Heath and C. O. Rock, J. Biol. Chem., 1995, 270, 26538–26542. 
86 R. Heath, S. White and C. Rock, Appl. Microbiol. Biotechnol., 2002, 58, 695–703. 
87 V. E. Lee and A. J. O’Neill, Int. J. Antimicrob. Agents, 2017, 49, 121–122. 
88 W. Mattheus, J. Masschelein, L. J. Gao, P. Herdewijn, B. Landuyt, G. Volckaert 
and R. Lavigne, Chem. Biol., 2010, 17, 1067–1071. 
89 S. Brinster, G. Lamberet, B. Staels, P. Trieu-Cuot, A. Gruss and C. Poyart, Nature, 
2009, 458, 83–86. 
90 W. Balemans, N. Lounis, R. Gilissen, J. Guillemont, K. Simmen, K. Andries and 
A. Koul, Nature, 2010, 463, E3–E4. 
91 S. Brinster, G. Lamberet, B. Staels, P. Trieu-Cuot, A. Gruss and C. Poyart, Nature, 




92 E. Cundliffe, Annu. Rev. Microbiol., 1989, 43, 207–233. 
93 H. Xu, L. Heide and S. M. Li, Chem. Biol., 2004, 11, 655–662. 
94 U. Galm, L. Wang, E. Wendt-Pienkowski, R. Yang, W. Liu, M. Tao, J. M. 
Coughlin and B. Shen, J. Biol. Chem., 2008, 283, 28236–28245. 
95 V. M. D’Costa, K. M. McGrann, D. W. Hughes and G. D. Wright, Science, 2006, 
311, 374–377. 
96 I. R. G. Thistlethwaite, F. M. Bull, C. Cui, P. D. Walker, S. S. Gao, L. Wang, Z. 
Song, J. Masschelein, R. Lavigne, M. P. Crump, P. R. Race, T. J. Simpson and C. 
L. Willis, Chem. Sci., 2017, 8, 6196–6201. 
97 I. Thistlethwaite, PhD Thesis, University of Bristol, 2015. 
98 F. M. Bull, PhD Thesis, University of Bristol, 2016. 
99 C. T. Lohans, D. Y. Wang, J. Wang, R. B. Hamed and C. J. Schofield, ACS Catal., 
2017, 7, 6587–6599. 
100 R. B. Hamed, E. T. Batchelar, I. J. Clifton and C. J. Schofield, Cell. Mol. Life Sci., 
2008, 65, 2507–2527. 
101 H. M. Holden, M. M. Benning, T. Haller and J. A. Gerlt, Acc. Chem. Res., 2001, 
34, 145–157. 
102 G. Agnihotri and H. W. Liu, Bioorganic Med. Chem., 2003, 11, 9–20. 
103 L. Hedstrom, Chem. Rev., 2002, 102, 4501–4523. 
104 H.-H. Otto and T. Schirmeister, Chem. Rev., 1997, 97, 133–172. 
105 F. Zhang, H. Y. He, M. C. Tang, Y. M. Tang, Q. Zhou and G. L. Tang, J. Am. 
Chem. Soc., 2011, 133, 2452–2462. 
106 H. Xiang, L. Luo, K. L. Taylor and D. Dunaway-Mariano, Biochemistry, 1999, 38, 
7638–7652. 
107 T. R. Kiema, C. K. Engel, W. Schmitz, S. A. Filppula, R. K. Wierenga and J. K. 
Hiltunen, Biochemistry, 1999, 38, 2991–2999. 




Gen. Subj., 2006, 1760, 1874–1883. 
109 D. J. Edwards, B. L. Marquez, L. M. Nogle, K. McPhail, D. E. Goeger, M. A. 
Roberts and W. H. Gerwick, Chem. Biol., 2004, 11, 817–833. 
110 J. Crosby and M. P. Crump, Nat. Prod. Rep., 2012, 29, 1111–1137. 
111 J. Beld, E. C. Sonnenschein, C. R. Vickery, J. P. Noel and M. D. Burkart, Nat. 
Prod. Rep., 2014, 31, 61–108. 
112 R. J. Cox, J. Crosby, O. Daltrop, F. Glod, M. E. Jarzabek, T. P. Nicholson, M. 
Reed, T. J. Simpson, L. H. Smith, F. Soulas, A. E. Szafranska and J. Westcott, J. 
Chem. Soc. Perkin Trans. 1, 2002, 14, 1644–1649. 
113 P. Dall Aglio, C. J. Arthur, C. Williams, K. Vasilakis, H. J. Maple, J. Crosby, M. 
P. Crump and A. T. Hadfield, Biochemistry, 2011, 50, 5704–5717. 
114 R. H. Lambalot, A. M. Gehring, R. S. Flugel, P. Zuber, M. LaCelle, M. A. 
Marahiel, R. Reid, C. Khosla and C. T. Walsh, Chem. Biol., 1996, 3, 923–936. 
115 L. E. Quadri, P. H. Weinreb, M. Lei, M. M. Nakano, P. Zuber and C. T. Walsh, 
Biochemistry, 1998, 37, 1585–1595. 
116 K. Reuter, M. R. Mofid, M. A. Marahiel and R. Ficner, EMBO J., 1999, 18, 6823–
6831. 
117 K. Finzel, D. J. Lee and M. D. Burkart, ChemBioChem, 2015, 16, 528–547. 
118 J. A. Shields, A. S. Rahman, C. J. Arthur, J. Crosby, J. Hothersall, T. J. Simpson 
and C. M. Thomas, ChemBioChem, 2010, 11, 248–255. 
119 J. Crosby, D. H. Sherman, M. J. Bibb, W. P. Revill, D. A. Hopwood and T. J. 
Simpson, Biochim. Biophys. Acta, 1995, 1251, 32–42. 
120 N. M. Kosa, K. M. Pham and M. D. Burkart, Chem. Sci., 2014, 5, 1179–1186. 
121 H. S. T. Bukhari, R. P. Jakob and T. Maier, Structure, 2014, 22, 1775–1785. 
122 R. E. Williams and N. C. Bruce, Microbiology, 2002, 148, 1607–1614. 
123 L. M. M. Mouterde and J. D. Stewart, Org. Process Res. Dev., 2016, 20, 954–959. 




S. Moore, Org. Lett., 2015, 17, 4452–4455. 
125 J. Zheng, C. A. Taylor, S. K. Piasecki and A. T. Keatinge-Clay, Structure, 2010, 
18, 913–922. 
126 D. T. Wagner, J. Zeng, C. B. Bailey, D. C. Gay, F. Yuan, H. R. Manion and A. T. 
Keatinge-Clay, Structure, 2017, 25, 1045–1055. 
127 D. C. Stevens, D. T. Wagner, H. R. Manion, B. K. Alexander and A. T. Keatinge-
Clay, J. Antibiot. (Tokyo)., 2016, 69, 567–570. 
128 I. Nazi, K. P. Koteva and G. D. Wright, Anal. Biochem., 2004, 324, 100–105. 
129 E. Strauss and T. P. Begley, J. Biol. Chem., 2002, 277, 48205–48209. 
130 D. C. Gay, P. J. Spear and A. T. Keatinge-Clay, ACS Chem. Biol., 2014, 9, 2374–
2381. 
131 L. Zhang, J. Ji, M. Yuan, Y. Feng, L. Wang, Z. Deng, L. Bai and J. Zheng, ACS 
Chem. Biol., 2018, 13, 871–875. 
132 A. S. Worthington and M. D. Burkart, Org. Biomol. Chem., 2006, 4, 44–46. 
133 X. Dong, C. D. Bailey, C. Williams, J. Crosby, T. J. Simpson, C. L. Willis and M. 
P. Crump, Chem. Sci., 2016, 7, 1779–1785. 
134 B. Uytterhoeven, T. Lathouwers, M. Voet, C. W. Michiels and R. Lavigne, Front. 
Microbiol., 2016, 7, 1726. 
135 T. Ackrill, PhD Thesis, University of Bristol, 2015. 
136 S. E. Evans, C. Williams, C. J. Arthur, E. Płoskoń, P. Wattana-amorn, R. J. Cox, 
J. Crosby, C. L. Willis, T. J. Simpson and M. P. Crump, J. Mol. Biol., 2009, 389, 
511–528. 
137 E. Płoskoń, C. J. Arthur, A. L. P. Kanari, P. Wattana-Amorn, C. Williams, J. 
Crosby, T. J. Simpson, C. L. Willis and M. P. Crump, Chem. Biol., 2010, 17, 776–
785. 
138 N. J. Greenfield, Nat. Protoc., 2007, 1, 2876–2890. 
139 M. A. Skiba, F. P. Maloney, Q. Dan, A. E. Fraley, C. C. Aldrich, J. L. Smith and 




140 D. A. Herbst, R. P. Jakob, F. Zähringer and T. Maier, Nature, 2016, 531, 533–537. 
141 H. M. Miziorko and M. D. Lane, J. Biol. Chem., 1977, 252, 1414–1420. 
142 Y. Li, E. Luxenburger and R. Müller, Angew. Chemie Int. Ed., 2013, 52, 1304–
1308. 
143 M. A. Larkin, G. Blackshields, N. P. Brown, R. Chenna, P. A. Mcgettigan, H. 
McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, J. D. Thompson, T. J. 
Gibson and D. G. Higgins, Bioinformatics, 2007, 23, 2947–2948. 
144 M. M. Benning, T. Haller, J. A. Gerlt and H. M. Holden, Biochemistry, 2000, 39, 
4630–4639. 
145 M. J. Bennett, M. P. Schlunegger and D. Eisenberg, Protein Sci., 1995, 4, 2455–
2468. 
146 D. C. Gay, D. T. Wagner, J. L. Meinke, C. E. Zogzas, G. R. Gay and A. T. 
Keatinge-Clay, J. Struct. Biol., 2016, 193, 196–205. 
147 E. B. Fuller, A. T.; Banks, G.T.; Mellows, G.; Barrow, K.D.; Woolford, M.; Chain, 
Nature, 1971, 234, 416–417. 
148 E. B. Chain and G. Mellows, J. Chem. Soc. Chem. Commun., 1974, 20, 847–848. 
149 E. B. Chain and G. Mellows, J. Chem. Soc., Perkin Trans. 1, 1977, 318–322. 
150 J. P. Clayton, P. J. O’Hanlon and N. H. Rogers, Tetrahedron Lett., 1980, 21, 881–
884. 
151 T. C. Feline, R. B. Jones, G. Mellows and L. Phillips, J. Chem. Soc., Perkin Trans. 
1, 1977, 309–318. 
152 J. P. Clayton, R. S. Oliver, N. H. Rogers and T. J. King, J. Chem. Soc., Perkin 
Trans. 1, 1979, 838–846. 
153 L. Wang, Unpublished Work. 
154 J. Hughes and G. Mellows, Biochem. J., 1978, 176, 305–318. 
155 L. F. Silvian, M. Ile, J. Wang and T. A. Steitz, Science, 1999, 285, 1074–1077. 




157 A. K. El-Sayed, J. Hothersall, S. M. Cooper, E. Stephens, T. J. Simpson and C. M. 
Thomas, Chem. Biol., 2003, 10, 419–430. 
158 S. S. Gao, J. Hothersall, J. Wu, A. C. Murphy, Z. Song, E. R. Stephens, C. M. 
Thomas, M. P. Crump, R. J. Cox, T. J. Simpson and C. L. Willis, J. Am. Chem. 
Soc., 2014, 136, 5501–5507. 
159 L. Wang, A. Parnell, C. Williams, N. A. Bakar, M. R. Challand, M. W. van der 
Kamp, T. J. Simpson, P. R. Race, M. P. Crump and C. L. Willis, Nat. Catal., 2018, 
1, 968–976. 
160 R. Gurney and C. M. Thomas, Appl. Microbiol. Biotechnol., 2011, 90, 11–21. 
161 S. S. Gao, L. Wang, Z. Song, J. Hothersall, E. R. Stevens, J. Connolly, P. J. Winn, 
R. J. Cox, M. P. Crump, P. R. Race, C. M. Thomas, T. J. Simpson and C. L. Willis, 
Angew. Chemie Int. Ed., 2017, 56, 3930–3934. 
162 J. Hothersall, J. Wu, A. S. Rahman, J. A. Shields, J. Haddock, N. Johnson, S. M. 
Cooper, E. R. Stephens, R. J. Cox, J. Crosby, C. L. Willis, T. J. Simpson and C. 
M. Thomas, J. Biol. Chem., 2007, 282, 15451–15461. 
163 J. Wu, S. M. Cooper, R. J. Cox, J. Crosby, M. P. Crump, J. Hothersall, T. J. 
Simpson, C. M. Thomas and C. L. Willis, Chem. Commun., 2007, 20, 2040–2042. 
164 S. M. Cooper, W. Laosripaiboon, A. S. Rahman, J. Hothersall, A. K. El-Sayed, C. 
Winfield, J. Crosby, R. J. Cox, T. J. Simpson and C. M. Thomas, Chem. Biol., 
2005, 12, 825–833. 
165 C. M. Thomas, J. Hothersall, C. L. Willis and T. J. Simpson, Nat. Rev. Microbiol., 
2010, 8, 281–289. 
166 X.-H. Chen, J. Vater, J. Piel, P. Franke, R. Scholz, K. Schneider, A. Koumoutsi, 
G. Hitzeroth, N. Grammel, A. W. Strittmatter, G. Gottschalk, R. D. Sussmuth and 
R. Borriss, J. Bacteriol., 2006, 188, 4024–4036. 
167 W. Zhang, B. D. Ames, S. C. Tsai and Y. Tang, Appl. Environ. Microbiol., 2006, 
72, 2573–2580. 
168 S. C. Findlow, C. Winsor, T. J. Simpson, J. Crosby and M. P. Crump, Biochemistry, 




169 J. Wu, J. Hothersall, C. Mazzetti, Y. O’Connell, J. A. Shields, A. S. Rahman, R. J. 
Cox, J. Crosby, T. J. Simpson, C. M. Thomas and C. L. Willis, ChemBioChem, 
2008, 9, 1500–1508. 
170 J. Hothersall, A. C. Murphy, Z. Iqbal, G. Campbell, E. R. Stephens, J. Wu, H. 
Cooper, S. Atkinson, P. Williams, J. Crosby, C. L. Willis, R. J. Cox, T. J. Simpson 
and C. M. Thomas, Appl. Microbiol. Biotechnol., 2011, 90, 1017–1026. 
171 A. C. Murphy, S.-S. Gao, L.-C. Han, S. Carobene, D. Fukuda, Z. Song, J. 
Hothersall, R. J. Cox, J. Crosby, M. P. Crump, C. M. Thomas, C. L. Willis and T. 
J. Simpson, Chem. Sci., 2014, 5, 397–402. 
172 B. Li, W. J. Wever, C. T. Walsh and A. A. Bowers, Nat. Prod. Rep., 2014, 31, 
905–923. 
173 Z. Qin, S. Huang, Y. Yu and H. Deng, Mar. Drugs, 2013, 11, 3970–3997. 
174 I. A. Berg, D. Kockelkorn, W. Buckel and G. Fuchs, Science (80-. )., 2007, 318, 
1782–1786. 
175 D. Fukuda, A. S. Haines, Z. Song, A. C. Murphy, J. Hothersall, E. R. Stephens, R. 
Gurney, R. J. Cox, J. Crosby, C. L. Willis, T. J. Simpson and C. M. Thomas, PLoS 
One, 2011, 6, e18031. 
176 A. M. Gulick, ACS Chem. Biol., 2009, 4, 811–827. 
177 S. Schmelz and J. H. Naismith, Curr. Opin. Struct. Biol., 2009, 19, 666–671. 
178 R. D. Süssmuth and A. Mainz, Angew. Chemie Int. Ed., 2017, 56, 3770–3821. 
179 T. Stachelhaus, H. D. Mootz and M. A. Marahiel, Chem. Biol., 1999, 6, 493–505. 
180 R. B. Hamed, L. Henry, J. R. Gomez-Castellanos, A. Asghar, J. Brem, T. D. W. 
Claridge and C. J. Schofield, Org. Biomol. Chem., 2013, 11, 8191–8196. 
181 T. L. Hwang and A. J. Shaka, J. Magn. Reson. Ser. A, 1995, 112, 275–279. 
182 R. D. Peterson, C. A. Theimer, H. Wu and J. Feigon, J. Biomol. NMR, 2004, 28, 
59–67. 
183 A. L. Breeze, Prog. Nucl. Magn. Reson. Spectrosc., 2000, 36, 323–372. 




Am. Chem. Soc., 1997, 119, 6711–6721. 
185 N. M. Gaudelli and C. A. Townsend, J. Org. Chem., 2013, 78, 6412–6426. 
186 A. Verma, D. M. Wong, R. Islam, F. Tong, M. Ghavami, J. M. Mutunga, C. 
Slebodnick, J. Li, E. Viayna, P. C. H. Lam, M. M. Totrov, J. R. Bloomquist and P. 
R. Carlier, Bioorganic Med. Chem., 2015, 23, 1321–1340. 
187 S. Mo, D. H. Kim, J. H. Lee, J. W. Park, D. B. Basnet, Y. H. Ban, Y. J. Yoo, S. W. 
Chen, S. R. Park, E. A. Choi, E. Kim, Y. Y. Jin, S. K. Lee, J. Y. Park, Y. Liu, M. 
O. Lee, K. S. Lee, S. J. Kim, D. Kim, B. C. Park, S. G. Lee, H. J. Kwon, J. W. Suh, 
B. S. Moore, S. K. Lim and Y. J. Yoon, J. Am. Chem. Soc., 2011, 133, 976–985. 
188 E. Bardshiri, T. J. Simpson, A. Ian Scott and K. Shishido, J. Chem. Soc. Perkin 
Trans. 1, 1984, 1765–1767. 
189 H. A. Duong, P. B. Huleatt, Q. W. Tan and E. L. Shuying, Org. Lett., 2013, 15, 
4034–4037. 
190 D. Seebach and M. F. Züger, Tetrahedron Lett., 1984, 25, 2747–2750. 
191 K. Mori and T. Ebata, Tetrahedron, 1986, 42, 4413–4420. 
192 J. C. Barrish, H. L. Lee, T. Mitt, G. Pizzolato, E. G. Baggiolini and M. R. 
Uskokovic, J. Org. Chem., 1988, 53, 4282–4295. 
193 C. Bauder, Tetrahedron Lett., 2008, 49, 2243–2246. 
194 P. Renaud and D. Seebach, Helv. Chim. Acta, 1986, 69, 1704–1710. 
195 S. Nishiguchi, M. O. Sydnes, A. Taguchi, T. Regnier, T. Kajimoto, M. Node, Y. 
Yamazaki, F. Yakushiji, Y. Kiso and Y. Hayashi, Tetrahedron, 2010, 66, 314–320. 
196 S. G. Davies, O. Ichihara, P. M. Roberts and J. E. Thomson, Tetrahedron, 2011, 
67, 216–227. 
197 J. Zhu and D. Ma, Angew. Chemie Int. Ed., 2003, 42, 5348–5351. 
198 A. D. Fotiadou and A. L. Zografos, Org. Lett., 2011, 13, 4592–4595. 





200 P. A. Ledin, F. Friscourt, J. Guo and G. J. Boons, Chem. - A Eur. J., 2011, 17, 839–
846. 






5.1 Materials and Methods 
Reagents were purchased from Sigma Aldrich, Thermo Fisher or Merck Millipore. 
Isotopically enriched 15NH4Cl and 
13C6-D-glucose were purchased from Goss Scientific. 
E. coli competent cells were purchased from New England Biolabs (T7 express and 5-α) 
or Merck Millipore (Novagen BL21 (DE3)). All enzymes used were purchased from 
Thermo Fisher Scientific.  
Buffers were prepared by adding the solid reagents and made up to 80% of the final 
volume using distilled water. The pH was adjusted using either 6 M HCl or 6 M NaOH 
and monitored using a Jenway pH meter. Buffers required for protein purification using 
a GE Healthcare AKTA FPLC were vacuum filtered through a Whatman cellulose nitrate 
0.22 μM membrane and degassed by stirring under reduced pressure for 15 minutes. 
Buffers were stored at 4 °C and warmed to room temperature prior to use. Antibiotic and 
glucose solutions were sterilised with a 0.22 µM syringe filter (Thermo) 
Recipes 
LB broth Tryptone (10 g/L), yeast extract (5 g/L) and NaCl (5 g/L) 
LB agar Tryptone (10 g/L), yeast extract (5 g/L) and NaCl (5 g/L), 
agar (15 g/L) 
M9 Na2HPO4 (13.6 g/L), KH2PO4 (6 g/L), NaCl (1 g/L), pH 7.0 
Re-suspension Buffer 50 mM Tris, 0.5 M NaCl, 10% (v/v) glycerol, 0.01% (v/v), 
Triton X-100, pH 8.0 
Column Buffer A 50 mM Tris, 0.5 M NaCl, 10% (v/v) glycerol, pH 8.0 
Column Buffer B 50 mM Tris, 0.1 M NaCl, 0.8 M imidazole, 10% (v/v) 
glycerol, pH 8.0 
Reaction Buffer 50 mM Tris, 0.1 M NaCl, pH 8.0 
Storage Buffer 50 mM Tris, 0.1 M NaCl, 10% (v/v) glycerol, pH 8.0 
NMR Buffer 50 mM Sodium Phosphate, 0.1 M NaCl, 10% D2O, pH 8.0 
(10% D2O was added prior to transferring to an NMR tube).  
Trace metal mix 
(1000x) stock 
FeCl3.6H2O (50 mM), CaCl2 (20 mM), MnCl2.4H2O 
(10 mM), ZnSO4.7H2O (2 mM), CoCl2.6H2O (2 mM), 
CuCl2.2H2O (2 mM), NiCl2.6H2O (2 mM), Na2MoO4.2H2O 





All media and glassware were autoclaved prior to use to minimise contamination. An 
Astell Scientific ASA270 autoclave ran at 120 °C, 15 psi for 15 minutes and media was 
cooled to room temperature before use. Procedures requiring a sterile environment were 
either carried out under aseptic conditions with a Bunsen flame or in a Medical Air 
Technology LTD BioMat Class II microbiological safety cabinet.  
PCR 
Primers were designed in house then synthesised by IPT Technologies or Sigma Aldrich. 
Forward and reverse primers (bold type) incorporated an adapter region (normal type) to 
allow recombination into a pre-linearised POPINF vector. 100 μM primer stock solutions 
were prepared in sterile water and 25 μM working solutions were prepared by further 
dilution. PCR reactions were performed using a KOD DNA Polymerase kit (Merck 
Millipore) or KAPA HiFi HotStart ReadyMixPCR kit (KAPABIOSYSTEMS) following 
manufacturer’s instructions. Gradient PCR was run to optimise annealing temperature for 
each primer pair. All reactions were performed using a peqSTAR 96x Universal Gradient 
or a SureCycler 8800 (Agilent Technologies)and 200 μL PCR tubes. To confirm 
amplification, the products were analysed by gel electrophoresis using a 1% agarose gel. 
PCR products were purified using a PureLink PCR Purification kit (Thermo Fisher).  
KOD DNA Polymerase kit 
Component Volume (μL) 
10x Buffer 10 
MgSO4 6 
dNTPs 10 
Forward Primer 3 
Reverse Primer 3 
Template DNA 2 
Water 64 
KOD Hot Start DNA Polymerase 2 
Total Volume 100 
1) Polymerase activation at 95 °C for 5 mins; 2) Denaturation at 95 °C for 45 s; 3) 
Annealing at optimal temperature for 30 s; 4) Extension for 30 s. Steps 2-4 were repeated 






KAPA HiFi HotStart ReadyMixPCR kit 
Component Volume (μL) 
2 x KAPA premix 25 
Forward Primer 1.5 
Reverse Primer 1.5 
Template DNA 1 
Water 21 
Total Volume 50 
1) Initial denaturation at 95 °C for 3 mins; 2) Denaturation at 98 °C for 20 s; 3) Annealing 
at optimal temperature for 15 s; 4) Extension at 72 °C for 30 s. Step 2-4 were repeated 30 

















TacpD_For aagttctgtttcagggcccgATGTTAAACGTACAGCAAATTAAGAATGAA  
TacpD_Rev atggtctagaaagctttaTCACCTTACTTGGTTTTTAATGGCCTTAAG  
TmlQ_For aagttctgtttcagggcccgAATAGAACATGGATTTCCGATCGAGTAAAC 
TmlQ_Rev atggtctagaaagctttaTTATATCTTATTGATTTTTTTGAATCTTTC  
TmlS_For aagttctgtttcagggcccgATGGAAAGTGAAAATGGTACAGTGATAATA  


















16 µL of POPINF plasmid (~100 ng/µL) was incubated with 10x Fast Digest buffer 
(2 µL), 10 units/µL KpnI (1 µL) and 20 units/µL HindIII (1 µL) and incubated at 37 °C 
for 3 hours. The DNA was purified by PCR purification kit (Thermo).  
Cloning 
PCR fragments were recombined into a pre-linearised POPINF vector using either T4 
polymerase or Infusion (Clontech).  
For T4 polymerase, the reagents were mixed and incubated at room temperature for 
15 mins.  
Reagent Volume (μL) 
Water 4 
PCR product 2 
Cut POPINF vector 1 
10x buffer 1 
BSA 1 
T4 DNA polymerase 1 
 
For Infusion reactions, the reagents were mixed and incubated at 50 °C for 20 mins.  
Reagent Volume (μL) 
Water 4 
PCR product 3 
Cut POPINF vector 1 





Following incubation, 3 μL of the reaction was transformed into 50 μL NEB 5-α E. coli 
competent cells and plated on LB agar plates supplemented with carbenicillin 
(100 µg/mL), X-gal (40 µg/mL) and IPTG (1 mM). Single, white colonies were picked, 
cultured in LB (5 mL) supplemented with carbenicillin (100 μg/mL) for 16 h at 37 °C. 
The cells were pelleted by centrifugation at 6,000 rpm for 5 mins and the plasmid DNA 
purified using a GenElute (Sigma Aldrich) or QIAprep (Qiagen) Spin Miniprep Kit. The 
plasmid DNA was sequenced by Genewiz.  
Plasmids 
The nucleotide sequence for BatA, BatD, BatE, ACP3/4, mECH and MacpD were codon 
optimised for E. coli, then synthesised and subcloned into a pET151/D-TOPO vector by 
Thermo Fisher.  
Transformation 
To 20 μL of E. coli competent cells thawed on ice was added 1 μL of plasmid DNA. The 
cells were incubated on ice for 30 min then heat shocked by incubating at 42 °C for 30 s 
and cooled on ice for 2 mins. 200 μL SOC medium was added and the mixture incubated 
at 37 °C with shaking at 220 rpm for 1 h. The cells were plated, diluted where appropriate 
with SOC, on to LB agar supplemented with antibiotic (100 μg/mL) and incubated at 
37 °C for 16 h.  
General Expression Procedure 
E. coli competent cells transformed with plasmid DNA were grown on LB agar 
supplemented with 100 μg/mL carbenicillin (LB/carb) at 37 °C overnight. A single colony 
was picked and added to 50 mL LB/carb and grown at 37 °C for 16 h with shaking at 
200 rpm. 2 mL of this seed broth was used to inoculate flasks containing 200 mL LB/carb 
medium and incubated at 37 °C with shaking at 200 rpm until an OD600 of 1.0 was 
reached. The culture was then induced with 250 µM isopropyl-β-D-thiogalactopyranoside 
(IPTG) and incubated for 16 h at 16 °C. The cells were harvested by centrifugation at 
6,000 rpm and re-suspended in column buffer A (50 mM Tris, 500 mM NaCl, 10% 
glycerol, pH 8.0). The cells were lysed by sonication and the soluble fraction applied to 
a HisTrap HP 5 mL Ni column (GE Life Sciences). Protein was eluted via a linear gradient 
from 5 to 100% column buffer B (50 mM Tris, 100 mM NaCl, 10% glycerol, 0.8 M 




PAGE and those containing the protein of interest were pooled, buffer exchanged in to 
reaction buffer (50 mM Tris, 100 mM NaCl, pH 8.0) using a HiPrep 26/10 desalting 
column (GE Life Sciences) or further purified by Superdex S75 size exclusion 
chromatography (SEC) using reaction buffer. Protein was concentrated and stored at 4 °C, 
or supplemented with 10% glycerol, aliquoted, flash frozen and stored at -80 °C.  
M9 expression 
A single colony was picked and cultured in 50 mL LB medium supplemented with 
carbenicillin (100 µg/mL) for 16 h at 37 °C. 2 mL of pre-culture was added to 100 mL 
M9 containing carbenicillin (100 µg/mL), NH4Cl (1 g/L), glucose (2 g/L) and metal mix 
(100 µL) and incubated at 37 °C until an optical density of 1.0 was reached. The culture 
was induced with IPTG (250 µM) and incubated for 16 h at 16 °C. The protein was 
purified as per the unlabelled material.  
M9 expression via media transfer 
A single colony was picked and cultured in 50 mL LB medium supplemented with 
carbenicillin (100 µg/mL) for 16 h at 37 °C. 2 mL of pre-culture was added to 200 mL 
LB/carb and incubated at 37 °C until OD600 1.0 was reached. The cells were harvested by 
centrifugation (6000 rpm for 10 mins) and washed twice with sterile M9 medium. They 
were then resuspended in M9 and used to inoculate 100 mL M9 supplemented with 
carbenicillin (100 µg/mL), NH4Cl (1 g/L), glucose (2 g/L) and metal mix (100 µL) and 
incubated at 16 °C for 1 h. The culture was induced with IPTG (250 µM) and incubated 
for 16 h at 16 °C. The protein was purified as per the unlabelled material.  
Expression of ACPs 
ACP4 and 4M were expressed following the general procedure, except 1 mM IPTG was 
used to induce the culture, which was then incubated at 16 °C for 5 h. All modular ACPs 
(3/4, 4, 5, 6 and 4M) were desalted into reaction buffer (~100 µM) and were stable at 4 °C 
for up to 7 days. ACP3/4, ACP4 and ACP5 were stable to freeze-thaw conditions, ACP6 
was not stable to these conditions and 4M was not frozen.  
BatC 
BatC was expressed and purified following the general procedure, desalted into reaction 




BatD and BatE 
BatD and BatE were expressed and purified following the general procedure. Both 
proteins (~200 µM) could be stored at 4 °C for up to 3 days, however, loss of activity was 
observed after 1 week at 4 °C. Both proteins were stable to a single freeze-thaw cycle, 
however, catalytic activity declined with number of freeze-thaw cycles and the length of 
storage. Optimal results were obtained with freshly purified protein.  
MupQ and TmlQ 
MupQ and TmlQ were expressed and purified following the general procedure and 
desalted into reaction buffer supplemented with 10% glycerol. Difficulties concentrating 
both proteins were encountered due to precipitation in a Vivaspin (GE Life Sciences) or 
Amicon (Merck) spin concentrator with a 10 kDa molecule weight cut-off. A maximum 
concentration of ~50 µM was achieved and the protein was flash frozen in aliquots.  
MupS and TmlS 
MupS and TmlS were both expressed according to the general procedure. During 
purification, 0.5 M NaCl and 10% glycerol was required in the reaction buffer to prevent 
precipitation on the desalting column.  
Holo-ACP preparation 
The reagents were added to apo-ACP in reaction buffer and incubated at room 
temperature for 1 h. Reaction progress was monitored by ESI-MS.  
Reagent Stock Volume (μL) Final 
apo-ACP  87 50-100 µM 
MgCl2 1 M 1 10 mM 
CoA 100 mM 1 1 mM 
MupN 15 μM 10 1.5 μM 
TCEP 100 mM 1 1 mM 
 
One-pot pantetheine upgrade and loading of ACPs 
Adapting literature procedures,124,180 to apo-ACP in reaction buffer was added each 
reagent in series and the reaction mixture was incubated at room temperature until 




reaction times were 1 h (100 µL reactions) or 1-3 h (1 mL or larger reactions). Once full 
loading was achieved, excess reagents were removed using a HiPrep 26/10 desalting 
column (GE Life Sciences) or Zeba column (Thermo Fisher) equilibrated with reaction 
buffer. Loaded ACPs were concentrated using Sartorius Vivaspin20 with a 3 or 10 kDa 
molecular weight cut-off.  






ACP  84 900 50-100 µM 
MgCl2 1 M 1 10 10 mM 
Pantetheine 100 mM 1 5 1/0.5 mM 
CoA mix (A, D, E) 33 μM each 3 30 1 μM each 
MupN 15 μM 10 100 1.5 μM 
ATP 100 mM 1 10 1 mM 
 
ESI-MS sample preparation 
Samples were desalted for ESI-MS analysis using a C4 ZipTip™ (Millipore). The Ziptip 
was activated with two 10 μL aspirations of solution A (50% acetonitrile in water) and 
equilibrated with five 10 μL aspirations of solution B (0.1% TFA in water). A 10 µL 
sample was then loaded onto the ZipTip with 15-20 aspirations, returning the sample to 
the same tube between aspirations. The protein was desalted with ten 10 μL washes with 
solution C (5% MeOH, 0.1% TFA in water) and discarded to waste. Finally, the sample 
was eluted with 10 μL of solution D (70% acetonitrile, 0.1% TFA in water).  
Denatured samples were analysed on a Synapt G2-Si (Waters) fitted with a TriVersa 
NanoMate® (Advion) using the following parameters: sample cone 10 V, capillary 
voltage 1.5 kV, transfer collision energy 5 V. The source was set to positive mode and 
spectra were acquired over 600-3000 m/z and analysed using MassLynx™ 4.1 software. 
The spectra were smoothed, and background subtraction applied. Deconvolution of the 
charge states was undertaken using MagTran 1.03. For Ppant ejection assays, an 
appropriate charge state was isolated using the MSMS functionality. The trap collision 
energy was increased until fragmentation was observed (typically between 5 V and 30 V) 




For analysis by LC/MS, assay samples were diluted with acetonitrile (v/v) and 20 µL 
injected for analysis. An UltiMate 3000 UPLC (Thermo) fitted with an ACQUITY UPLC 
Protein BEH C4 column (300 Å, 1.7 µM, 2.1 mm x 150 mm) was used for LC separation. 
HPLC grade H2O (A) and acetonitrile (B) supplemented with 0.1 % formic acid were 
used as the solvents at a flow rate of 0.2 mL/min. The following gradient was run:  
Time Eluent 
0-2 min 30% B 
2-22 min Linear gradient to 30-50% B 
22-23 min 50% B 
23-24 min Linear gradient to 30% B 
24-25 min 30% B 
The sample was analysed using an Orbitrap Elite (Thermo) across the mass range 200-
2000 Da. Collison-induced dissociation (CID) at 20 V was used for Ppant ejection assays.  
β-branching assay by MS 
BatA was loaded with Ac-pantetheine 60 and the modular ACP (ACP4, 5 or 6) was loaded 
with Acac-pantethine 62 (100 µL total volume per reaction). Once full loading was 
achieved, the sample was desalted into reaction buffer using a Zeba column (Thermo 
Fisher). Ac-BatA (50 µM) and Acac-ACP (50 µM) were mixed and BatC (5 µM) added 
to the 100 µL reaction, which was incubated at room temperature for 1 h. A 10 µL sample 
was taken for MS analysis and 5 µM of the required catalytic domains 
(BatD/BatE/mECH) was added. The reaction was incubated at room temperature for 1 h 
and analysed by MS (10 µL aliquot).  
BatK reduction 
The modular ACP (~100 µM) was loaded with enoyl-pantetheine 64 and monitored by 
MS until complete loading was achieved (~1 h). BatK (5 µM) and NADH (1 mM) were 
added and the reaction mixture incubated at room temperature for 1 h. MS analysis by 
Ppant ejection was used to determine the outcome of the reaction.  
β-branching assay by NMR 
Apo-BatA was loaded with [13C]-Ac-pantethine 85, monitored by MS until complete 
loading was achieved (typically 1 to 3 h). The loaded ACP was desalted into NMR buffer 




Sciences) or Amicon (Merck) spin concentrators. [13C]-Ac-BatA was stored in aliquots 
at -80 °C and single aliquots thawed on ice when required. Modular ACPs were freshly 
loaded with Acac-pantethine 62, desalted and concentrated as described, however, these 
ACPs would be used immediately due to hydrolytic instability of the β-keto thioester.  
To form [13C]-HMG-ACP, Acac-ACP, [13C]-Ac-BatA and BatC were incubated at room 
temperature for 1 h. 10% D2O was added to the sample and the mixture transferred to an 
NMR tube for analysis. To assess ECH function, [13C]-HMG-ACP was formed over 1 h, 
then BatD and/or BatE were added to the reaction. After incubation for 1 h, 10% D2O 
was added and the sample transferred to an NMR rube.  
Optimisation meant the concentration of modular ACP, BatA and the catalytic enzymes 
varied with each experiment according to the table below. This was determined by protein 












[13C]-Ac-BatA 345             
[13C]-Ac-ACP4 340       
Acac-ACP4 215 
[13C]-Ac-
BatA 198 1.1 7     
Acac-ACP4 342 
[13C]-Ac-
BatA 145 2.4 5.4 26.8  
Acac-ACP4 267 
[13C]-Ac-
BatA 196 1.4 7 5 5 
Acac-ACP5 156 
[13C]-Ac-
BatA 168 0.9 13.5 10.2 9.8 
[13C]-Ac-4M 150             
Acac-4M 202 
[13C]-Ac-
BatA 150 1.3 13   
Acac-4M 226 
[13C]-Ac-
BatA 164 1.4 5.4 24.2   
Acac-4M 261 
[13C]-Ac-
BatA 272 1.0 10.9 13.5 11.8 
 
NMR parameters 
All protein NMR experiments were acquired on a Varian VNMRS 600 cryo spectrometer 
at 20 °C and spectra referenced using 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS). 
Spectra recorded in 10% D2O used a 
1H DPFGSE with a sweep width of 8000 Hz with 
32000 points.181 Standard experiments were used for 13C, DEPT, HSQC and HMBC 
TOCSY and NOESY data collection. 13C,15N (F1, F2) filtered NOESY and TOCSY 




implemented in Biopack (VnmrJ v4.2) with calibrated 13C and 15N pulse widths and a 1H 
observe sweep width of up to 8000 Hz with 2048 points.182,183 These sequences are 
modifications of the original implementation by Zwahlen et al.184 
Circular Dichroism 
Samples were prepared in 50 mM sodium phosphate (pH 8.0) and the concentration 
adjusted to 10 µM. Spectra were averaged over 5 scans recorded at 5 °C using a 1 cm 
quartz cuvette and a JASCO J-1500 Spectrophotometer. Background subtraction and 
analysis took place using the Spectra Manager™ suite (JASCO).  
Analytical S200 Gel Filtration 
500 µL of protein was injected onto a Superdex 200 column (GE Healthcare) equilibrated 
with 25 mM Tris, 150 mM NaCl, pH7.5 at 0.5 mL/min. The column was pre-calibrated 
with blue dextran (2000 kDa), β-amylase (200 kDa), alcohol dehydrogenase (150 kDa), 
conalbumin (75 kDa), bovine serum albumin (66 kDa), ovalbumin (44 kDa), carbonic 
anhydrase (29 kDa) and cytochrome C (12.4 kDa) from a Gel Filtration Calibration Kit 
(GE Healthcare). By plotting the gel-phase distribution coefficient (Kav) against the 
logarithm of the molecular weight (Log MW) and fitting with a straight line (y = -0.256x 
+ 0.870, R2  = 0.9876) a calibration curve may be obtained. The elution volume of an 
analyte may be used to estimate its molecular weight.  




Kav = gel-phase distribution coefficient, Ve = elution volume, Vo = column void volume 
= 7.08 mL (based on blue dextran), Vc = geometric column volume = 24 mL.  
Culturing P. fluorescens BCCM_ID9359 
A glycerol stock of P. fluorescens BCCM_ID9359 was streaked onto an agar plate an 
incubated at 28 °C for 16 h. A single colony was picked and used to inoculate 100 mL 
LB medium, which was incubated at 25 °C for 16 h. The seed culture (5%) was used to 
inoculate 2 L LB medium supplemented with 4% glucose and incubated at 16 °C for 96 
h. To harvest, the cells were removed by centrifugation (8000 rpm) and the supernatant 
extracted with ethyl acetate (2 x v/v), washed with sat. aq. NaCl, dried over MgSO4 and 




steps - 5% MeOH/CH2Cl2/0.1% AcOH followed by 2% MeOH/EtOAc/0.1% AcOH – 
furnishing kalimantacin A as a colourless oil (batch 1 - 38 mg/L, batch 2 - 50 mg/L).  
Acidification 
P. fluorescens was cultured as described above and following centrifugation the 
supernatant divided into two portions. One portion was acidified to pH 2 with conc. HCl, 
then both portions were separately extracted with ethyl acetate (2 x v/v), concentrated and 
purified by the standard column chromatography conditions. The non-acidified portion 
furnished 18 mg and the acidified portion 19 mg per 500 mL of culture.  
Analytical LCMS 
For analysis of natural product crude extracts, a 10 mg/mL sample was made up in HPLC-
grade MeOH. 20 µL of the extracts were injected and analysed on a Waters 2795HT or 
Waters 2545SFO HPLC system with the following detectors: 
Waters 2795HT HPLC system 
- Waters 998 diode array detector for UV between 200 and 400 nm.  
-  Electrospray (ES) Waters ZQ mass spectrometry with detection between 150 and 800 
m/z units in positive and negative modes.  
Waters 2445SFO HPLC system 
- Waters 2298 diode array detector for UV between 200 and 400 nm. 
- Waters Quattro Micro ESI mass spectrometer in positive and negative modes, with 
detection between 150 and 1200 m/z units.  
Both systems were equipped with a Phenomenex Kinetex column (2.6 µ, C18, 100 Å, 4.6 
x 100 mm) fitted with a Phenomenex Security Guard column (Luna C5 300 Å) eluting 
with a flow rate of 1 mL/min. HPLC grade H2O (A) and acetonitrile (B) supplemented 
with 0.05 % formic acid were used as the solvents. The following gradient was run: 
Time Eluent 
0-2 min 5% B 
2-15 min Linear gradient to 90% B 
15-17 min 95% B 
17-18 min Linear gradient to 5% B 







Preparative purification of compounds was carried out using a Waters 2545SFO HPLC 
system with the following set up:  
-  Waters 2767 autosampler 
-  Waters 2545 pump system. 
- Phenomenex Kinetex column (5 μ, C18, 100 Å, 250 x 21.20 mm) fitted with a 
Phenomenex Security Guard column (Luna C5 300 Å) eluting at a flow rate of 16 
mL/min.   
HPLC grade H2O (A) and acetonitrile (B) supplemented with 0.05 % formic acid were 
used as the solvents. The post-column flow was split (100:1) and the minor flow was 
made up with solvent A to 1 ml/min for simultaneous analysis by diode array detector 
(Waters 2998), and ESI mass spectrometry in positive and negative modes (Waters 
Quatro Micro). The following gradient was run: 
Time Eluent 
0-2 min 5% B 
2-15 min Linear gradient to 90% B 
15-16 min 95% B 
16-17 min Linear gradient to 5% B 
17-20 min 5% B 
 
Starter unit assay 
Apo-ACP (~200 µM) was converted to holo-ACP by the addition of MgCl2 (10 mM), 
CoA (1 mM), MupN (1.5 µM) and TCEP (1 mM). The reaction was monitored by MS 
and upon completion was desalted into reaction buffer supplemented with 1 mM TCEP 
using a HiPrep 26/10 desalting column. Holo-ACP was adjusted to ~100 µM, aliquoted 
and stored at – 20 °C. To holo-ACP (100 µM) were added MupQ/TmlQ (5 µM), 
malonyl/succinyl CoA (1 mM) and ATP (1 mM). The reaction was incubated at room 
temperature for 1 h then monitored by MS. MupS/TmlS (5 µM) and NADH (1 mM) were 
added and the reaction incubated for a further 1 h prior to MS analysis.  
To pre-formed 3-HP-MacpD was added MupB (5 µM) and 3,3-dimethyl acrylic acid 68 
or enoyl-pantetheine 64 (1 mM). The reaction was incubated at room temperature for 1 h 




General experimental for chemical synthesis 
All air and moisture sensitive reactions were carried out under an N2 atmosphere using 
anhydrous solvents, obtained by passing solvent through a column of anhydrous alumina 
using equipment from Anhydrous Engineering and stored in a Straus flask fitted with a J. 
Youngs valve before use. Commercially available reagents were used without further 
purification. Flash column chromatography was performed with silica gel (technical 
grade, 40-63 μM particle size). Analytical thin layer chromatography (TLC) was 
performed on Merck, aluminium backed 60 F254 silica plates. TLC plates were visualised 
by UV fluorescence (UV254 lamp), basic KMnO4 solution or an ethanolic solution of 
phosphomolybdic acid.  
Nuclear magnetic resonance (NMR) spectra were recorded at ambient temperature in 
CDCl3 (unless stated otherwise) on one of the following spectrometers; Varian 400-MR, 
Varian VNMRS500, Bruker Advance III HD 500 Cryo, Bruker VNMRS600 Cryo, 
Bruker 700 micro-cryo. 1H NMR are reported in the format: chemical shift (ppm), 
integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br 
= broad, dd = doublet of doublets, ddd = doublet of doublets of doublets, dt = doublet of 
triplets, qd = quartet of doublets), coupling constant (J, in Hertz), assignment. Infrared 
spectra were recorded on a Perkin Elmer Spectrum One Fourier Transform Infrared 
Spectrometer (FT-IR) with signal intensities reported as follows: br = broad, w = weak, 
m = medium, s= strong. Optical rotations were measured on a Bellingham and Stanley 
Ltd ADP220 polarimeter and melting points were determined on an Electrothermal 
IA6301 melting point apparatus. Small molecule high resolution mass spectrometry 
(HRMS) was performed on a Bruker microTOF spectrometer using electrospray 





5.2 Compound Characterisation 
(R)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propionic acid 58 
 
To flame dried molecular sieves under a nitrogen atmosphere was added acetone 
(250 mL). After stirring for 20 min, D-pantothenic acid hemicalcium salt 57 (5.00 g, 
21.0 mmol) and para-toluenesulfonic acid (4.79 g, 25.2 mmol) were added and the thick 
white slurry was stirred at room temperature for 16 h. The reaction mixture was filtered 
through a bed of Celite, washed with acetone (2 x 50 mL) and the solvent removed under 
reduced pressure. The residue was dissolved in EtOAc (100 mL) and washed with half 
saturated brine (3 x 100 mL) and dried over MgSO4. The crude product was triturated 
with n-hexane furnishing 58 as a white solid (3.96 g, 73 %). [𝛼]𝐷
24 +62.0 (c 1.0, CHCl3). 
δH (400 MHz, CDCl3) 10.50 (1H, br s, OH), 7.07 (1H, t, J 6.0, NH), 4.11 (1H, s, 4-H), 
3.67 (1H, d, J 12.0, 1-HH), 3.63-3.53 (1H, m, 6-HH), 3.51-3.42 (1H, m, 6-HH), 3.27 (1H, 
d, J 12.0, 1-HH), 2.59 (2H, t, J 6.0, 7-H2), 1.43 (3H, s, 10-H3), 1.41 (3H, s, 10-H3), 1.01 
(3H, s, 3-H3), 0.95 (3H, s, 3-H3). δC (100 MHz, CDCl3) 176.5 (C-8), 170.3 (C-5), 99.2 
(C-9), 77.1 (C-4), 71.5 (C-1), 34.2 (C-6), 33.9 (C-7), 33.0 (C-2), 29.5 (C-10), 22.1 (C-3), 
18.9 (C-3), 18.8 (C-10). νmax (neat) / cm
-1 3388 (br, w), 2957 (w), 1723 (s), 1194 (s), 1097 
(s). m/z (ESI+) calc. for [C12H21NO5Na] 282.1312 found 282.1309. The data are in 
accordance with the literature.124 
Pantetheine dimethyl ketal 59 
 
To acid 58 (2.00 g, 7.71 mmol) in dry THF (40 mL) under a nitrogen atmosphere was 
added CDI (1.87 g, 11.6 mmol). The reaction mixture was stirred at room temperature for 
30 min then cysteamine hydrochloride (1.31 g, 11.6 mmol) was added and stirred for 
16 h. The reaction was quenched with sat. aq. NH4Cl (30 mL) the phases separated, and 




washed with brine (20 mL), dried over MgSO4 and concentrated in vacuo. The colourless 
oil was purified by column chromatography (80-100% EtOAc:petrol) furnishing 59 as a 
white solid (1.73 g, 71%). m.p. 99-101 °C. [𝛼]𝐷
24 +48.0 (c 1.0, CHCl3). Lit
185 [𝛼]𝐷
24 +33.4 
(c 1.0, MeOH). δH (400 MHz, CDCl3) 7.01 (1H, br s, NH), 6.42 (1H, br s, NH), 4.06 (1H, 
s, 4-H), 3.66 (1H, d, J 12.0, 1-HH), 3.61-3.49 (2H, m, 6-H2), 3.48-3.33 (2H, m, 11-H2), 
3.26 (1H, d, J 12.0, 1-HH), 2.64 (2H, q, J 7.0, 12-H2), 2.45 (2H, t, J 6.0, 7-H2), 1.44 (3H, 
s, 10-H3), 1.40 (3H, s, 10-H3), 1.36 (1H, t, J 8.5, SH), 1.01 (3H, s, 3-H3), 0.95 (3H, s, 3-
H3). δC (100 MHz, CDCl3) 171.1 (C-8). 170.2 (C-5), 99.1 (C-9), 77.1 (C-4), 71.4 (C-1), 
42.4 (C-11), 36.1 (C-7), 34.8 (C-6), 32.9 (C-2), 29.5 (C-10), 24.5 (C-12), 22.1 (C-3), 18.9 
(C-3), 18.7 (C-10). νmax (neat) / cm
-1 3300 (br, w), 2938 (w), 2550 (w), 1650 (s), 1524 (s), 
1196 (m), 1096 (s). m/z (ESI+) calc. for [C14H26N2O4SNa] 341.1505 found 341.1507. The 
data are in accordance with the literature.124,185 
S-Acetyl-pantetheine 60 
 
To thiol 59 (0.15 g, 0.47 mmol) in dry CH2Cl2 (10 mL) at 0 °C under a nitrogen 
atmosphere was added acetyl chloride (0.10 mL, 1.41 mmol) and DMAP (0.12 g, 
0.94 mmol). The reaction mixture was allowed to warm to room temperature and stirred 
for 16 h, then quenched with 1 M HCl (15 mL). The aqueous phase was extracted with 
CH2Cl2 (2 x 20 mL), the combined organic phases were washed with brine (15 mL), dried 
over MgSO4 and concentrated in vacuo. The crude oil was purified by column 
chromatography (5% MeOH:CH2Cl2) furnishing a colourless oil (80 mg, 47%). To the 
protected pantetheine (70 mg, 0.19 mmol) was added 2:1 AcOH: H2O (8 mL), the reaction 
mixture stirred at room temperature for 5 h then concentrated under reduced pressure. 
The crude oil was purified by column chromatography (5-7% MeOH:CH2Cl2) furnishing 
60 as a colourless oil (50 mg, 81%). [𝛼]𝐷
24 +22.0 (c 1.0, CHCl3). δH (500 MHz, CD3OD) 
3.90 (1H, s, 4-H), 3.55-3.48 (2H, m, 6-H2), 3.47-3.40 (2H, m, 1-H2), 3.40-3.34 (2H, m, 
9-H2), 3.01 (2H, t, J 7.0, 10-H2), 2.42 (2H, t, J 7.0, 7-H2), 2.34 (3H, s, 12-H3), 0.93 (6H, 
s, (CH3)2). δC (125 MHz, CD3OD) 197.0 (C-11), 176.0 (C-5), 173.9 (C-8), 77.3 (C-4), 




(C-3), 20.9 (C-3). νmax (neat) / cm
-1 3298 (br), 2874 (br, w), 1644 (s), 1530 (s). m/z (ESI+) 
calc. for [C13H24N2O5SNa] 343.1298 found 343.1293. The data are in accordance with 
the literature.124 
S-Propyl Pantetheine 61 
 
To thiol 59 (0.15 g, 0.47 mmol) in dry CH2Cl2 (10 mL) at 0 °C under a nitrogen 
atmosphere was added propionyl chloride (42 µL, 0.47 mmol) and DMAP (0.12 g, 
0.94 mmol). The reaction mixture was allowed to warm to room temperature and stirred 
for 5 h, then quenched with 1 M HCl (10 mL). The aqueous phase was extracted with 
CH2Cl2 (2 x 15 mL), the combined organic phases were washed with brine (15 mL), dried 
over MgSO4 and concentrated in vacuo. To the crude protected pantetheine was added 
2:1 AcOH: H2O (9 mL), the reaction mixture stirred at room temperature for 16 h then 
concentrated under reduced pressure. The crude oil was purified by column 
chromatography (5-10% MeOH:CH2Cl2) furnishing 61 as a colourless oil (103 mg, 66%). 
δH (500 MHz, CD3OD) 3.90 (1H, s, 4-H), 3.55-3.48 (2H, m, 6-H2), 3.48-3.39 (2H, m, 1-
H2), 3.39-3.34 (2H, m, 9-H2), 3.02 (2H, t, J 6.5, 10-H2), 2.61 (2H, q, J 7.5, 12-CH2), 2.42 
(2H, t, J 6.5, 7-H2), 1.16 (3H, t, J 7.5, 13-H3), 0.94 (6H, s, (CH3)2). δC (125 MHz, CD3OD) 
201.3 (C-11), 176.0 (C-5), 173.9 (C-8), 77.3 (C-4), 70.3 (C-1), 40.4 (C-2), 40.1 (C-9), 
38.2 (C-12), 36.4 (C-7), 36.3 (C-6), 29.1 (C-10), 21.3 (C-3), 20.9 (C-3), 10.0 (C-13). m/z 
(ESI+) calc. for [C14H26N2O5SNa] 357.1455 found 357.1454.  
Acetyl Meldrum’s Acid 66 
 
To Meldrum’s acid 65 (0.40 g, 2.78 mmol) in dry CH2Cl2 (8 mL) at 0 °C under a nitrogen 
atmosphere was added acetyl chloride (0.24 mL, 3.33 mmol) and DMAP (0.68 g, 




for 1 h, then quenched by the addition of 1 M HCl (15 mL). The aqueous phase was 
extracted with CH2Cl2 (2 x 20 mL), the combined organic phases washed with brine 
(15 mL), dried over MgSO4 and concentrated in vacuo furnishing 66 as an orange solid 
(510 mg, 99%) that did not require further purification. δH (400 MHz, CDCl3) 15.13 (1H, 
s, OH), 2.66 (3H, s, 1-H3), 1.74 (6H, s, (CH3)2). δC (100 MHz, CDCl3) 194.6 (C-2), 170.2 
(CO), 160.5 (CO), 104.9 (C-6), 91.9 (C-3), 26.8 (C-7), 23.5 (C-1). The data are in 
accordance with the literature.186  
S-Acetoacetyl-pantetheine 62 
 
To thiol 59 (0.10 g, 0.31 mmol) and Meldrum’s acid 66 (0.12 g, 0.63 mmol) under a 
nitrogen atmosphere was added dry toluene (4 mL). The reaction mixture was heated to 
reflux and stirred for 16 h. Following cooling to room temperature the solvent was 
removed under reduced pressure and the crude oil was purified by column 
chromatography (0-10% MeOH:CH2Cl2) furnishing a colourless oil (96 mg). To the 
protected pantetheine (80 mg, 0.20 mmol) was added 2:1 AcOH:H2O (8 mL) and the 
reaction mixture stirred at room temperature for 5 h. The solvent was removed under 
reduced pressure and the crude oil was purified by column chromatography (5% 
MeOH:CH2Cl2) furnishing 62 as a colourless oil (51 mg, 54%). [𝛼]𝐷
24 +20.0 (c 1.0, 
MeOH). δH (500 MHz, CD3OD) 3.90 (1H, s, 4-H), 3.54-3.48 (2H, m, 6-H2), 3.48-3.41 
(2H, m, 1-H2), 3.40-3.35 (2H, m, 9-H2), 3.07 (2H, t, J 6.5, 10-H2), 2.43 (2H, t, J 6.5, 7-
H2), 2.24 (2.2H, s, 14-H3 keto), 1.94 (0.6H, s, 14-H3 enol), 0.93 (6H, s, (CH3)2). δC 
(125 MHz, CD3OD) 202.4 (C-13), 193.7 (C-11), 176.0 (C-5), 174.0 (C-8), 77.3 (C-4), 
70.4 (C-1), 40.4 (C-2), 39.8 (C-9), 36.4 (C-7), 36.3 (C-6), 30.3 (C-14 keto), 29.7 (C-10), 
21.3 (C-3), 20.9 (C-3), 20.8 (C-14 enol). νmax (neat) / cm
-1
 3300 (br), 2931 (br, w), 1719 
(w), 1644 (s), 125 (m). m/z (ESI+) calc. for [C15H26N2O6SNa] 385.1409 found 385.1400. The 





Propyl Meldrum’s Acid 67 
 
To Meldrum’s acid 65 (1.00 g, 6.94 mmol) in dry CH2Cl2 (20 mL) at 0 °C under a nitrogen 
atmosphere was added propionyl chloride (0.62 mL, 6.94 mmol) in dry CH2Cl2 (10 mL) 
and DMAP (1.69 g, 13.9 mmol). The reaction mixture was allowed to warm to room 
temperature and stirred for 16 h, then quenched by the addition of 0.1 M HCl (40 mL). 
The phases were separated and the aqueous phase extracted with CH2Cl2 (2 x 30 mL). 
The combined organic phases were washed with brine (20 mL), dried over MgSO4 and 
concentrated in vacuo. The crude oil was purified by column chromatography (80% 
EtOAc:petrol) furnishing 67 as an orange solid (950 mg, 68%). δH (400 MHz, CDCl3) 
3.11 (2H, q, J 7.5, 2-H2), 1.73 (6H, s, (CH3)2), 1.26 (3H, t, J 7.5, 1-H3). δH (100 MHz, 
CDCl3) 199.1 (C-3), 170.8 (CO), 160.4 (CO), 105.0 (C-7), 91.1 (C-4), 29.6 (C2), 27.0 
(C-8), 9.9 (C-1). The data are in accordance with the literature.187  
S-13-oxopentanethioic-pantetheine 63 
 
Thiol 59 (0.20 g, 0.63 mmol) and Meldrum’s acid 67 (0.15 g, 0.76 mmol) in dry toluene 
(15 mL) under a nitrogen atmosphere were heated to 90 °C and stirred for 16 h. After 
cooling to room temperature, the solvent was removed under reduced pressure. To the 
crude orange oil was added AcOH (6 mL) and H2O (3 mL) and the reaction mixture was 
stirred at room temperature for 4 h. The solvent was removed in vacuo and the residue 
was purified by column chromatography (10% MeOH:CH2Cl2) furnishing 63 as a light-
yellow oil (75 mg, 32%). δH (500 MHz, CD3OD) 3.90 (1H, s, 4-H), 3.55-3.47 (2H, m, 6-
H2), 3.47-3.40 (2H, m, 1-H2), 3.40-3.33 (2H, m, 9-H2), 3.07 (1.3H, t, J 6.5, 10-H2), 2.83 




q, J 7.5, 14-H2), 1.04 (2H, t, J 7.5, 15-H3), 0.93 (6H, s, (CH3)2). δC (125 MHz, CD3OD) 
205.0 (C-13), 193.8 (C-11), 176.0 (C-5), 174.0 (C-8), 77.3 (C-4), 70.4 (C-1), 40.4 (C-2), 
39.8 (C-9), 37.3 (C-14), 36.4 (C-7), 36.3 (C-6), 29.7 (C-10), 21.3 (C-3), 20.9 (C-3), 7.7 
(C-15). m/z (ESI+) calc. for [C16H28N2O6SNa] 399.1560 found 399.1543.  
S-(13-Methylbut-12-enoyl)-pantetheine 64 
 
To thiol 59 (0.15 g, 0.47 mmol), acid 3,3-dimethylacrylic acid 68 (57 mg, 0.57 mmol) 
and EDCI (0.14 g, 0.71 mmol) under a nitrogen atmosphere was added CH2Cl2 (5 mL) 
and DIPEA (0.16 mL, 0.94 mmol). The reaction mixture was stirred at room temperature 
for 16 h then concentrated under reduced pressure. The crude oil was purified by column 
chromatography (EtOAc) furnishing a colourless oil (95 mg, 51%). To the protected 
pantetheine (80 mg, 0.20 mmol) was added 2:1 AcOH: H2O (8 mL), the reaction mixture 
stirred at room temperature for 5 h then concentrated under reduced pressure. The crude 
oil was purified by column chromatography (5-7% MeOH:CH2Cl2) furnishing 64 as a 
colourless oil (66 mg, 92%). [𝛼]𝐷
24 +24.0 (c 1.0, MeOH). δH (400 MHz, CD3OD) 6.04 
(1H, s, 12-H), 3.88 (1H, s, 4-H), 3.52-3.44 (2H, m, 6-H2), 3.44-3.39 (2H, m, 1-H2), 3.37-
3.31 (2H, m, 9-H2), 3.01 (2H, t, J 7.0, 10-H2), 2.40 (2H, t, J 7.0, 7-H2), 2.14 (3H, s, 14-
H3), 1.89 (3H, s, 15-H3), 0.91 (6H, s, (CH3)2). δC (100 MHz, CD3OD) 190.0 (C-11), 176.0 
(C-5), 173.9 (C-8), 155.8 (C-13), 123.9 (C-12), 77.3 (C-4), 70.4 (C-1), 40.4 (C-2), 40.3 
(C-9), 36.4 (C-7), 36.3 (C-6), 29.0 (C-10), 27.2 (C-15), 21.3 (C-3), 21.2 (C-14), 20.9 (C-
3). νmax (neat) / cm
-1 3296 (br, w), 2930 (w), 1629 (s), 1527 (s). m/z (ESI+) calc. for 
[C16H28N2O5SNa] 383.1617 found 383.1623.  
4-Methylhepta-1,6-dien-4-ol 76 
 
To freshly distilled ethyl acetate 75 (1.80 g, 20.5 mmol) in dry THF (10 mL) at 0 °C under 




Et2O). The reaction mixture was allowed to warm to room temperature, stirred for 16 h 
then quenched with 1 M HCl (30 mL). The aqueous phase was extracted with Et2O (3 x 
30 mL), the combined organic phases were then dried over MgSO4 and concentrated in 
vacuo. The crude yellow oil was purified by column chromatography (10% EtOAc:petrol) 
furnishing 76 as a colourless oil (1.05 g, 41%). δH (400 MHz, CDCl3) 5.87 (2H, ddt, J 
17.5, 10.5, 7.5, 2-H and 6-H), 5.17-5.07 (4H, m, 1-H2 and 7-H2), 2.22 (4H, m, 3-H2 and 
5-H2), 1.17 (3H, s, CH3). δC (100 MHz, CDCl3) 134.0 (C-2 and C-6), 118.9 (C-1 and C-
7), 71.8 (C-4), 46.3 (C-3 and C-5), 26.8 (CH3). m/z (ESI
+) calc. for [C8H14O] 149.1 found 
149.1. The data are in accordance with the literature.188 
3-Hydroxy-3-methylpentanedioic acid 77 and HMG-anhydride 78 
 
Alcohol 76 (0.50 g, 3.96 mmol) was dissolved in CH2Cl2 (10 mL) and AcOH (1 mL) at -
78 °C and the tip of a spatula of sudan-III dye was added. Ozone was passed through the 
solution until the red colour dissipated then the reaction mixture was allowed to warm to 
room temperature. The solvent was removed under a stream of nitrogen. To the crude oil 
was added AcOH (20 mL) and 30% solution of H2O2 (13 mL), the reaction mixture was 
heated to reflux and stirred for 16 h. After cooling to 0 °C, the reaction was quenched 
with sat. aq. Na2SO3 (20 mL), extracted with EtOAc (2 x 20 mL), the combined organic 
extracts washed with brine (15 mL), dried over MgSO4 and concentrated in vacuo. Diacid 
77 was isolated as a white solid that didn’t require any further purification (97 mg, 15%). 
δH (400 MHz, (CD3)2CO) 2.69 (4H, s, 2-H2 and 4-H2), 1.38 (3H, s, CH3). δC (100 MHz, 
(CD3)2CO) 173.2 (CO), 70.1 (C-3), 45.2 (C-2 and C-4), 27.6 (CH3). m/z (ESI
+) calc. for 
[C6H10O5Na] 185.0420 found 185.0414.  
The combined aqueous extracts were concentrated in vacuo, and to the resulting white 
solid at 0 °C was added Ac2O (20 mL). The reaction mixture was allowed to warm to 
room temperature and stirred for 16 h. The subsequent red reaction mixture was 
concentrated under reduced pressure, the residue dissolved in CH2Cl2 and washed with 
brine (10 mL), dried over MgSO4 and concentrated in vacuo furnishing 78 (102 mg, 15%) 
as a red solid. δH (400 MHz, (CD3)2CO) 4.65 (1H, br s, OH), 3.01 (2H, d, J 16.0, 2-HH 




(CD3)2CO) 167.4 (C-1 and C-5), 67.8 (C-3), 44.3 (C-2 and C-4), 27.9 (CH3). m/z (ESI
+) 
calc. for [C6H8O4Na] 167.0315 found 167.0310. The data are in accordance with the 
literature.188 
 
Diacid 77 (55 mg, 0.34 mmol) and Ac2O (2 mL) were stirred at room temperature for 
16 h. The reaction mixture was concentrated under reduced pressure furnishing 78 as a 
grey solid (48 mg, 99%). Spectroscopic data were in accordance with the data above.  
S-(3-Hydroxy-3-methylglutaryl)-pantetheine 79 
 
To thiol 59 (30 mg, 92.5 µmol) and anhydride 78 (20 mg, 139 µmol) under a nitrogen 
atmosphere was added dry toluene (6 mL) and Et3N (5 drops). The reaction mixture was 
stirred at room temperature for 1 h then the solvent removed under reduced pressure. 
AcOH (4 mL) and H2O (2 mL) were added and the reaction mixture was stirred for 5 h, 
then the solvent removed under reduced pressure. The crude red oil was purified by 
column chromatography (10% MeOH:CH2Cl2 + 0.1% AcOH) furnishing 79 as a 
colourless oil (21 mg, 54%). δH (400 MHz, CD3OD) 3.88 (1H, s, 4-H), 3.53-3.46 (2H, m, 
6-H2), 3.46-3.40 (2H, m, 1-H2), 3.38-3.33 (2H, m, 9-H2), 3.01 (2H, t, J 6.5, 10-H2), 2.95 
(2H, d, J 3.0, 14-H2), 2.61 (2H, s, 12-H2), 2.40 (2H, t, J 6.5, 7-H2), 1.35 (3H, s, 16-H3), 
0.91 (6H, s, (CH3)2). δC (125 MHz, CD3OD) 198.3 (C-11), 176.1 (C-5), 175.2 (C-15), 
173.9 (C-8), 77.3 (C-4), 71.1 (C-13), 70.4 (C-1), 55.0 (C-14), 46.1 (C-12), 40.4 (C-2), 
39.9 (C-9), 36.4 (C-7), 36.3 (C-6), 29.5 (C-10), 27.8 (C-16), 21.3 (C-3). 20.9 (C-3). m/z 






S-[13C]-Acetyl pantetheine 85 
 
To thiol 59 (0.10 g, 0.34 mmol) in CH2Cl2 under a nitrogen atmosphere was added [2-
13C]-acetic acid (25  µL, 0.41 mmol), EDCI (90 mg, 0.50 mmol) and DIPEA (120 µL, 
0.68 mmol.). The reaction mixture was stirred for 16 h, then the solvent removed under 
reduced pressure. The crude colourless oil was purified by column chromatography (50-
80% EtOAc:hexane) furnishing a colourless oil (75 mg, 60%). To the oil (50 mg, 
0.14 mmol) was added acetic acid (6 mL) and water (3 mL), the solution was stirred at 
room temperature for 3 h then concentrated in vacuo. The crude oil was purified by 
column chromatography (80% EtOAc:hexane) furnishing 85 as a colourless oil (44 mg, 
98%). δH (500 MHz, CD3OD) 3.90 (1H, s, 4-H), 3.55-3.48 (2H, m, 6-H2), 3.47-3.40 (2H, 
m, 1-H2), 3.40-3.34 (2H, m, 9-H2), 3.01 (2H, t, J 6.5, 10-H2), 2.42 (2H, t, J 6.5, 7-H2), 
2.34 (3H, d, J 130 Hz, 12-H3), 0.93 (6H, s, (CH3)2). δC (125 MHz, CD3OD) 197.0 (d, 
J 48.0 Hz, C-11), 176.0 (C-5), 173.9 (C-8), 77.3 (C-4), 70.3 (C-1), 40.4 (C-2), 40.0 (C-
9), 36.4 (C-7), 36.3 (C-6), 30.5 (enhanced C-12), 29.5 (C-10), 21.3 (C-3), 20.9 (C-3). m/z 
(ESI+) calc. for [13C1C12H24N2O5SNa] 344.1332 found 344.1345. 
S-[13C]-Acetyl Meldrum’s Acid 87 
 
To Meldrum’s acid 65 (0.20 g, 1.38 mmol) in dry CH2Cl2 (5 mL) at 0 °C under a nitrogen 
atmosphere was added 2-[13C]-acetyl chloride (118 µL, 1.67 mmol) and DMAP (0.34 g, 
2.78 mmol). The reaction mixture was allowed to warm to room temperature and stirred 
for 3 h, then quenched by the addition of 1 M HCl (15 mL). The aqueous phase was 
extracted with CH2Cl2 (2 x 15 mL), the combined organic phases washed with brine 
(10 mL), dried over MgSO4 and concentrated in vacuo. The crude oil was purified by 
column chromatography (50% EtOAc:petrol) furnishing 87 as a yellow solid (203 mg, 




(CH3)2). δC (125 MHz, CDCl3) 194.6 (C-2), 170.2 (CO), 160.5 (CO), 104.9 (C-6), 91.9 
(C-3), 26.8 (C-7), 23.5 (enhanced C-1). m/z (ESI+) calc. for [13C1C7H10O5Na] 210.0454 
found 210.0446.  
S-[13C]-Acetoacetyl-pantetheine 83 
 
To thiol 59 (0.10 g, 0.31 mmol) and Meldrum’s acid 87 (70 mg, 0.38 mmol) under a 
nitrogen atmosphere was added dry toluene (10 mL). The reaction mixture was heated to 
reflux and stirred for 16 h. Following cooling to room temperature the solvent was 
removed under reduced pressure and the crude oil was purified by column 
chromatography (4% MeOH:CH2Cl2) furnishing a colourless oil (65 mg, 52%). To the 
protected pantetheine (52 mg, 0.13 mmol) was added 2:1 AcOH:H2O (4.5 mL) and the 
reaction mixture stirred at room temperature for 16 h. The solvent was removed under 
reduced pressure and the crude oil was purified by column chromatography (8% 
MeOH:CH2Cl2) furnishing 83 as a colourless oil (35 mg, 74%). δH (500 MHz, CD3OD) 
3.90 (1H, s, 4-H), 3.54-3.48 (2H, m, 6-H2), 3.48-3.41 (2H, m, 1-H2), 3.40-3.35 (2H, m, 
9-H2), 3.07 (2H, t, J 6.5, 10-H2), 2.43 (2H, t, J 6.5, 7-H2), 2.24 (2H, d, J 128 Hz, 14-H3 
keto), 1.94 (0.6H, d, J 128 Hz, 14-H3 enol), 0.93 (6H, s, (CH3)2). δC (125 MHz, CD3OD) 
202.5 (d, J 43.0 Hz, C-13), 193.7 (C-11), 176.0 (C-5), 174.0 (C-8), 77.3 (C-4), 70.4 (C-
1), 40.4 (C-2), 39.8 (C-9), 36.4 (C-7), 36.3 (C-6), 30.3 (enhanced C-14 keto), 29.7 (C-
10), 21.3 (C-3), 20.9 (C-3), 20.8 (enhanced C-14 enol). m/z (ESI+) calc. for 
[13C1C14H26N2O6SNa] 386.1437 found 386.1451.  
3-Methylbut-3-enoic acid 90 
 
To 3-methylbut-3-en-1-ol (1.00 mL, 9.90 mmol) in acetone (50 mL) at 0 °C was added 




the solution was added Et2O (30 mL) and 2 M NaOH (40 mL). The aqueous layer was 
then acidified to pH 2 with 1 M HCl and extracted with Et2O (3 x 40 mL). The combined 
organic layers were washed with brine (2 x 20 mL), dried over MgSO4 and the solvent 
removed in vacuo furnishing 90 as a pale-yellow oil (560 mg, 56%). 1H NMR (400 MHz, 
CDCl3) δ 11.33 (1H, br s, COOH), 4.95 (1H, s, 4-HH), 4.88 (1H, s, 4-HH), 3.08 (2H, s, 
2-H2), 1.83 (3H, s, 5-H3). 
13C NMR (100 MHz, CDCl3) δ 177.6 (C-1), 138.1 (C-3), 115.5 
(C-4), 43.2 (C-2), 22.5 (C-5). The data are in accordance with the literature.189  
S-(13-Methylbut-13-enoyl) pantetheine 81 / S-(13-Methylbut-12-enoyl) pantetheine 
64 
 
To thiol 59 (50 mg, 0.16 mmol) in DCM (3 mL) at room temperature under a nitrogen 
atmosphere was added 3-methyl-3-butenoic acid 90 (16 μL, 17.7 mg, 0.16 mmol), N,N’-
dicyclohexylcarbodiimide (29.2 μL, 39 mg, 0.19 mmol) and DMAP (4.8 mg, 39 µmol). 
The reaction mixture stirred for 2 h then the solution was filtered and washed with 1 M 
HCl (5 mL), sat. aq. NaHCO3 (5 mL) and brine (10 mL). The combined organic phases 
were dried over MgSO4 and concentrated in vacuo. The crude oil was purified by column 
chromatography (60% EtOAc:petrol) furnishing a colourless oil (40 mg, 57%) as a 1:1 
mixture of endo and exo isomers. The mixture of isomers (5 mg, 12 µmol) was stirred in 
H2O (2 mL) and AcOH (2 mL) at room temperature for 3 h. The solvent was removed in 
vacuo and the crude oil purified by column chromatography (70-100% EtOAc:petrol) 
furnishing 81 and 64 as a colourless oil (4 mg, 92%) as a 60:40 mixture of exo and endo 
isomers. 1H NMR (600 MHz, 50 mM sodium phosphate, 100 mM NaCl, pH 8.0, 10% 
D2O) δ 8.18 (1H, br s, NH), 8.05 (1H, br s, NH), 6.17 (1H, s, 12-H (endo)), 5.01 (1H, s, 
14-HH (exo)), 3.98 (1H, s, 4-H (exo)), 3.97 (1H, s, 4-H (endo)), 3.52 – 3.44 (3H, obscured 
multiplet, 1-HH, 6-H2), 3.41 – 3.36 (5H, obscured multiplet, 1-HH, 9-H2 12-H2 (exo)), 
3.05 (2H, t, J 6.5, 10-H2), 2.46 (overlapping t, J 6.5, 7-H2 (endo and exo)), 2.11 (3H, s, 
14-H3 (endo)), 1.90 (3H, s, 15-H3 (endo)), 1.75 (3H, s, 15-H3 (exo)), 0.90 (3H, s, 3-H3), 
0.87 (3H, s, 3-H3). 14-HH obscured by solvent suppression. 




δ 204.7 (C-11 (exo)), 195.4 (C-11 (endo)), 177.8 (C-5), 176.7 (C-8), 160.2 (C-13 (endo)), 
141.9 (C-13 (exo)), 124.9 (C-12 (endo)), 118.4 (C-14 (exo)), 78.5 (C-4), 71.2 (C-1), 54.7 
(C-12 (exo)), 41.6 (C-9 (endo)), 41.3 (C-9 (exo)), 41.3 (C-2), 38.3 (C-6), 38.2 (C-7 (exo)), 
38.0 (C-7 (endo)), 30.9 (C-10 (exo)), 30.6 (C-10 (endo)), 29.2 (C-15 (endo)), 24.2 (C-15 
(exo)), 23.5 (C-14 (endo)), 23.2 (C-3), 21.8 (C-3); νmax (thin film)/cm
-1 3290 (br), 2940 
(m), 2800 (m), 1648 (s), 1536 (s), 1047 (s); m/z (ESI+) HRMS: Calculated for 
C16H29N2O5S [M+H




24 -20.0 (c 1.0, MeOH). δH (600 MHz, CDCl3) 6.28-6.25 (1H, m, NH), 6.24 (1H, m, 
12-H), 5.95 (1H, t, J 11.0, 11-H), 5.70 (1H, s, 2-H), 5.59 (1H, dt, J 15.0, 7.0, 13-H), 5.31 
(1H, dt, J 11.0, 7.5, 10-H), 4.90 (1H, dq, J 8.0, 6.0, 27-H), 4.79 (1H, s, 23-HH), 4.72 (1H, 
s, 23-HH), 4.19-4.15 (1H, m, 19-H), 3.44 (1H, ddd, J 14.0, 7.0 5.5, 20-HH), 3.31 (1H, 
ddd, J 14.0, 5.0, 3.0, 20-HH), 2.59 (1H, dd, J 18.0, 4.0, 18-HH), 2.54 (1H, dd, J 18.0, 9.0, 
18-HH), 2.47 (1H, overlapping-m, 26-H), 2.43 (1H, overlapping-m, 16-HH), 2.30 (1H, 
overlapping-m, 9-HH), 2.27 (1H, overlapping-m, 16-HH), 2.23 (1H, overlapping-m, 9-
HH), 2.15 (3H, d, J 1.0, 21-H3), 2.10 (1H, overlapping-m, 6-HH), 2.09 (1H, overlapping-
m, 15-H), 2.08 (1H, overlapping-m, 14-HH), 2.07 (2H, overlapping-m, 8-H2), 2.06 (2H, 
overlapping-m, 4-H2), 1.97-1.92 (1H, m, 14-HH), 1.91-1.86 (1H, m, 5-H), 1.68 (1H, dd, 
J 14.0, 9.5, 6-HH), 1.29 (3H, d, J 6.0, 28-H3), 1.15 (3H, d, J 7.0, 29-H3), 0.89 (3H, d, J 
6.5, 24-H3), 0.87 (3H, d, J 6.5, 22-H3). δC (150 MHz, CDCl3) 211.9 (C-17), 174.6 (C-25), 
169.3 (C-1), 160.8 (C-3), 157.4 (C-30), 147.2 (C-7), 132.4 (C-13), 129.8 (C-10), 128.9 
(C-11), 127.5 (C-12), 116.7 (C-2), 112.1 (C-23), 73.8 (C-27), 67.4 (C-19), 50.4 (C-16), 
49.1 (C-4), 47.0 (C-26), 46.9 (C-18), 44.2 (C-20), 42.9 (C-6), 40.1 (C-14), 35.5 (C-8), 
29.3 (C-15), 28.9 (C-5), 26.3 (C-9), 20.0 (C-22), 19.7 (C-24), 19.0 (C-21), 18.1 (C-28), 
13.8 (C-29). νmax (neat) / cm
-1 2957 (br, m), 2926 (br, m), 1731 (s), 1235 (m), 1164 (m). 
m/z (ESI+) calc. for [C30H48N2O7Na] 571.3354 found 571.3350. The data are in 






Ethyl (R)-3-hydroxybutanoate 97 
 
Poly-(R)-3-hydroxybutanoate 104 (10.0 g), ethanol (130 mL) and concentrated sulfuric 
acid (4 mL) were heated to 80 °C and stirred for 7 days. The reaction mixture was cooled 
to room temperature and diluted with CH2Cl2 (60 mL), washed with brine (30 mL) and 
sat. aq. NaHCO3 (30 mL). The combined aqueous phases were extracted with CH2Cl2 
(3 x 70 mL), organic extracts were combined, dried over MgSO4 and concentrated in 
vacuo. The crude oil was purified by vacuum distillation at 80 °C/12 mm Hg, furnishing 
97 as a colourless oil (11.2 g, 73 %). [𝛼]𝐷
24 -43.5 (c 2.0, CHCl3), [lit.
190 [𝛼]𝐷
24 -43.2 (c 1.0, 
CHCl3)]. δH (400 MHz, CDCl3) 4.21-4.18 (1H, m, 3-H), 4.15 (2H, q, J 7.0, OCH2CH3), 
3.05-2.78 (1H, br s, OH), 2.47 (1H, dd, J 16.5, 3.5, 2-HH), 2.39 (1H, dd, J 16.5, 8.5, 2-
HH), 1.26 (3H, t, J 7.0, OCH2CH3), 1.21 (3H, d, J 6.0, 4-H3). δC (100 MHz, CDCl3) 172.9 
(C-1), 64.3 (C-3), 60.7 (OCH2CH3), 42.9 (C-2), 22.5 (C-4), 14.2 (OCH2CH3). νmax 
(neat) / cm-1 3425 (br), 2975 (w), 1731 (s), 1178 (s). The data are in accordance with the 
literature.190 
Ethyl (2R, 3R)-3-hydroxy-2-methylbutanoate 105 
 
Butyllithium (83.2 mmol, 51.4 mL, 1.62 M in hexanes) was added dropwise to 
diisopropylamine (8.40 g, 83.2 mmol, 11.6 mL) in dry THF (50 mL) at 0 °C under a 
nitrogen atmosphere. The reaction mixture was stirred for 1 h, cooled to – 78 °C and 
alcohol 97 (5.00 g, 37.8 mmol) in dry THF (10 mL) was added dropwise. After stirring 
for 1.5 h, methyl iodide (6.40 g, 45.4 mmol, 2.82 mL) was added and the reaction mixture 
allowed to warm to 0 °C. After stirring for 4 h, the reaction was quenched with sat. aq. 
NH4Cl (30 mL), acidified to pH 2 with 2 M HCl and extracted with EtOAc (3 x 60 mL). 
The combined organic extracts were washed with brine (40 mL), dried over MgSO4 and 
concentrated in vacuo. The crude brown oil was purified by column chromatography (10-
33% EtOAc:petrol), furnishing 105 as a colourless oil (4.20 g, 76 %). [𝛼]𝐷






24 -30.3 (c 1.0, CHCl3)]. δH (400 MHz, CDCl3) 4.17 (2H, q, J 7.0, 
OCH2CH3), 3.88 (1H, quintet, J 6.5, 3-H), 2.44 (1H, quintet, J 7.0, 2-H), 1.28 (3H, t, 
J 7.0, OCH2CH3), 1.22 (3H, d, J 6.5, 4-H3), 1.19 (3H, d, J 7.0, 5-H3). δC (100 MHz, 
CDCl3) 175.9 (C-1), 69.4 (C-3), 60.6 (OCH2CH3), 46.9 (C-2), 20.7 (C-4), 14.3 
(OCH2CH3), 14.2 (C-5). νmax (thin film) / cm
-1 3442 (br, w), 1714 (s), 1183 (s). m/z (ESI+) 
calc. for [C7H14O3Na] 169.1 found 169.1. The data are in accordance with the literature.
191 
Ethyl (2R, 3R)-3-(tert-Butyldimethylsilyloxy)-2-methylbutanoate 106 
 
To ester 105 (3.00 g, 20.5 mmol) in dry CH2Cl2 (40 mL) under a nitrogen atmosphere 
was added TBSCl (3.70 g, 24.6 mmol), imidazole (4.20 g, 61.5 mmol) and DMAP 
(125 mg, 1.03 mmol). The reaction mixture was stirred at room temperature for 16 h, 
quenched with sat. aq. NH4Cl (40 mL) and extracted with CH2Cl2 (3 x 30 mL). The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo. Column 
chromatography (10% EtOAc:petrol) furnished 106 as a colourless oil (4.95 g, 93%). 
[𝛼]𝐷
24 -35.0 (c 2.0, CHCl3), [lit.
192,193 [𝛼]𝐷
24 +29.4 (c 1.0, CHCl3) and [𝛼]𝐷
24 +31.1 (c 1.0, 
CHCl3) for enantiomer]. δH (400 MHz, CDCl3) 4.11 (2H, q, J 7.0, OCH2CH3), 4.02 (1H, 
quintet, J 6.5, 3-H), 2.48 (1H, quintet, J 7.0, 2-H), 1.26 (3H, t, J 7.0, OCH2CH3), 1.13 
(3H, d, J 6.5, 4-H3), 1.08 (3H, d, J 7.0, 5-H3), 0.86 (9H, s, SiC(CH3)3), 0.06 (3H, s, SiCH3), 
0.03 (3H, s, SiCH3). δC (100 MHz, CDCl3) 175.1 (C-1), 70.1 (C-3), 60.1 (OCH2CH3), 
48.1 (C-2), 25.7 (SiC(CH3)3), 20.5 (C-4), 17.9 (SiC(CH3)3), 14.2 (OCH2CH3), 12.6 (C-
5), -4.3 (SiCH3), -5.1 (SiCH3). νmax (neat) / cm
-1 2930 (br, w), 1736 (s). m/z (ESI+) calc. 
for [C13H28O3SiNa] 283.2 found 283.2. The data are in accordance with the 
literature.192,193 





To ester 106 (0.20 g, 0.76 mmol) in THF (1 mL) and water (2 mL) was added anhydrous 
LiOH (55 mg, 0.23 mmol) in water (0.5 mL). After stirring at 60 °C for 16 h, LiOH 
monohydrate (0.16 g, 3.80 mmol) in water (1 mL) and MeOH (2 mL) were added and the 
reaction mixture stirred for 6 h. After cooling to room temperature, water (10 mL) was 
added and the mixture was extracted with Et2O (2 x 10 mL). The aqueous phase was 
acidified to pH 3 with 6 M HCl and extracted with EtOAc (3 x 10 mL). The combined 
organic extracts were dried over MgSO4 and concentrated in vacuo. The crude colourless 
oil was purified by column chromatography (5-10% EtOAc:petrol + 1% acetic acid), 
furnishing 107 as a colourless oil (120 mg, 68%). [𝛼]𝐷
24 -13.0 (c 1.0, CHCl3), [lit.
194 [𝛼]𝐷
24 
-12.5 (c 1.0, CHCl3)]. δH (400 MHz, CDCl3) 4.01 (1H, quintet, J 6.5, 3-H), 2.52 (1H, 
quintet, J 7.0, 2-H), 1.22 (3H, d, J 6.5, 4-H3), 1.19 (3H, d, J 7.0, 5-H3), 0.90 (9H, s, 
SiC(CH3)3), 0.11 (3H, s, SiCH3), 0.09 (3H, s, SiCH3). δC (CDCl3, 100 MHz) 179.0 (C-1), 
70.4 (C-3), 47.6 (C-2), 25.7 (SiC(CH3)3), 21.1 (C-4), 17.9 (SiC(CH3)3), 13.7 (C-5), -4.4 
(SiCH3), -5.2 (SiCH3). m/z (ESI
+) calc. for [C11H24O3SiNa] 255.1 found 255.1. The data 
are in accordance with the literature.194 
Ethyl (R)-4-azido-3-hydroxybutanoate 108 
 
To ester 103 (1.00 g, 6.00 mmol) in DMF (16 mL) at room temperature under a nitrogen 
atmosphere was added NaN3 (0.78 g, 12.0 mmol). The reaction mixture was heated to 
100 °C and stirred for 16 h. After cooling to room temperature, EtOAc (40 mL) was added 
and the reaction mixture washed with water (2 x 30 mL). The organic extracts were dried 
over MgSO4 and concentrated in vacuo. The crude orange oil was purified by column 
chromatography (EtOAc) furnishing 108 as an orange oil (0.98 g, 95 %).  +7.0 (c 4.0, 
MeOH) [lit.195,196  +7.1 (c 4.1, MeOH), [𝛼]𝐷
24 +7.4 (c 4.05, MeOH)]. δH (400 MHz, 
CDCl3) 4.23-4.15 (3H, m, 3-H and OCH2CH3), 3.38-3.28 (2H, m, 4-H2), 2.60-2.48 (2H, 
m, 2-H2), 1.28 (3H, t, J 7.0, OCH2CH3). δC (100 MHz, CDCl3) 172.1 (C-1), 67.4 (C-3), 
61.0 (OCH2CH3), 55.5 (C-4), 38.4 (C-2), 14.1 (OCH2CH3). νmax (thin film) / cm
-1 3451 
(br), 2098 (s), 1717 (s), 1271 (m), 1174 (m). m/z (ESI+) calc. for [C6H11N3O3Na] 196.1 





Ethyl (R)-4-Azido-3-(tert-butyldimethylsilyloxy) butanoate 109 
 
To alcohol 108 (0.97 g, 5.60 mmol) in dry DMF (30 mL) at room temperature under a 
nitrogen atmosphere was added TBSCl (1.69 g, 11.2 mmol) and imidazole (0.87 g, 
12.9 mmol) and stirred for 16 h. EtOAc (30 mL) was added and the reaction mixture 
washed with water (2 x 20 mL), brine (20 mL), dried over MgSO4 and concentrated in 
vacuo. The crude yellow oil was purified by column chromatography (10% EtOAc:petrol) 
furnishing 109 as a colourless oil (1.75 g, 99%). [𝛼]𝐷
24 +2.0 (c 1.0, CHCl3) [lit.
195 [𝛼]𝐷
24 
+2.2 (c 0.33, CHCl3)]. δH (400 MHz, CDCl3) 4.25 (1H, quintet, J 5.5, 3-H), 4.18-4.09 
(2H, m, OCH2CH3), 3.38 (1H, dd, J 12.5, 4.0, 4-HH), 3.24 (1H, dd, J 12.5, 5.0, 4-HH), 
2.60-2.50 (2H, m, 2-H2), 1.27 (3H, t, J 7.0, OCH2CH3), 0.89 (9H, s, SiC(CH3)3), 0.13 
(3H, s, SiCH3), 0.09 (3H, s, SiCH3). δC (100 MHz, CDCl3) 170.8 (C-1), 68.7 (C-3), 60.6 
(OCH2CH3), 56.4 (C-4), 40.1 (C-2), 25.6 (SiC(CH3)3), 17.9 (SiC(CH3)3), 14.1 
(OCH2CH3), -4.8 (SiCH3), -5.1 (SiCH3). νmax (thin film) / cm
-1 2930 (br, w), 2101 (s), 
1734 (s), 836 (s). m/z (ESI+) calc. for [C12H25N3O3SiNa] 310.2 found 310.2. The data are 
in accordance with the literature.195 
Ethyl (R)-4-Azido-3-(tert-butyldimethylsilyloxy) butanal 110 
 
To ester 109 (0.20 g, 0.70 mmol) in dry CH2Cl2 (10 mL) at -78 °C under a nitrogen 
atmosphere was added DIBAL-H (0.90 mL, 0.90 mmol, 1.0 M in hexanes). The reaction 
mixture was stirred for 10 min then quenched with sat. aq. Rochelle’s salt (10 mL) and 
stirred vigorously for 16 h. The mixture was extracted with CH2Cl2 (3 x 15 mL), the 
combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude 
yellow oil was purified by column chromatography (10% EtOAc:petrol) furnishing 110 
as a colourless oil (0.16 g, 96%). [𝛼]𝐷
24 -6.0 (c 1.0, CHCl3). δH (400 MHz, CDCl3) 9.81 
(1H, s, 1-H), 4.34 (1H, quintet, J 5.0, 3-H), 3.39 (1H, dd, J 12.5, 5.0, 4-HH), 3.23 (1H, 
dd, J 12.5, 5.0, 4-HH), 2.62-2.74 (2H, m, 2-H2), 0.90 (9H, s, SiC(CH3)3), 0.14 (3H, s, 




48.7 (C-2), 25.7 (SiC(CH3)3), 17.9 (SiC(CH3)3), -4.7 (SiCH3), -5.0 (SiCH3). m/z (ESI
+) 
calc. for [C10H21N3O2SiNa] 266.1 found 266.1. The compound has been reported in the 
literature but not fully characterised.195 
(R)-4-Azido-3-((tert-butyldimethylsilyl)oxy) butanoic acid 111 
 
To ester 109 (0.50 g, 1.74 mmol) in MeOH (27 mL) and water (3 mL) was added Ba(OH)2 
(0.90 g, 5.22 mmol) and the reaction mixture was stirred at room temperature for 16 h. 
The MeOH was removed under reduced pressure and the residue diluted with water 
(5 mL) and EtOAc (15 mL). The phases were separated and the aqueous phase adjusted 
to pH 2 with 1 M HCl, extracted with EtOAc (4 x 15 mL) and the combined organic 
phases were washed with brine (15 mL), dried over MgSO4 and concentrated in vacuo. 
The light-yellow oil was purified by column chromatography (20% EtOAc:petrol) 
furnishing 111 as a colourless oil (366 mg, 82%). [𝛼]𝐷
24 +4.0 (c 1.0, CHCl3). δH 
(400 MHz, CDCl3) 4.25 (1H, quintet, J 5.0, 3-H), 3.38 (1H, dd, J 12.5, 5.0, 4-HH), 3.26 
(1H, dd, J 12.5, 5.0, 4-HH), 2.63 (1H, dd, J 16.0, 6.0, 2-HH), 2.57 (1H, dd, J 16.0, 6.5, 2-
HH), 0.89 (9H, s, SiC(CH3)3), 0.13 (3H, s, SiCH3), 0.10 (3H, s, SiCH3). δC (100 MHz, 
CDCl3) 176.6 (C-1), 68.4 (C-3), 56.2 (C-4), 39.8 (C-2), 25.6 (SiC(CH3)3), 17.9 
(SiC(CH3)3), -4.7 (SiCH3), -5.1 (SiCH3). νmax (neat) / cm
-1 2929 (m), 2857 (m), 2102 (s), 
1711 (s), 1255 (m). m/z (ESI+) calc. for [C10H21N3O3SiNa] 282.1244 found 282.1236. 
The compound is reported in the literature but not fully characterised.197 
(R)-4-Azido-3-(tert-butyldimethylsilyloxy)-N-methoxy-N-methylbutanamide 112 
 
To acid 111 (0.35 g, 1.35 mmol) in CH2Cl2 (15 mL) under a nitrogen atmosphere was 
added N,O-dimethylhydroxylamine hydrochloride (0.66 g, 6.75 mmol) and EDCI.HCl 
(0.52 g, 2.70 mmol). DMAP (83 mg, 0.68 mmol) and triethylamine (0.94 mL, 6.75 mmol) 
were added and the reaction mixture stirred at room temperature for 4 h. The reaction was 




extracted with CH2Cl2 (2 x 20 mL). The combined organic phases were dried over MgSO4 
and concentrated in vacuo. The colourless residue was purified by column 
chromatography (20% EtOAc:petrol) furnishing 112 as a colourless oil (364 mg, 89%). 
[𝛼]𝐷
24 -25.0 (c 1.0, CHCl3). δH (400 MHz, CDCl3) 4.40-4.33 (1H, m, 3-H), 3.70 (3H, s, 
OCH3), 3.42 (1H, dd, J 12.5, 4.0, 4-HH), 3.19 (1H, overlapping dd, 4-HH), 3.16 (3H, s, 
NCH3), 2.74 (1H, J 16.0, 6.0, 2-HH), 2.60 (1H, dd, J 16.0, 7.0, 2-HH), 0.89 (9H, s, 
SiC(CH3)3), 0.12 (3H, s, SiCH3), 0.08 (3H, s, SiCH3). δC (100 MHz, CDCl3) 171.3 (C-1), 
68.8 (C-3), 61.3 (OCH3), 56.6 (C-4), 36.9 (C-2), 31.9 (NCH3), 25.7 (SiC(CH3)3), 17.9 
(SiC(CH3)3), -4.8 (SiCH3), -4.9 (SiCH3). νmax (neat) / cm
-1 2929 (w), 2100 (s), 1660 (s), 
1097 (s). m/z (ESI-) calc. for [C12H26N4O3SiNa] 325.1666 found 325.1658.  
(R)-4’-Benzyl-N-propionyloxazolidin-2’-one 114 
 
n-Butyllithium (4.50 mL, 6.77 mmol, 1.5 M in hexanes) was added dropwise to auxiliary 
113 (1.00 g, 5.64 mmol) in dry THF (25 mL) at -78 °C under a nitrogen atmosphere. 
Propionyl chloride (0.54 mL, 6.20 mmol) was added and the reaction mixture stirred at -
78 °C for 30 min, quenched with sat. aq. NH4Cl (15 mL) and extracted with EtOAc (3 x 
30 mL). The combined organic extracts were washed with sat. aq. NaHCO3 (15 mL), 
brine (15 mL), dried over MgSO4 and concentrated in vacuo. The crude colourless oil 
was purified by column chromatography (10-20 % EtOAc:petrol) furnishing 114 as a 
waxy white solid (0.77 g, 58%). [𝛼]𝐷
24 -54.0 (c 1.0, CHCl3), [lit.
198 [𝛼]𝐷
24 -65.1 (c 1.0, 
CHCl3)]. δH (400 MHz, CDCl3) 7.38-7.31 (2H, m, Ar-H), 7.31-7.27 (1H, m, Ar-H), 7.24-
7.20 (2H, m, Ar-H), 4.68 (1H, ddt, J 10.5, 7.0, 3.0, NCH), 4.24-4.16 (2H, m, OCH2), 3.32 
(1H, dd, J 13.5, 3.0, CHHPh), 3.05-2.88 (2H, m, 2-H2), 2.78 (1H, dd, J 13.5, 10.0, 
CHHPh), 1.21 (3H, t, J 7.5, 3-H3). δC (100 MHz, CDCl3) 174.1 (C-1), 153.5 (OC(O)N), 
135.3 (Ar-C), 129.4 (Ar-CH), 129.0 (Ar-CH), 127.3 (Ar-CH), 66.2 (OCH2), 55.2 (NCH), 
37.9 (CH2Ph), 29.2 (C-2), 8.3 (C-3). νmax (thin film) / cm
-1 1774 (s), 1698 (s), 1211 (m), 
703 (m). m/z (ESI+) calc. for [C13H15NO3Na] 256.1 found 256.1. The data are in 







To NaHMDS (0.47 mmol, 0.47 mL, 1.0 M in THF) in dry THF (4 mL) at -78 °C under a 
nitrogen atmosphere was added auxiliary 114 (0.10 g, 0.43 mmol) in dry THF (2 mL). 
The reaction mixture was stirred for 1 h, then bromide 115 (0.16 g, 0.86 mmol) in dry 
THF (2 mL) was added dropwise and stirred at -78 °C for 4 h. The reaction mixture was 
allowed to warm to room temperature over 16 h, quenched with sat. aq. NH4Cl (15 mL) 
and extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. The crude orange oil was purified by column 
chromatography (20% EtOAc:petrol) furnishing 116 as a waxy white solid (24 mg, 16%). 
δH (400 MHz, CDCl3) 7.38-7.32 (2H, m, Ar-H), 7.31-7.28 (1H, m, Ar-H), 7.26-7.22 (2H, 
m, Ar-H), 4.71 (1H, ddt, J 10.5, 7.0, 3.0, NCH), 4.25-4.16 (2H, m, OCH2), 3.95 (1H, sex, 
J 6.5, 2-H), 3.31 (1H, dd, J 13.5, 3.0, CHHPh), 2.77 (1H, dd, J 13.5, 9.5, CHHPh), 2.63 
(1H, dd, J 17.0, 7.0, 3-HH), 2.55 (1H, dd, J 17.0, 7.0, 3-HH), 1.28 (3H, d, J 7.0, 6-H3), 
0.13 (9H, s, Si(CH3)3). δC (100 MHz, CDCl3,) 175.2 (C-1), 153.0 (OC(O)N), 135.2 (Ar-
C), 129.4 (Ar-CH), 129.0 (Ar-CH), 127.4 (Ar-CH), 103.7 (C-5), 86.5 (C-4), 66.1 (OCH2), 
55.3 (NCH), 38.0 (CH2Ph), 37.4 (C-2), 24.1 (C-3), 16.5 (C-6), 0.1 (Si(CH3)3).  
5-(Trimethylsilyl)pent-4-yn-1-ol 126 
 
n-Butyllithium (34.4 mL, 49.9 mmol, 1.45 M in hexanes) was added to alcohol 125 
(2.00 g, 23.8 mmol) in dry THF (40 mL) at -78 °C under a nitrogen atmosphere. The 
reaction mixture was stirred for 1 h, then TMSCl (5.40 g, 49.9 mmol, 6.30 mL) was added 
and allowed to warm to room temperature over 16 h. 1 M HCl (40 mL) was added, the 
reaction mixture stirred for 16 h then extracted with CH2Cl2 (2 x 30 mL). The combined 
organic extracts dried over MgSO4 and concentrated in vacuo. The crude yellow oil was 
purified by column chromatography (20% EtOAc:petrol) furnishing 126 as a colourless 
oil (3.71 g, 99%). δH (400 MHz, CDCl3,) 3.76 (2H, t, J 6.0, 1-H2), 2.35 (2H, t, J 7.0, 3-




4), 85.3 (C-5), 61.9 (C-1), 31.1 (C-2), 16.6 (C-3), 0.1 (Si(CH3)3). νmax (thin film) / cm
-1 
3324 (br), 2956 (br, w), 2174 (w), 1248 (m), 838 (s). m/z (ESI+) calc. for [C8H16OSiNa] 
179.1 found 179.1. The data are in accordance with the literature.199 
5-(Trimethylsilyl)pent-4-ynoic acid 123 
 
To alcohol 126 (1.80 g, 11.5 mmol) in MeCN (30 mL) and water (30 mL) at room 
temperature was added TEMPO (0.54 g, 3.46 mmol) and BAIB (9.30 g, 28.8 mmol) and 
stirred for 16 h. The reaction mixture was extracted with CH2Cl2 (30 mL), the aqueous 
phase acidified to pH 1 with 2 M HCl and extracted with CH2Cl2 (2 x 20 mL). The 
combined organic extracts were washed with brine (20 mL), dried over MgSO4 and 
concentrated in vacuo. The crude brown oil was purified by column chromatography 
(15% EtOAc:petrol + 0.5% acetic acid) furnishing 123 as an orange solid (1.34 g, 68%). 
δH (400 MHz, CDCl3) 2.65-2.52 (4H, m, 2-H2 and 3-H2), 0.15 (9H, s, Si(CH3)3). δC 
(100 MHz, CDCl3) 177.6 (C-1), 104.5 (C-4), 85.7 (C-5), 33.4 (C-2), 15.5 (C-3), 0.0 
(Si(CH3)3). νmax (thin film) / cm
-1 2958 (br, w), 2176 (w), 1710 (m). m/z (ESI-) calc. for 




To alcohol 126 (2.00 g, 12.8 mmol) in dry CH2Cl2 (50 mL) at 0 °C under a nitrogen 
atmosphere was added PPh3 (4.00 g, 15.4 mmol) and NBS (2.70 g, 15.4 mmol). The 
reaction mixture was stirred for 3 h, Et2O (50 mL) added and stirred for a further 16 h. 
The precipitate was filtered under vacuum and the filtrate concentrated in vacuo. 
Purification by column chromatography (10% EtOAc:petrol) furnished 127 as a 
colourless oil (2.80 g, 99%). δH (400 MHz, CDCl3) 3.51 (2H, t, J 6.5, 1-H2), 2.42 (2H, t, 
J 7.0 , 3-H2), 2.05 (2H, pent, J 7.0, 2-H2), 0.15 (9H, s, Si(CH3)3). δC (100 MHz, CDCl3) 
104.9 (C-4), 85.8 (C-5), 32.3 (C-1), 31.4 (C-2), 18.6 (C-3), 0.1 (Si(CH3)3). νmax (thin film) 







To 5-(trimethylsilyl)pent-4-ynoic acid 123 (0.24 g, 1.41 mmol) in dry THF (7 mL) at -
78 °C under a nitrogen atmosphere was added Et3N (0.49 mL, 3.52 mmol) and PivCl 
(0.17 mL, 1.41 mmol). The reaction mixture was allowed to warm to 0 °C over 1 h, then 
LiCl (89 mg, 2.11 mmol) and auxiliary 117 (0.25 g, 1.41 mmol) were added. After stirring 
at 0 °C for 1.5 h, the reaction mixture was quenched with sat. aq. NH4Cl (15 mL) and 
extracted with EtOAc (3 x 10 mL). The combined organic extracts were washed with 
brine (10 mL), dried over MgSO4 and concentrated in vacuo. The crude orange oil was 
purified by column chromatography (30% EtOAc:petrol) furnishing 118 as a colourless 
oil (385 mg, 83%). [𝛼]𝐷
24 +75 (c 1.0, CHCl3). δH (400 MHz, CDCl3) 7.37-7.31 (2H, m, 
Ar-H), 7.31-7.27 (1H, m, Ar-H), 7.23-7.19 (2H, m, Ar-H), 4.73-7.66 (1H, m, NCH), 4.26-
4.17 (2H, m, OCH2), 3.32-3.20 (2H, m, CHHPh and 2-HH), 3.18-3.09 (1H, m, 2-HH), 
2.80 (1H, dd, J 13.5, 9.5, CHHPh), 2.64 (2H, t, J 7.5, 3-H2), 0.15 (9H, s, Si(CH3)3). δC 
(100 MHz, CDCl3) 171.3 (C-1), 153.4 (NCO), 135.1 (Ar-C), 129.4 (Ar-CH), 129.0 (Ar-
CH), 127.4 (Ar-CH), 105.0 (C-4), 85.4 (C-5), 66.3 (OCH2), 55.1 (NCH), 37.8 (PhCH2), 
34.9 (C-2), 15.0 (C-3), 0.0 (Si(CH3)3). νmax (neat) / cm
-1 2970 (w, br), 2172 (w), 1788 (s), 
1702 (s), 1193 (s). m/z (ESI+) calc. for [C18H23NO3NaSi] 352.1339 found 352.1349.  
(S)-4’-Benzyl-N-((S)-2-methyl-5-(trimethylsilyl)pent-4-ynoyl)oxazolidin-2’-one 119 
- 
To auxiliary 118 (50 mg, 0.15 mmol) in dry THF (2 mL) at -78 °C under a nitrogen 
atmosphere was added NaHMDS (0.18 mmol, 0.18 mL, 1.0 M in THF). After stirring for 
1 h, MeI (11 μL, 0.18 mmol) was added and stirring continued for a further 4 h. The 
reaction mixture was quenched with sat. aq. NH4Cl (10 mL), extracted with CH2Cl2 (2 x 
10 mL) and the combined organic extracts washed with brine (10 mL), dried over MgSO4 
and concentrated in vacuo. The crude orange oil was purified by column chromatography 
(10-20% EtOAc:petrol) furnishing 119 as a white solid (20 mg, 40%). [𝛼]𝐷
24 +72.0 (c 1.0, 




7.19 (2H, m, Ar-H), 4.72-4.66 (1H, m, NCH), 4.24-4.16 (2H, m, OCH2), 3.92 (1H, sex, J 
7.0, 2-H), 3.26 (1H, dd, J 13.5, 3.5, PhCHH), 2.79 (1H, dd, J 13.5, 9.5, PhCHH), 2.57 
(1H, dd, J 17.0, 7.0, 3-HH), 2.46 (1H, dd, J 17.0, 7.5, 3-HH), 1.32 (3H, d, J 7.0, 6-H3), 
0.14 (9H, s, Si(CH3)3). δC (100 MHz, CDCl3) 175.4 (C-1), 153.0 (NCO), 135.1 (Ar-C), 
129.4 (Ar-CH), 128.9 (Ar-CH), 127.4 (Ar-CH), 104.0 (C-4), 86.3 (C-5), 66.2 (OCH2), 
55.3 (NCH), 37.9 (PhCH2), 37.5 (C-2), 23.8 (C-3), 17.0 (C-6), 0.0 (Si(CH3)3). νmax (neat) 
/ cm-1 2959 (br,w), 2176 (w), 1781 (s), 1698 (m), 841 (s). m/z (ESI+) calc. for 
[C19H25NO3NaSi] 366.1496 found 366.1487.  
(S)-4’-Benzyl-N-(pent-4-ynoyl)oxazolidin-2’-one 120 
 
To pent-4-ynoic acid 124 (1.00 g, 10.2 mmol) in dry THF (50 mL) at -78 °C under a 
nitrogen atmosphere was added Et3N (3.55 mL, 25.5 mmol) and PivCl (1.26 mL, 
10.2 mmol). The reaction mixture was allowed to warm to 0 °C over 1 h, then LiCl 
(648 mg, 15.3 mmol) and auxiliary 117 (1.81 g, 10.2 mmol) were added. After stirring 
for 3 h, the reaction mixture was quenched with sat. aq. NH4Cl (30 mL) and extracted 
with EtOAc (3 x 30 mL). The combined organic extracts were washed with brine (30 mL), 
dried over MgSO4 and concentrated in vacuo. The crude yellow oil was purified by 
column chromatography (20-40% EtOAc:petrol) furnishing 120 as a colourless oil 
(2.02 g, 77%). [𝛼]𝐷
24 +76.0 (c 1.0, CHCl3), [lit.
201 [𝛼]𝐷
24 +98.6 (c 1.8, CH2Cl2)]. δH 
(400 MHz, CDCl3) 7.37-7.31 (2H, m, Ar-H), 7.31-7.27 (1H, m, Ar-H), 7.23-7.19 (2H, m, 
Ar-H), 4.73-4.67 (1H, m, NCH), 4.26-4.17 (2H, m, OCH2), 3.31 (1H, dd, J 13.5, 3.0, 
PhCHH), 3.27-3.13 (2H, m, 2-H2), 2.80 (1H, dd, J 13.5, 9.5, PhCHH), 2.61 (2H, td, J 7.0, 
3.0, 3-H2), 2.01 (1H, t, J 3.0, 5-H). δC (100 MHz, CDCl3) 171.2 (C-1), 153.4 (NCO), 
135.1 (Ar-C), 129.4 (Ar-CH), 129.0 (Ar-CH), 127.4 (Ar-CH), 82.6 (C-4), 69.0 (C-5), 66.4 
(OCH2), 55.1 (NCH), 37.8 (PhCH2), 34.8 (C-2), 13.5 (C-3). νmax (neat) / cm
-1 3290 (s), 
2915 (br, w), 1766 (s), 1702 (s). m/z (ESI+) calc. for [C15H15NO3Na] 280.0944 found 








To NaHMDS (2.52 mmol, 2.52 mL, 1.0 M in hexanes) in dry THF (5 mL) at -78 °C under 
a nitrogen atmosphere was added auxiliary 120 (0.50 g, 1.94 mmol) in dry THF (5 mL) 
over 20 min. After stirring for 1 h, MeI (0.60 mL, 9.70 mmol) was added and stirring 
continued for a further 2 h at -50 °C. The reaction mixture was quenched with sat. aq. 
NH4Cl (20 mL), extracted with CH2Cl2 (3 x 15 mL) and the combined organic extracts 
washed with brine (10 mL), dried over MgSO4 and concentrated in vacuo. The crude 
orange oil was purified by column chromatography (20% EtOAc:petrol) furnishing 121 
as a white solid (273 mg, 52%). [𝛼]𝐷
24 +88 (c 1.0, CHCl3). δH (400 MHz, CDCl3) 7.37-
7.31 (2H, m, Ar-H), 7.31-7.24 (1H, m, Ar-H), 7.23-7.19 (2H, m, Ar-H), 4.75-4.68 (1H, 
m, NCH), 4.26-4.17 (2H, m, OCH2), 3.93 (1H, sex, J 7.0, 2-H), 3.27 (1H, dd, J 13.5, 3.5, 
PhCHH), 2.79 (1H, dd, J 13.5, 9.5, PhCHH), 2.58 (1H, ddd, J 17.0, 7.0, 3.0, 3-HH), 2.42 
(1H, ddd, J 17.0, 7.0, 3.0, 3-HH), 1.99 (1H, t, J 3.0, 5-H), 1.33 (3H, t, J 7.0, 6-H3). δC 
(100 MHz, CDCl3) 175.2 (C-1), 153.0 (NCO), 135.1 (Ar-C), 129.4 (Ar-CH), 128.9 (Ar-
CH), 127.4 (Ar-CH), 81.6 (C-4), 69.8 (C-5), 66.2 (OCH2), 55.3 (NCH), 37.9 (PhCH2), 
37.5 (C-2), 22.2 (C-3), 17.1 (C-6). νmax (neat) / cm
-1 3264 (s), 1775 (s), 1695 (s), 1192 (s). 





















































































































































































































Molecular weight 12615.39 











Molecular weight 48784.25 








Molecular weight 30399.84 








Molecular weight 31363.10 











Molecular weight 31406.81 



















Molecular weight 53189.95 







Molecular weight 26609.94 











Molecular weight: 12647.3 





Molecular weight 10697.9 





Molecular weight 11200.63 





Molecular weight 11352.06 










Molecular weight: 42994.67 











Molecular weight: 13267.96 





Molecular weight: 14922.78 











Molecular weight: 51752.31 








Molecular weight: 29454.35 














Molecular weight: 12378.85 





Molecular weight: 14266.01 











Molecular weight: 52091.05 








Molecular weight: 27959.94 







7.2 Sequence Alignments 
Full sequence alignment of ECH2 domains presented in Figure 63.  
BatE                       ---MNRSDVVQFSEVEPGIIQITMQDRENKNTFSRELVKGLINAFRHIRESERYRVVVLT 
MupK                       -----MDSVIDFQARDDGVVVLTLQDREHKNTFTPALIDGLIQAYARINASDAYKAVVIT 
CalR                       --------MVDLSEIEPGIVLLQMQDRIHKNAFTDDMTLALLNAFDTIAHHDRYKVVVLT 
BaeI                       ----MPNAAVELLEIEPDIIQVTMQDKAHKNAFSKELTDGLMEAFTRIKKSSVYKAVILT 
VirE                       --------MVH-LSWQGPVAVIRMADHEGRNTFGPALSRGLVDAVDRAVAEERTRVLVVE 
pksI                       ----MTHSVVELIEIESAIIQVKMQDRTHKNAFSQELTDDLIQAFEYIRQNPKYKAVILT 
TmpE                       MNKTIINSAVYTVENANGVVQITLEDRANKNMFTRDIIAGLMQAYKNIDENQSCKVVIIT 
TaY                        -----MAPVVTLHEVEEGVAQITLVDRENKNMFSEQLVRELITVFGKVNGNERYRAVVLT 
OocC                       ----MSTDVIDFQEIEPGIAHIRMQDRAYKNTFSRALVDALILAFKQIESAERYKAVILT 
CurF                       -----NSEVVQLTELGNGVVQITMKDESSRNGFSPSIVEGLRHCFSVVAQNQQYKVVILT 
JamJ_ECH_1_14-255          -----NSEVVQLAELGDGIVQITMNDEKNRNSFSKNFIDKLFRCFELVNQNPIYKVVIIA 
Bat3_ECH_1_2986-3226       ------ESVVRMQEIEPGIVQITMADREHKNMFSNALISGLTQAFEAIRNNETYKVVVLT 
PedI_ECH2_2878-3125        ------SEVARLSRYRNGVLLMTLCERQSKNTFSRIFVEGVIGAFEHISGNPSYKVVVLT 
OnnB_ECH_2_2961-3192       -----------------GVVLVSLCDRENKNMFSKAFLQGFDEAFEHIRGNAAYKVVIIT 
NspA_ECH_2_3211-3455       -------DVVHVHAFGNGVVQVTLADTANKNMFSNAFSEGLTQAFEHIESVPTYKVVVLI 
DipP_ECH_1_2970-3215       ------SHVIKLEKYYNDILILTICDRENKNMFSSSVVKGITDAFSYINSSVQYKVIIIT 
PsyA_ECH_1_1536-1762       -------------------------DRASKNSFSEAFLDGMCEAFDHIRAQEAYKVVVLA 
PhmE_ECH_2_2206-2441       -----------------GVLLVTLCDRNSRNTFSKAFIAGINEVFALVRDNPRYKVLVLT 
PhmI_ECH_2_1102-1349       ------SKVVKLEIFSDGVAVLTMDDRDSKNTFTEALAQGLTEAFAWVEKTFSIKVVVLT 
Fr9GH_ECH_2_3120-3369      ----LPHTCIELTLDDLGVAVARMCDPDTKNAFTPAFVAAMEAVMTWAGETPACKVLILT 
OocJ_mECH_2_2220-2467      ----LTSAAIEAEVYDNGVLLVRLCERDSRNKFSKAFVAGFEEIFAHIRQNQRYKVVVLT 
                                                    :   :* *   .   .             :.:::  
 
BatE                       GYDTYFCSGGTKEGLLMLHEGQGKFTDM-NIYSVPLECEIPVISAMQGHGIGGGFVFGLF 
MupK                       GYDSFFCSGGTREGLLALNQTRGDFTDA-NVYSLAFECKIPVIAAMQGHAIGGGLVMGLF 
CalR                       GFDSYFSTGGDQASLLRLHEGRGHFATT-NLYSLALNCRIPVISAMQGHGIGGGFVIGLF 
BaeI                       GYGHYFASGGTQEGLLRIQQGITKFTED-RMYSLALECDIPVISAMQGHGIGGGFVMGLF 
VirE                       GMPELFCAGGSQRELVHFARGDGSFDTD-DFFRVLARCPLPVVAAVQGHAIGGGLVLALY 
pksI                       GYDNYFASGGTQEGLLRIQQGLTKFTDD-NLYSLALDCEIPVIAAMQGHGIGGGFVMGLF 
TmpE                       GFDSYFCSGGTQDSLLSLNDTQGNFSDV-NIYSLPLECRVPVISAIQGHAIGGGLVMGLF 
TaY                        GYDTYFALGGTKAGLLSICDGIGSFNVT-NFYSLALECDIPVISAMQGHGVGGGFAMGLF 
OocC                       GYDNYFATGGTQEDLFALQAGKGKFTDT-NIYSLPLECPIPVISAMQGHAVGGGLVMGLF 
CurF                       GYGNYFSSGASKEYLIRKTRGEVEV---LDLSGLILDCEIPIIAAMQGHSFGGGLLLGLY 
JamJ_ECH_1_14-255          GTSHYFSTGATQEQLQSIFREEIKFTDFYEILTLALDCPLPVIAAMEGHALGGGLNLGLY 
Bat3_ECH_1_2986-3226       GYDTYFCCGGTKESLLDIQSGRVSFTDA-SVFSIPLDCKIPVIAALQGHAIGAGWALAMF 
PedI_ECH2_2878-3125        GYDNYFACGGTKQGLLDIQSGKARFTDE-QSYRMPLSCDIPVIAAMQGHAIGAGWAMGLF 
OnnB_ECH_2_2961-3192       GYDSYFACGGTKESLQAIQQGAEKFTDT-RIYGRPLECEIPVIAAIQGHALGGGWSMGMY 
NspA_ECH_2_3211-3455       GYNQYFACGGTKSGLQDIYNGRARFTDN-DIHSLPLRCHLPAIAAMQGHAIGGGWSLGMF 
DipP_ECH_1_2970-3215       GYENYFACGGTKEGLLKIQKGISRFTDE-KSYCMPLYCKIPVIAAMQGHAIGAGWAMGLF 
PsyA_ECH_1_1536-1762       GFDHYFCCGGTKEGLLSIQQGQVQFTDF-KVFSLPLQCELPVIAAMQGHAIGAGWSLGLF 
PhmE_ECH_2_2206-2441       GYDSYFACGGTQETLLSIQGGTARFTDD-KIFSLPLECEIPVIAAMQGHGIGPGWALGMF 
PhmI_ECH_2_1102-1349       GYGHYFACGGTREALLAIQAGRARFTDS-RVTSLPLECNIPVIAAMQGHGIGAGWALGMF 
Fr9GH_ECH_2_3120-3369      GYGHYFATGGTRQGMQAIQQGNATFTDA-RLYELPLACPVPVIAAMQGHAIGAGWSMGMV 
OocJ_mECH_2_2220-2467      GYDHYFASGGTMETLQAIQRGEAKFTDE-KIFALPLECDIPVIAAMQGHGIGPGWAVGMF 
                           *    *. *.    :         .            * :* ::*::**..* *  ..:  
BatE                       ADCVVLSRESVYTTNFMKYGFTPGMGATYVLPEKLGLGLAEEMLLSARTYRGADLEKRGV 
MupK                       CDIVVLSRESLYTANFMKYGFTPGMGATYILPSRLG-SLGQEMLLAAQSYSGALLEARGA 
CalR                       ADVVILSRESVYTTNFMRYGFTPGMGATYIVPLKLGTALGHEMLFLARNYRGEELKQRGA 
BaeI                       SDFVILSKESVYTANFMKYGFTPGMGATFIVPEKLGASLGHEMLLNGGHYRGGDLEKRGV 
VirE                       ADLAVFSERSVYAANFMRYGFTPGMGATHLLPARFGHQLGTEMLYTARNHRGAELRERGA 
pksI                       ADIVILSRESVYTANFMKYGFTPGMGATFIVPKKLGFSLAQEILLNAGSYRGADLEKRGV 
TmpE                       SDIVLLSKESYYTLNFMKYGFTPGMGSTLIVPTKLGTDLGNEMLLSANQYRGDELQQRGV 
TaY                        ADFVVLSRESVYTTNFMRYGFTPGMGATYIVPKRLGYSLGHELLLNARNYRGADLEKRGV 
OocC                       ADFVIMSKESIYTANFMKYGFTPGMGGTLIVPEKLGLALGHEMLMLGNNYRGEALRQRGV 
CurF                       ADFVVFSQESVYATNFMKYGFTPVGATSLILREKLGSELAQEMIYTGENYRGKELAERGI 
JamJ_ECH_1_14-255          ADFLVLSRESFYANNLMKYGLTPVGSTSLILPKKLGAELGQEMIYTGRQYRGEELAQRGI 
Bat3_ECH_1_2986-3226       SDFVVFSQQGCYESNYMKFGFTPGAGATLIFPEKFSSGLAHEILFTGRQFTGSDLEQRGI 
PedI_ECH2_2878-3125        CDCSVYSEESIYQSPYMRYDFTPGAGSTLIFPLRLGHDLSREVLLTAREFHGRELRRRGI 
OnnB_ECH_2_2961-3192       CDQVIFSLESLYQSPYMQFGFTPGAGSTLIFPHRFGKDFAGEILLSASAYRGSDFERQGI 
NspA_ECH_2_3211-3455       CDVNIFSEESIYQTPYMQYGFTPGAGSTLIFPARLGPNLSREILFGGREYKGAELKERGI 
DipP_ECH_1_2970-3215       CDYTIFSEESVYQSPYMRYGFTPGAGSTLIFPQRFGKILSREILFTASEFKGKELKERGI 
PsyA_ECH_1_1536-1762       CDVTIMAEERVYEAPYMRYGFTPGAGSTLVFPARLGFDLAGEILFTGESYRGAELRDRGI 
PhmE_ECH_2_2206-2441       CDQAIFSEESLYFSPYMQYGFTPGAGATLIFPDRFGWDLGREILFTAREYKGHELRSRGI 
PhmI_ECH_2_1102-1349       CDGAVFSAESVYHSPYMQYGFTPGAGSTLIIPHQFGHDLGGEILFGAREFKGHELKRRGI 
Fr9GH_ECH_2_3120-3369      CDAVLFAEESVYHSPYLSYGFTPGAGSTLVFPMRLGLDLGREILFGAQPYKGRALRERLP 
OocJ_mECH_2_2220-2467      CDEAIFSLESVYYSPYMRYGFTPGAGATLILPSRLGLDLAREVLFTANEYKGYELHARGL 








BatE                       PFP-VLPRAEVLEYALQLARDLAE-KPRISLVTLKSHLVAEMRARLPTIVEQEIAMHDKT 
MupK                       PFA-VLPRAQVLAHALELAMELAD-KPRLSLVTLKHHLNRKLREDLPAVIERELAMHALT 
CalR                       PFT-VLPRAEVLPEAMKMSRQLAE-KPRVSLMTLKDHLVADQRRKLPDIIRSEVAMHEQT 
BaeI                       PFP-VLPRQEVLDYAQELARELAE-KPRNSLITLKRHLVTPFREQLPAVIEKELIMHDET 
VirE                       PVR-VVAHDDVASTAHALAAGVAN-APRASLELLKQDLAAPLLAATDAAIEREAAMHRTT 
pksI                       PFK-VLPRAEVLDYAVELAQELAE-KPRNSLVTLKDHLVAPLRDQLPRVIEQELMMHEKT 
TmpE                       PLQ-VLLRKQVLSRAYELADLIAQ-KPIRSVHLLKQHLCQNICTQLPKYIEQELAMHAQT 
TaY                        PFP-VLPRKEVLPHAYEIARDLAA-KPRLSLVTLKRHLVRDIRRELPDVIERELEMHGIT 
OocC                       PFP-VYPRADVAAAALSIARDLVK-KPRLSLITLKAHLTQHLRAQLSTYTAQEVLMHEKT 
CurF                       PFP-VVSRQDVLNYAQQLGQKIAK-SPRLSLVALKQHLSADIKAKFPEAIKKELEIHQVT 
JamJ_ECH_1_14-255          PFP-VLPRKEVLNSARKLAKEIAE-KPRLSLLALKENLTAEIRTKLPEVVSKELEMHEKT 
Bat3_ECH_1_2986-3226       PYP-VVHRDQVLVQAIDLARSLCQ-SPRIALMELKEHTANPIREKLQRTYEKEVAMHQKT 
PedI_ECH2_2878-3125        DMP-VLPRRQVLAYALSLAAHLAI-TSRQQLVEQKNRRVQPVRELLPRFFEQELAMHEKT 
OnnB_ECH_2_2961-3192       QMP-VLPRRRVLAHAMEMANEMAL-SSRDELVETKVVRCQHLRHRLEETYLQELAMHEKT 
NspA_ECH_2_3211-3455       SMP-VLPRSQVLGYALKLAHHLAK-FSQNELIQRKNQATAGLRDLLDKVHTQELAMHEKT 
DipP_ECH_1_2970-3215       SMP-VLPRKQVLFYSLKLAKKLSL-LSKKELELQKKYYSHSLQKKLSTIFLHELTMHDYT 
PsyA_ECH_1_1536-1762       AWP-VLPAGEVETYALQVAREWAR-RPREVLMAEKAARCTPLRDRLADTLAQELSMHEAT 
PhmE_ECH_2_2206-2441       NMDVVLPRAQVLGQALQRAGELAR-QSRHELVRRKAERSRLLRTLLEPNYAQELAMHDKT 
PhmI_ECH_2_1102-1349       TMP-VLPRSDVLAGAMAAAHHLAS-ASRQTLMDWKQTRVRVLRQRLESIYAAELAMHEQT 
Fr9GH_ECH_2_3120-3369      GLS-VVPRGEVLAQARRLAAQWAMRRTRDALIRDKGRRLAALAQALPAMIRKELDMHELT 
OocJ_mECH_2_2220-2467      KNP-VLERARVLPFALAVANALAL-QPRAELVAAKTQRSQRLRDQVEANYERELQMHERT 
                               *     *   :   .           :   *                 *  :*  * 
 
BatE                       FHQ-PEVKARIENVFGN------ 
MupK                       MHQ-PEVGERISTLFGR------ 
CalR                       FHQ-DEVKQNILSLFGK------ 
BaeI                       FHD-DEVKKRITTMYGV------ 
VirE                       FRL-PEVMDRIVDGYGAAGLRHP 
pksI                       FHH-EEVKSRIKGLYGN------ 
TmpE                       MHQ-PEVANNIKQLFGQ------ 
TaY                        FHH-DDVRRRIEQLFL------- 
OocC                       FFQ-PEVRQNIDRLFGN------ 
CurF                       FNQ-PEIASRIQQEF-------- 
JamJ_ECH_1_14-255          FQQ-VKVASQ------------- 
Bat3_ECH_1_2986-3226       FVDNPEVLAR------------- 
PedI_ECH2_2878-3125        FVGNQQVIEKLNRHFY------- 
OnnB_ECH_2_2961-3192       YVGNPDVFAKIQ----------- 
NspA_ECH_2_3211-3455       FVGQSQVLKNIQERF-------- 
DipP_ECH_1_2970-3215       FVNNPSVITNIERYF-------- 
PsyA_ECH_1_1536-1762       FVGRDDIAAAIEASF-------- 
PhmE_ECH_2_2206-2441       FVGNQEVQERIRKYY-------- 
PhmI_ECH_2_1102-1349       FVGSQEVRARIETLYGG------ 
Fr9GH_ECH_2_3120-3369      FRHNPDVARLIDRAYG------- 
OocJ_mECH_2_2220-2467      FVGNQEVLSRIQQHF-------- 









DifC            MEQTKEM-KQIIAQIIQDIQEQQSYRA--VEAGDDVRVIEDLGFSSLDIA 
MacpD           MLNHQVM-DQVFDQVEHQIAQVLGAKGGPLVAVEIDSRFSDLGLSSLDLA 
TacpD           MLNVQQIKNEVLDSIIQEVATILSEKLLPITHIENSTAFSELSLTSLDLA 
                * : : : .::: .: :::    . :   :   :    :.:*.::***:* 
 
DifC            QLVAQMEMETGVDPFSQGETISSITTVGSICDIYQKY------------- 
MacpD           TLISNLEAVYGTDPFADAVAITSIVTVADLCRAYAQQG--VPGPSPDPLD 
TacpD           ELISNLEARYEVDPFEELVAITSIVTIEDLASAYALSLSGNTEDSHDLLS 
                 *::::*    .*** :  :*:**.*: .:.  *                 
 
DifC            -----MDSAQS 
MacpD           AQ--LRDLRQL 
TacpD           DELKAIKNQVR 
 
MupQ/TmlQ/DifD 
DifD            MKTESGGDISWVTDKLRETQDSEFLIFKGQTFTYDDLLARISFFQKELEQ 
MupQ            MRE----ERNWISDRLASFGDGIALIADGQQSSFNAIGQAMMSWQALLAH 
TmlQ            MN------RTWISDRVNSFGDSLAVVEGDNQTTFNAITKSTASW---LEN 
                *.       .*::*:: .  *.  ::  .:  ::: :      :   * : 
 
DifD            NGIREGECVALIGDYSPNAIFLLMALLLNRNIVVPLSNESREKHLDMFED 
MupQ            QNIACCT-VIINGDYSCAMVGAILALYTRHCVVVPLNRSSSERCAAVART 
TmlQ            ESIAPQSVIVINGIFNATSIGLILCAYIKECIIVPLFNYDEEKVRTILDM 
                :.*     : : * :.   :  ::.   .. ::*** . . *:   :    
 
DifD            AKVNQIIEINENDSWTLRGGSESASHP-LLDDLRERGESGIIIFTSGTSG 
MupQ            TGASWIIDADHSGDLQAL-TTQLPTHE-LVAGLFDRREAGLILLSSGSSG 
TmlQ            VQPDLLCDTRSDTARCILFDTPPNSKPALFREINTRRESGLVLYSSGSTG 
                .  . : :   .        :   ::  *.  :  * *:*::: :**::* 
 
DifD            KSKASVLSAGRLLEKYKTAKR-KPLRTLIFLKLDHIGGINTLFAILFNGG 
MupQ            EPKAILLSLERLFAKYRDAPRSRPRTTAAFLLLDHIGGFNTLLHCLFSGS 
TmlQ            TPKAILLSLDKLLHRYQQHNQRSALTIAGFLFFDHIGGFDVMMQCLLTGN 
                 .** :**  :*: :*:   :  .     ** :*****::.::  *:.*. 
 
DifD            TIVTSDSRTPESVYQAVDKHAVQVLPATPTFLNMLLMSKADAGYNLSSLK 
MupQ            TLVKLDSRDAVSICRQIAEHRIQLLPATPTFLNMLLWGRAYETYDLSSLE 
TmlQ            TLVSMTQRTPDDVCKAIEKHRINVLPTTPTFLNMLLINRAYQRCDLSSLT 
                *:*.  .* . .: : : :* :::**:********* .:*    :****  
 
DifD            LITYGTEPMPQSTLRGIHRLFPDVRLKQTYGLTELGIFSTKSKDSQSTWM 
MupQ            LVTYGTETMPESTLAALNEVFPAVRFKQTYGMSELGILSTRSESSDSLWI 
TmlQ            VIAYGSEVMPKATLNLLHQALPEVMLKQTYGMSELGVLPTESKMGNSLWL 
                :::**:* **::**  ::. :* * :*****::***::.*.*: .:* *: 
 
DifD            KVGGAGTETKITGGTLWVRSESAMLGYLNAPSPFDEDGWYDTGDQVETDG 
MupQ            QIATDDVQVKVVDQILWIKTRTAMLGYLNAPSVIDQEGWLCTGDLVETRG 
TmlQ            KIKKA--KYKVQDGVLWIKSPTAMLGYLNKESDELNDEWLCTGDLVEEQG 
                ::     : *: .  **::: :*******  *   :: *  *** **  * 
 
DifD            EYIRILGRKSEIINVGGEKVFPAEVESVFLEIPNVRDVLITGRKNPITGE 
MupQ            DYFRILGRGESLINVGGLKVLPVEVESRLLSLPFVKDAVVWGRKSPVTGQ 
TmlQ            EYIRILGRQSTVINVAGEKVFPAEIEALLLQIPYVKNSLVWGKKSHITGK 






DifD            IVAAEAVLEKEEDIKSFRKRAVAHCKQKLQPYQIPQIISVTDRKLSNDRF 
MupQ            IVAATVVLEGELDTDDTKRQIMLHCQQGLEDFKVPRHIEFVTGRLHSDRF 
TmlQ            IVAATIFIDEDIDQKQAKKHISDFCKQALEPYKIPRYFEFVNDPYHSERF 
                ****  .:: : * .. :::   .*:* *: :::*: :...     .:** 
 
DifD            KKIR--NV 
MupQ            KKIKVASQ 
TmlQ            KKIN--KI 




DifE            MNNG-----------------KVAVVSGGSRGLGKAIVQTLLDEDYKVAA 
MupS            MTDAVSDALHTRHDSAPSAVKGTIIVSGGSQGLGLTTVRCFLEAGYNVAT 
TmlS            ME----------------SENGTVIISGGSRGLGFEIASQFLAQGYAVAT 
                *                     . ::****:***   .  :*  .* **: 
 
DifE            FSRSESDFINTLRESEKYRGRFYWDAADAADDAAMKQFVLQVYRKFSRID 
MupS            FSRRESPAVTELSE----RADFHWQALDCTDYSALTAFVQQVEKRFGGLD 
TmlS            FSRGSSEQVVALAE----EPRFFWKSVDGSDYQALTEFLKEAQKKLGNIV 
                *** .*  :  * *    .  *.*.: * :*  *:. *: :. :::. :  
 
DifE            GLVNNAGLNLDQLLPLTNDEDIDRILNLNIGSVIKLTRNVSRVMLKQNSG 
MupS            GLVNNAATGVEGILSTMRVADIDSALDINLKGQLYLTKLVTAKLLKRGAG 
TmlS            GLVNNAAIGADGVLSTMRTSDIDRAIDVNLKAQIYLSKLVSKKLLQNRDG 
                ******. . : :*.  .  ***  :::*: . : *:: *:  :*:.  * 
 
DifE            SIVNISSIIGSRGFKGTSVYSASKAALDGLTRSLARELGSKGIRVNSLAP 
MupS            SVVNVSSINALRGHSGLTVYSATKAAMDGLTRSLAKELGPRGIRVNSVSP 
TmlS            FIINISSIMGVRGLPGVSIYSATKAAMDGITRSLAKELGRKGIRVNSVSP 
                 ::*:*** . **  * ::***:***:**:*****:*** :******::* 
 
DifE            GFVDTDMTKNMPEKQKSQIIRRTPMGRLGETDDMTGLVRFLLSPESSFMT 
MupS            GYFSSDMVKDLSPQTLSRIERRTPLGRLGTQQEVADLILYLV-DRGTFVT 
TmlS            GYFSSDMVKDLSDDILRKIERRTPLGRLGTQDEIAKLVLFLA-TEGKFIT 
                *:..:**.*::. .   :* ****:****  :::: *: :*   ...*:* 
 
DifE            GQTMAIDGGLTC 
MupS            GQNIAVDGGFTC 
TmlS            GQNIVIDGGFTC 
                **.:.:***:** 
 
